




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 493/04, 311/22, 407/12, A61K 31/35 // (C07D 493/04, 311:00, 311:00)</b>		A1	(11) International Publication Number: <b>WO 95/29920</b> (43) International Publication Date: 9 November 1995 (09.11.95)
(21) International Application Number: <b>PCT/US94/12630</b>		(74) Agent: COOPER, Iver, P.; Browdy and Neimark, Suite 300, 419 Seventh Street, N.W., Washington, DC 20004 (US).	
(22) International Filing Date: 1 November 1994 (01.11.94)		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 08/235,852 29 April 1994 (29.04.94) US		Published <i>With international search report.</i>	
(71) Applicants (for all designated States except US): THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; Office of Technology Development, Campus Box 4100, 302 Bynum Hall, Chapel Hill, NC 27599-4100 (US). BIOTECH RESEARCH LABORATORIES [US/US]; 3 Taft Drive, Rockville, MD 20850 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Kuo-Hsiung [US/US]; 1426 Gray Bluff Trail, Chapel Hill, NC 27514 (US). KASHIWADA, Yoshiki [US/US]; 1340 Ephesus Church Road, Chapel Hill, NC 27514 (US). HUANG, Li [US/US]; 209 Pinegate Circle, No. 9, Chapel Hill, NC 27514 (US). LEE, Thomas, Tung-Ying [US/US]; 1426 Gray Bluff Trail, Chapel Hill, NC 27514 (US). COSENTINO, Mark [US/US]; 6648 Green Ash Drive, Springfield, VA 22152 (US). SNIDER, Jim [US/US]; 66 Redwood Drive, Hagerstown, MD 21740 (US). MANAK, Mark [US/US]; 200 Stanley Place, Laurel, MD 20707 (US).			
(54) Title: KHELLACTONE DERIVATIVES AND RELATED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AND IMMUNOSTIMULATING AGENTS			
(57) Abstract			
<p>Compounds, including compositions and methods of making and using these compounds for treating retroviral infections, are provided according to formula (G-1): wherein M is O or NH; Z is O, NH or S; R<sup>240</sup> and R<sup>250</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> aryl, alkyl, amide, or CH<sub>2</sub>COOR<sup>260</sup>, where R<sup>260</sup> is C<sub>1-10</sub> alkyl or acyl; R<sup>200</sup>, R<sup>210</sup>, R<sup>220</sup> and R<sup>230</sup> are each H, halogen, hydroxyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, O-alkyl, O-acyl, COCF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>COO NH-alkyl; or R<sup>200</sup> and R<sup>210</sup> form C<sub>5</sub>-C<sub>10</sub> cyclo or heterocyclo optionally substituted with one or more of halogen, hydroxyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sup>2</sup>, O-acyl, O-alkyl, CO, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub> COONH-alkyl; wherein C3 and C4 can be bound by a single or double bond; configurations at 3' or 4' can be (R) or (S); and R<sup>240</sup> and R<sup>250</sup> are either <i>cis</i>-<math>\beta</math> or <i>cis</i>-<math>\alpha</math>, or <i>trans</i>-3'-<math>\alpha</math> or <i>trans</i>-3'-<math>\beta</math> oriented.</p>			
 <b>(G-1)</b>			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

KHELLACTONE DERIVATIVES AND RELATED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AND IMMUNOSTIMULATING AGENTS

This application was funded under National Institute of  
5 Allergies grant # AI-33066, such that the U.S. government has  
certain rights in the invention.

**FIELD OF THE INVENTION**

The present invention relates to the field of virology,  
organic chemical synthesis and therapeutics. More  
10 particularly, the present invention relates to suksdorfin  
analogs discovered to be useful in treating viral infections,  
such as HIV infections, *in vitro* and/or *in vivo*.

**BACKGROUND OF THE INVENTION**

**Retroviruses**

15       Retroviruses are small, single-stranded positive-sense RNA  
viruses. A retroviral particle comprises two identical  
single-stranded positive sense RNA molecules. Their genome  
contains, among other things, the sequence for the  
RNA-dependent DNA polymerase, also known as reverse  
20 transcriptase. Many molecules of reverse transcriptase are  
found in close association with the genomic RNA in the mature  
viral particle. Upon entering a cell, this reverse  
transcriptase produces a double-stranded DNA copy of the viral  
genome, which is inserted into the host cell's chromatin. Once  
25 inserted, the viral sequence is called a provirus. Retroviral  
integration is directly dependent upon viral proteins. Linear  
viral DNA termini (the LTRs) are the immediate precursors to  
the integrated proviral DNA. There is a characteristic  
duplication of short stretches of the host's DNA at the site of  
30 integration.

Progeny viral genomes and mRNAs are transcribed from the  
inserted proviral sequence by host cell RNA polymerase II in  
response to transcriptional, regulatory signals in the terminal  
regions of the proviral sequence, the long terminal repeats or  
35 LTRs. The host cell's protein production machinery is used  
to produce viral proteins, many of which are inactive until  
processed by virally encoded proteases. Typically, progeny  
viral particles bud from the cell surface in a non-lytic

manner. Retroviral infection does not necessarily interfere with the normal life cycle of an infected cell or organism. However, neither is it always benign with respect to the host organism. While most classes of DNA viruses can be implicated 5 in tumorigenesis, retroviruses are the only taxonomic group of RNA viruses that are oncogenic. Various retroviruses, such as the Human Immunodeficiency Virus (HIV), which is the etiological agent responsible for acquired immune deficiency syndrome (AIDS) in humans, are also responsible for several 10 very unusual diseases of the immune systems of higher animals.

#### **HIV INFECTION AND AIDS**

Human Immunodeficiency Virus (HIV), the etiological agent for AIDS (acquired immune deficiency syndrome), is a member of the lentiviruses, a subfamily of retroviruses. Many 15 retroviruses are well-known carcinogens. HIV *per se* is not known to cause cancer in humans or other animals, but it does present a formidable challenge to the host. HIV integrates its genetic information into the genome of the host. The viral genome contains many regulatory elements which allow the virus 20 to control its rate of replication in both resting and dividing cells. Most importantly, HIV infects and invades cells of the immune system; it breaks down the body's immune system and renders the patient susceptible to opportunistic infections and neoplasms. The immune defect appears to be progressive and 25 irreversible, with a high mortality rate that approaches 100% over several years.

HIV-1 is trophic and cytopathic for T4 lymphocytes, cells of the immune system which express the cell surface differentiation antigen CD4 (also known as OKT4, T4 and leu3). 30 The viral tropism is due to the interactions between the viral envelope glycoprotein, gp120, and the cell-surface CD4 molecules (Dalgleish, et al., *Nature* 312:763-767, 1984. These interactions not only mediate the infection of susceptible cells by HIV, but are also responsible for the virus-induced 35 fusion of infected and uninfected T cells. This cell fusion results in the formation of giant multinucleated syncytia, cell death, and progressive depletion of CD4 cells in AIDS patients. These events result in HIV-induced immunosuppression and its

subsequent sequelae, opportunistic infections and neoplasms.

In addition to CD4+ T cells, the host range of HIV includes cells of the mononuclear phagocytic lineage (Dagleish et al., *supra*), including blood monocytes, tissue macrophages, 5 Langerhans cells of the skin and dendritic reticulum cells within lymph nodes. HIV is also neurotropic, capable of infecting monocytes and macrophages in the central nervous system causing severe neurologic damage. Macrophage/monocytes are a major reservoir of HIV. They can interact and fuse with 10 CD4-bearing T cells, causing T cell depletion and thus contributing to the pathogenesis of AIDS.

#### **ANTI-HIV DRUGS**

Intensive efforts are currently under way to develop therapies to prevent or intervene in the development of 15 clinical symptoms in HIV-infected individuals. For the most part, efforts have been focused on the use of nucleoside analogue drugs such as AZT (azidothymidine), and on other dideoxynucleoside derivatives such as ddA, ddT, ddI, and ddC. These drugs inhibit the viral enzyme, reverse transcriptase, 20 thereby inhibiting *de novo* infection of cells. However, once viral infection has been established within a cell, viral replication utilizes host cell enzymes. Thus, drugs which inhibit only reverse transcriptase tend to have limited effects. While the spread of free virus within the organism 25 can be blocked, the mechanisms of syncytium formation and pathogenesis through direct intercellular spread remain. Accordingly, there is a need to provide a new anti-HIV drugs which are not limited to inhibiting reverse transcription as their mechanism of action.

30 **Coumarins and Photoactive Compounds** *Lomatium suksdorfii* (*Umbelliferae*) is distributed on the United States western coast. The roots of several *Lomatium* species were used medicinally by the Gosiute Indians who called the plant "pia-a-na-tsu" or "great medicine". The oil and a crystalline 35 substance obtained from *L. suksdorfii* were previously found to exhibit antispasmodic and antibacterial activities (Pettinate et al, *J. Amer. Pharm. Assoc.*, 48:423 (1959)).

Powers et al, U.S. patent no. 5,089,634, discloses

isocoumarins with cationic substituents for use in inhibiting serine proteases with trypsin-like, chymotrypsin-like and elastase-like specificity and their roles as anticoagulant agents and anti-inflammatory agents. Isocoumarin and related 5 heterocyclic compounds represented according to disclosed formula (I) or a pharmaceutically acceptable salt are also disclosed.

Gulliya et al, U.S. patent no. 5,177,073, discloses therapeutic compositions derived from a pre-activated 10 photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues, wherein the conveyor can be a matrix support or an antibody. The activation of the photoactive compound is used to produce the pre-activated photoactive compound retaining 15 therapeutic activity subsequent to activation. Such photodynamic therapy involves the administration of one or more photoactive agents to a subject to be treated followed by exposing the specific target location or target organ of the subject to light. The photoactive compound is required to have 20 one or more chromophores capable of absorbing light energy and capable of being coupled to a matrix support or antibody.

Call and Green, *Proc. Montana. Acad. Sci.* 16:49 (1956) describe methods for activation of pyronocoumarin derivatives.

Citation of documents herein is not intended as an 25 admission that any of the documents cited herein is pertinent prior art, or an admission that the cited documents is considered material to the patentability of the claims of the present application. All statements as to the date or representation as to the contents of these documents is based 30 on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.

#### SUMMARY OF THE INVENTION

The present invention is intended to overcome one or more 35 deficiencies of the related art.


The present invention is intended to also provide suksdorfin analogs which have anti-viral activity and/or

anti-retroviral activity, such as anti-HIV activity, *in vitro*, *in situ* and/or *in vivo*.

The present invention provides suksdorfin analogs according to the general formula (G-1) which can be used to 5 inhibit retroviral growth, replication, binding and/or metabolism, and/or to treat a retroviral infection or related symptoms.

The present invention also provides a process for purifying suksdorfin or suksdorfin analogs having anti-HIV 10 activity from a sample containing such a compound, such as, but not limited to, the fruit of the plant *Lomatium suksdorfi*, the method comprising: (a) extracting sample preparations with hexane to provide active fractions; (b) centrifuging the active 15 fractions at least once; (c) recovering the supernatant; and (d) purifying the precipitate by silica gel chromatography to recover the suksdorfin analog, thereby purifying the protein.


The present invention also provides alternative synthetic methods for obtaining suksdorfin analogs according to formula (G-1), such as at least one of formula (G-2) and formulae (I) 20 to (XX):



wherein M is O or NH; Z is O, NH or S;  $R^{240}$ , and  $R^{250}$  are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> aryl, alkyl, amide, or  $CH_2COOR^{260}$ , where  $R^{260}$  is C<sub>1-10</sub> alkyl or acyl;  $R^{200}$ ,  $R^{210}$ ,  $R^{220}$  and  $R^{230}$  are each H, halogen, 25 hydroxyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, O-alkyl, O-acyl, COCF<sub>3</sub>, OCF<sub>3</sub> or  $CH_2COO$  NH-alkyl; or  $R^{200}$  and  $R^{210}$  form C<sub>5</sub>-C<sub>10</sub> cyclo or heterocyclo optionally substituted with one or more halogen, hydroxyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sup>2</sup>, O-acyl, O-alkyl, CO, CF<sub>3</sub>,

OCF<sub>3</sub>, or CH<sub>2</sub> COONH-alkyl, and wherein C3 and C4 can be bound by a single or double bond, R<sup>240</sup> and R<sup>250</sup> are either *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$  oriented.

Analogs according to (G-1) can also be according to  
5 formula (G-2), such as at least one of (I), (III), (IV), (V),  
(VI), (VII), (X), (XIII), (XIV), (XV) or (XVI):



wherein M is O or NH; X and Y are each  $\text{CH}_2$ , CO,  $\text{NH}_2$ , S, O, Z is O, NH or S;  $\text{R}^{340}$ , and  $\text{R}^{350}$  are each H,  $\text{C}_{1-10}$  alkyl,  $\text{C}_{1-10}$  aryl, alkyl, amide, or  $\text{CH}_2\text{COOR}^{360}$ , where  $\text{R}^{360}$  is  $\text{C}_{1-10}$  alkyl or acyl;  $\text{R}^{300}$ ,  $\text{R}^{310}$ ,  $\text{R}^{320}$  and  $\text{R}^{330}$  are each H, halogen, hydroxyl,  $\text{NH}_2$ , NH-alkyl, N-(alkyl) $^2$ , O-alkyl, O-acyl,  $\text{COCF}_3$ ,  $\text{OCF}_3$  or  $\text{CH}_2\text{COO NH-alkyl}$ , and wherein C3 and C4 can be bound by a single or double bond,  $\text{R}^{340}$  and  $\text{R}^{350}$  are either *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$  oriented, wherein  $\text{R}^{300}$ ,  $\text{R}^{310}$  optionally a form  $\text{C}_5\text{-C}_{10}$  cyclo or heterocyclo optionally substituted with one or more halogen, hydroxyl,  $\text{NH}_2$ , NH-alkyl, N-(alkyl) $^2$ , O-acyl, O-alkyl, CO,  $\text{CF}_3$ ,  $\text{OCF}_3$  or  $\text{CH}_2\text{ COONH-alkyl}$ .

The present invention is also directed to synthetic methods for making suksdorfin analogs according to formula (I) or formula (II).

The invention is also directed to a method for treating a subject infected with HIV-1 by administering at least one suksdorfin analog, optionally in combination with any one or more of the known anti-AIDS therapeutics or an immunostimulant.

The treatment methods of the invention also include administering to a subject infected with HIV-1 a conjugate of

a suksdorfin derivative with soluble CD4, CD4 derivatives, antibodies specific for CD4, or HIV-coded glycoproteins such as gp120 and gp41, or antibodies thereto.


Other features, advantages, embodiments, aspects and objects of the present invention will be clear to those skilled in the areas of relevant art, based on the description, teaching and guidance presented herein.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to suksdorfin analogs according to formula (G-1), which are now discovered and/or expected to have anti-retroviral activity so as to be useful for inhibiting retroviral infection and/or replication in eukaryotic cells and/or for the treatment of retroviral infections, such as HIV infection.

Suksdorfin analogs of the present invention can be according to formula (G-1) or any subset thereof. Non-limiting examples of subgenus' of the present invention may include any subset of formulae (I)-(XX), such as formula (G-2), or any other subset as one or more of formulae (I)-(XX).


An example of a suksdorfin analog according to formula (G-1) of the present invention is a suksdorfin analog according to formula (I).



wherein R<sup>1</sup>, R<sup>2</sup> are either cis- $\beta$  or cis- $\alpha$ , or trans-3'- $\alpha$  or 25 trans-3'- $\beta$ -oriented, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> O-acyl, O-alkyl, amide, or CH<sub>2</sub>COOR', where R' is C<sub>1-10</sub> alkyl or acyl; R<sup>5</sup> is H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, CF<sub>3</sub>, amide or CH<sub>2</sub>COOR', where R' is C<sub>1-10</sub> alkyl, acyl or amide; and R<sup>6</sup> is H, halogen, C<sub>1-10</sub>


alkyl, or  $\text{CH}_2\text{CH}_2\text{NCOOR}^8$ , where  $\text{R}^8$  is C<sub>1-10</sub> alkyl; C3 or C4 can be bound by a single or double bond;  $\text{R}^1$  or  $\text{R}^2$  can be *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$ -oriented.

Another non-limiting example of a suksdorfin analog of the 5 present invention is a suksdorfin analog according to formula II.



wherein  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  and  $\text{R}^{12}$  are either *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$ -oriented, wherein  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  and  $\text{R}^{12}$  10 are H, C<sub>1-10</sub> acyl, amide-acyl, amide-alkyl or  $\text{CH}_2\text{OOR}'$ , where  $\text{R}'$  is C<sub>1-10</sub> alkyl or C<sub>1-10</sub> acyl.


Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula III.



15 wherein M is O or NH; X, Y and Z = O, NH or S;  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ , and  $\text{R}^{16}$ , are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, or  $\text{CH}_2\text{CONH}$ -alkyl;  $\text{R}^{17}$  and  $\text{R}^{18}$ , are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or  $\text{CH}_2\text{COOR}'$ , where  $\text{R}'$  20 is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl or (+)-camphanoyl or (-)-camphanoyl; and wherein the bond between C3 and C4 can be


double or single. Configurations at 3' or 4' can be (R) or (S). R<sup>17</sup> and R<sup>18</sup> can each be *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$ -oriented.

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula IV.



wherein M is O or NH; Z is O, NH or S; R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>25</sup> and R<sup>26</sup> are each H, C<sub>1-10</sub> alkyl, 10 C<sub>1-10</sub>acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>26</sup>, where R<sup>26</sup> is C<sub>1-10</sub>alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single, and wherein the configurations at 3' or 4' can be (R), or (S). R<sup>25</sup> and R<sup>26</sup> can be oriented *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .


Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (V):



wherein M is O or NH; X and Z = O, NH or S; R<sup>28</sup>, R<sup>29</sup>, R<sup>30</sup>, R<sup>31</sup> and


$R^{32}$  are each H, halogen, OH, O-alkyl, O-acyl,  $NH_2$ ,  $NH$ -alkyl,  $N$ -(alkyl)<sub>2</sub>,  $CF_3$ ,  $OCF_3$  or  $CH_2CONH$ -alkyl;  $R^{33}$  and  $R^{34}$  are each H,  $C_{1-10}$  alkyl,  $C_{1-10}$  acyl, aryl,  $COCF_3$ , amide or  $CH_2COO$   $R^{35}$ , where  $R^{35}$  is  $C_{1-10}$  alkyl,  $C_{1-10}$  acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl 5 and where the bond between C3 and C4 can be double or single. Configurations at 3' or 4' can be (R), or (S).  $R^{33}$  and  $R^{34}$  can be oriented *cis*- $\beta$  or *cis*- $\alpha$  or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (VI).




wherein M is O or NH; X and Z = O, NH or S;  $R^{36}$ ,  $R^{37}$ ,  $R^{38}$ , and  $R^{39}$ , are each H, halogen, OH, O-alkyl, O-acyl,  $NH_2$ ,  $NH$ -alkyl,  $N$ -(alkyl)<sub>2</sub>,  $CF_3$ ,  $OCF_3$  or  $CH_2CONH$ -alkyl;  $R^{40}$  and  $R^{41}$  are each H,  $C_{1-10}$  alkyl,  $C_{1-10}$  acyl, aryl,  $COCF_3$ , amide or  $CH_2COOR^{42}$ , where  $R^{42}$  is  $C_{1-10}$  alkyl,  $C_{1-10}$  acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; 15 wherein the bond between C3 and C4 can be double or single, and where the stereo configurations at 3' and 4' can be (R) or (S).  $R^{40}$  and  $R^{41}$  can be oriented *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

20 Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (VII).



wherein M is O or NH; Z = O, NH or S; R<sup>44</sup>, R<sup>45</sup>, R<sup>46</sup>, R<sup>47</sup>, R<sup>48</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>49</sup> and R<sup>50</sup>, are each H, C<sub>1-10</sub> alkyl, 5 C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR, where R<sup>51</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>49</sup> and R<sup>50</sup> can be oriented *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .


10 Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (VIII).



wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>52</sup>, R<sup>53</sup>, R<sup>54</sup>, R<sup>55</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, 15 N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>56</sup> and R<sup>57</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>58</sup>, where R<sup>58</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single and wherein stereo configurations at 3' or 4' can be (R), or (S). R<sup>56</sup> and R<sup>57</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$ ,


or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (IX).



5 wherein M is O or NH; Z = O, NH or S; R<sup>59</sup>, R<sup>60</sup>, R<sup>61</sup> and R<sup>62</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>63</sup> and R<sup>64</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>65</sup>, where R<sup>65</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; and wherein  
10 15 the bond between C3 and C4 can be double or single and wherein stereo configurations at 3', 4' can be (R), or (S). R<sup>63</sup> and R<sup>64</sup> can be reoriented *cis*- $\alpha$  or *cis*- $\beta$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .


Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (X).



15 wherein M is O or NH; Z = O, NH or S; R<sub>66</sub> and R<sub>67</sub> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>68</sup>, R<sup>69</sup>, R<sup>70</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>71</sup>, where R<sup>71</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl, wherein the  
20


bond between C3 and C4 can be double or single, and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>68</sup> and R<sup>69</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$  or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XI).



wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>72</sup> and R<sup>73</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, or CH<sub>2</sub>CONH-alkyl; R<sup>74</sup> and R<sup>75</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>76</sup>, where R<sup>76</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl, wherein the bond between C3 and C4 can be double or single, and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>74</sup> and R<sup>75</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XII).




wherein M is O or NH; Z = O, NH or S; R<sup>77</sup>, R<sup>78</sup>, R<sup>79</sup>, R<sup>80</sup>, R<sup>81</sup>, R<sup>82</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl,

N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>83</sup> and R<sup>84</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub>acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>85</sup>, where R<sup>85</sup> is C<sub>1-10</sub>alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be 5 double or single, and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>83</sup> and R<sup>84</sup> can be oriented cis- $\alpha$  or cis- $\beta$ , or trans-3'- $\beta$  or trans-3'- $\alpha$ .

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula XIII.

10




15

wherein M is O or NH; R<sup>86</sup>, R<sup>87</sup>, R<sup>88</sup>, R<sup>89</sup>, R<sup>90</sup>, R<sup>91</sup>, R<sup>92</sup>, R<sup>93</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>94</sup> and R<sup>95</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>96</sup>, where R<sup>96</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>94</sup> and R<sup>95</sup> can be oriented cis- $\alpha$  or cis- $\beta$ , or trans-3'- $\beta$  or trans-3'- $\alpha$ .


20

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XIV).



wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>97</sup> and R<sup>98</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>99</sup> and R<sup>100</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>101</sup>, where R<sup>101</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl group, wherein the bond between C3 and C4 can be double or single, and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>99</sup> and R<sup>100</sup> can be oriented *cis*- $\alpha$  or C IS- $\beta$ , or *trans*-3'- $\beta$  or 10 *trans*-3'- $\alpha$ .

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XV).




wherein M is O or NH; X and Z = O, NH or S; R<sup>102</sup>, R<sup>103</sup>, R<sup>104</sup>, R<sup>105</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>106</sup> and R<sup>107</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>108</sup>, where R<sup>108</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single, and wherein stereo configurations at 3' or 4' 15 double or single, and wherein stereo configurations at 3' or 4' 20 double or single, and wherein stereo configurations at 3' or 4'

can be R or S. R<sup>106</sup> and R<sup>107</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .


Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XVI).

5



wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>109</sup>, R<sup>110</sup>, R<sup>111</sup>, R<sup>112</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>113</sup> and R<sup>114</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sub>115</sub>, where R<sub>115</sub> 10 is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single, and wherein stereo, configurations at 3' or 4' can be (R) or (S). R<sup>113</sup> and R<sup>114</sup> can be oriented, *cis*- $\alpha$ , *cis*- $\beta$ , *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .


15 Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XVII).



wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>116</sup>, R<sup>117</sup>, R<sup>118</sup>, R<sup>119</sup>, R<sup>120</sup>, R<sup>121</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>,


NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>122</sup> and R<sup>123</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>124</sup>, where R<sup>124</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>122</sup> and R<sup>123</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$  or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$ .

Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XVIII).




wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>125</sup>, R<sup>126</sup>, R<sup>127</sup>, R<sup>128</sup> and R<sup>129</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>130</sup> and R<sup>131</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>132</sup>, where R<sup>132</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single and wherein stereo configurations at 3' and 4' can be (R) or (S). R<sup>130</sup> and R<sup>131</sup> can be oriented *cis*- $\alpha$ , *cis*- $\beta$ , *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

20 Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XIX).



wherein M is O or NH; Z = O, NH or S; R<sup>133</sup>, R<sup>134</sup>, R<sup>135</sup>, R<sup>136</sup>, R<sup>137</sup>, R<sup>138</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>139</sup> and R<sup>140</sup> are each H, 5 C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>141</sup>, where R<sup>141</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single, and wherein stereo configurations at 3' or 4' can be (R) or (S). R<sup>139</sup> and R<sup>140</sup> can be oriented *cis*- $\alpha$  or 10 *cis*- $\beta$ , *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .


Another example of a suksdorfin analog of the present invention is a suksdorfin analog according to formula (XX).



wherein M is O or NH; Z = O, NH or S; R<sup>142</sup>, R<sup>143</sup> and R<sup>144</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, 15 OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>145</sup>, R<sup>146</sup>, and R<sup>147</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>148</sup>, where R<sup>143</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl, wherein the bond between C3 and C4 can be double or single, and wherein 20 stereo configurations at 3' and 4' can be (R) or (S). R<sup>146</sup>, R<sup>147</sup>

and  $R^{148}$  can be oriented *cis*- $\alpha$ , *cis* $\beta$ , *trans*-3'- $\alpha$ , *trans*-3'- $\beta$ .

Non-limiting examples of suksdorfin analogs according to formula (I) include the following combinations of  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$ .

5 (I-A)  $R^1=R^2=R^3=R^4=R^5=R^6=H$   
 (I-B)  $R^1=R^2=R^4=R^5=R^6=H$ ,  $R^3=O\text{-alkyl}$   
 (I-C)  $R^1=R^2=R^3=R^4=R^6=H$ ,  $R^5=\text{alkyl}$ ,  $CF_3$ ,  $CH_2CO$  alkyl  
 (I-D)  $R^1=R^2=R^3=R^4=R^6=H$ ,  $R^5=CH_2CONH\text{-alkyl}$   
 (I-E)  $R^1=R^2=O\text{-acyl}$ ,  $R^3=R^4=R^5=R^6=H$   
 10 (I-F)  $R^1=R^2=O\text{-acyl}$ ,  $R^3=O\text{-alkyl}$ ,  $R^4=R^5=R^6=H$   
 (I-G)  $R^1=R^2=O\text{-acyl}$ ,  $R^3=R^4=R^6=H$ ,  $R^5=\text{alkyl}$ ,  $CF_3$ ,  $CH_2COOR\text{-alkyl}$   
 (I-H)  $R^1=R^2=O\text{-acyl}$ ,  $R^3=R^4=R^6=H$ ,  $R^5=CH_2CONH\text{-alkyl}$   
 (I-J)  $R^1=R^2=O\text{-acyl}$ ,  $R^3=R^4=H$ ,  $R^5=\text{alkyl}$ ,  $R^6=\text{halogen}$  or  
 $CH_2CH_2N\text{-alkyl}$   
 15 (I-K)  $R^3=R^4=R^5=R^6=R^1=H$ ,  $R^2=-O\text{-alkyl}$ ,  $OCOCH(CH_3)C_2H_5$   
 (I-L)  $R^3=R^4=R^5=R^6=R^2=H$ ,  $R^1=-O\text{-alkyl}$ ,  $OCOCH(CH_3)C_2H_5$   
 (I-M)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=R^2=-O\text{-alkyl}$   
 (I-N)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=R^2=OCOCH(CH_3)C_2H_5$   
 (I-O)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=R^2=OCOCH_2CH(CH_3)_2$   
 20 (I-P)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=R^2=O-C(=O)-$    
 (I-Q)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=-O\text{-acyl}$ ,  $OCOCH(CH_3)C_2H_5$   
 (I-R)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=OCOCH(CH_3)C_2H_5$ ,  $R^2=-O\text{-acyl}$   
 (I-S)  $R^3=R^4=R^5=R^6=R^2=H$ ,  $R^1=-O\text{-acyl}$   
 (I-T)  $R^3=R^4=R^5=R^6=R^2=H$ ,  $R^1=OCOCH_2CH(CH_3)_2$   
 25 (I-U)  $R^2=R^3=R^4=R^5=R^6=H$ ,  $R^1=-O-CH_2-\emptyset$ , where  $\emptyset=\text{phenyl}$   
 (I-V)  $R^2=R^3=R^4=R^5=R^6=H$ ,  $R^1=OMe$   
 (I-W)  $R^2=R^3=R^4=R^5=R^6=H$ ,  $R^1=O-C(=O)-$    
 (I-X)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=OMe$ ,  $R^2=-O\text{-acyl}$   
 (I-Y)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=O-C(=O)-$    $, R^2=OCOCH_2CH(CH_3)_2$   
 30 (I-Z)  $R^3=R^4=R^5=R^6=H$ ,  $R^1=OCH_2-\emptyset$ ,  $R^2=-O\text{-acyl}$

Non-limiting examples of suksdorfin analogs according to formula (II) include the following combinations of R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup>:

(II-A) R<sup>9</sup>=R<sup>10</sup>=R<sup>11</sup>=R<sup>12</sup>=H

5 (II-B) R<sup>10</sup>=R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=alkyl

(II-C) R<sup>9</sup>=R<sup>10</sup>=R<sup>11</sup>=H, R<sup>12</sup>=alkyl, CF<sub>3</sub>, or CH<sub>2</sub>CO-alkyl

(II-D) R<sup>9</sup>=R<sup>10</sup>=R<sup>11</sup>=H, R<sup>12</sup>=CH<sub>2</sub>CONH-alkyl

(II-E) R<sup>9</sup>=R<sup>10</sup>=acyl, R<sup>11</sup>=R<sup>12</sup>=H

(II-F) R<sup>9</sup>=R<sup>10</sup>=acyl, R<sup>11</sup>=-alkyl, R<sup>12</sup>=H

10 (II-G) R<sup>9</sup>=R<sup>10</sup>=acyl, R<sup>11</sup>=H, R<sup>12</sup>=alkyl, CF<sub>3</sub>, CH<sub>2</sub>COO-alkyl

(II-H) R<sup>9</sup>=R<sup>10</sup>=acyl, R<sup>11</sup>=H, R<sup>12</sup>=CH<sub>2</sub>CONH-alkyl

(II-J) R<sup>9</sup>=R<sup>10</sup>=acyl, R<sup>11</sup>=H, R<sup>12</sup>=alkyl,


(II-K) R<sup>11</sup>=R<sup>12</sup>=R<sup>9</sup>=H, R<sup>10</sup>=alkyl, COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>

(II-L) R<sup>10</sup>=R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=alkyl, COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>

15 (II-M) R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=R<sup>10</sup>=acyl

(II-N) R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=R<sup>10</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>

(II-O) R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=R<sup>10</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>



(II-Q) R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=acyl, R<sup>10</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>


20 (II-R) R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, R<sup>10</sup>=acyl

(II-S) R<sup>11</sup>=R<sup>12</sup>=R<sup>10</sup>=H, R<sup>9</sup>=acyl


(II-T) R<sup>11</sup>=R<sup>12</sup>=R<sup>10</sup>=H, R<sup>9</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>

(II-U) R<sup>10</sup>=R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=CH<sub>2</sub>Ø, where Ø=phenyl

(II-V) R<sup>10</sup>=R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=Me



(II-X) R<sup>10</sup>=R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=Mc, R<sup>10</sup>=acyl



(II-Z) R<sup>10</sup>=R<sup>11</sup>=R<sup>12</sup>=H, R<sup>9</sup>=CH<sub>2</sub>-Ø, R<sub>10</sub>=acyl

Non-limiting examples of suksdorfin analogs according to formula (III) include the following combinations R<sup>13</sup>, R<sup>14</sup> of R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, X, Y, Z and M.

(III-A) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=R<sup>18</sup>=H, M=Y=Z=O, X=NH

5 (III-B) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>18</sup>=H, R<sup>17</sup>=alkyl, M=Y=Z=O, X=NH

(III-C) R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=R<sup>18</sup>=H, R<sup>13</sup>=O-alkyl, M=Y=Z=O, X=NH

(III-D) R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=R<sup>18</sup>=H, R<sup>13</sup>=O-CH<sub>2</sub>CONH-alkyl, M=Y=Z=O, X=NH

(III-E) R<sup>17</sup>=R<sup>18</sup>=acyl, R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, M=Y=Z=O, X=NH

(III-F) R<sup>17</sup>=R<sup>18</sup>=acyl, R<sup>16</sup>=O-alkyl, R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=H, M=Y=Z=O, X=NH

10 (III-G) R<sup>17</sup>=R<sup>18</sup>=acyl, R<sup>13</sup>=O-alkyl, O-CF<sub>3</sub>, O-CH<sub>2</sub>COO-alkyl, R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, M=Y=Z=O, X=NH

(III-H) R<sup>17</sup>=R<sup>18</sup>=acyl, R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, R<sup>13</sup>=O-CH<sub>2</sub>CONH-alkyl, M=Y=Z=O, X=NH

(III-J) R<sup>17</sup>=R<sup>18</sup>=acyl, R<sup>15</sup>=R<sup>16</sup>=H, R<sup>13</sup>=halogen or CH<sub>2</sub>CH<sub>2</sub>N-alkyl, R<sup>14</sup>=alkyl, M=Y=Z=O, X=NH


15 (III-K) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>18</sup>=H, R<sup>17</sup>=alkyl or COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Y=Z=O, X=NH

(III-L) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=H, R<sup>18</sup>=alkyl or, COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Y=Z=O, X=NH

20 (III-M) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, R<sup>17</sup>=R<sup>18</sup>=acyl, M=Y=Z=O, X=NH

(III-N) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, R<sup>17</sup>=R<sup>18</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Y=Z=O, X=NH

(III-O) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, R<sup>17</sup>=R<sup>18</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, M=Y=Z=O, X=NH

25 (III-P) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, R<sup>17</sup>=R<sup>18</sup>= , M=Y=Z=O, X=NH

(III-Q) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, R<sup>17</sup>=acyl, R<sup>18</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Y=Z=O, X=NH

30 (III-R) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=H, R<sup>18</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, R<sup>17</sup>=acyl, M=Y=Z=O, X=NH

(III-S) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=H, R<sup>18</sup>=acyl, M=Y=Z=O, X=NH

(III-T) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=H, R<sup>18</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, M=Y=Z=O, X=NH

35 (III-U) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=H, R<sup>18</sup>=CH<sub>2</sub>Ø, where Ø=phenyl, M=Y=Z=O, X=NH

(III-V) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=H, R<sup>18</sup>=Me, M=Y=Z=O, X=NH

(III-W) R<sup>13</sup>=R<sup>14</sup>=R<sup>15</sup>=R<sup>16</sup>=R<sup>17</sup>=H, R<sup>18</sup>=O- , M=Y=Z=O, X=NH

(III-X)  $R^{13}=R^{14}=R^{15}=R^{16}=H, R^{18}=Me, R^{17}=\text{acyl}, M=Y=Z=O, X=NH$

(III-Y)  $R^{13}=R^{14}=R^{15}=R^{16}=H, R^{18}=-O-\text{cyclohexyl-}O-, R^{17}=\text{COCH}_2\text{CH}(\text{CH}_3)_2, M=Y=Z=O,$   
 $X=NH$

(III-Z)  $R^{13}=R^{14}=R^{15}=R^{16}=H, R^{18}=\text{CH}_2-\emptyset, R^{17}=\text{acyl}, M=Y=Z=O, X=NH$

5 Non-limiting examples of suksdorfin analogs according to formula (IV) include the following combinations of  $R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{25}, R^{26}, Z$  and  $M$ .

(IV-A)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=R^{25}=R^{26}=H, M=Z=O, X=NH;$

(IV-B)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=R^{26}=H, R^{25}=\text{alkyl}, M=Z=O;$

10 (IV-C)  $R^{20}=R^{22}=R^{23}=R^{24}=R^{25}=R^{26}=H, R^{21}=\text{O-alkyl}, M=Z=O;$

(IV-D)  $R^{20}=R^{22}=R^{23}=R^{24}=R^{25}=R^{26}=H, R^{21}=\text{O-CH}_2\text{CONH-alkyl}, M=Z=O;$

(IV-E)  $R^{25}=R^{26}=\text{acyl}, R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, M=Z=O;$

(IV-F)  $R^{25}=R^{26}=\text{acyl}, R^{24}=\text{O-alkyl}, R^{20}=R^{21}=R^{22}=R^{23}=H, M=Z=O;$

15 (IV-G)  $R^{25}=R^{26}=\text{acyl}, R^{20}=R^{21}=R^{23}=R^{24}=H, R^{22}=\text{alkyl}, CF_3,$   
 $CH_2\text{COO-alkyl}, M=Z=O;$

(IV-H)  $R^{25}=R^{26}=\text{-acyl}, R^{20}=R^{21}=R^{23}=R^{24}=H, R^{22}=\text{CH}_2\text{CONH-alkyl}, M=Z=O;$

(IV-J)  $R^{25}=R^{26}=\text{-acyl}, R^{20}=R^{23}=R^{24}=H, R^{22}=\text{alkyl}, R^{21}=\text{halogen or}$   
 $CH_2\text{CH}_2\text{N-alkyl}, M=Z=O;$

(IV-K)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{25}=\text{alkyl}, COCH(\text{CH}_3)\text{C}_2\text{H}_5, M=Z=O;$

20 (IV-L)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{26}=\text{alkyl}, COCH(\text{CH}_3)\text{C}_2\text{H}_5, M=Z=O;$

(IV-M)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{25}=R^{26}=\text{acyl}, M=Z=O;$

(IV-N)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{25}=R^{26}=COCH(\text{CH}_3)\text{C}_2\text{H}_5, M=Z=O;$

(IV-O)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{25}=R^{26}=\text{COCH}_2\text{CH}(\text{CH}_3)_2, M=Z=O;$

(IV-P)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{25}=R^{26}=\text{---}\begin{array}{c} \text{C} \\ \text{H} \\ \text{C} \\ \text{C} \\ \text{C} \end{array}\text{---}, M=Z=O;$

25 (IV-Q)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{25}=\text{acyl}, R^{26}=COCH(\text{CH}_3)\text{C}_2\text{H}_5, M=Z=O;$

(IV-R)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H, R^{25}=COCH(\text{CH}_3)\text{C}_2\text{H}_5, R^{26}=\text{acyl}, M=Z=O;$

(IV-S)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=R^{26}=H, R^{25}=\text{acyl}, M=Z=O;$

(IV-T)  $R^{20}=R^{22}=R^{23}=R^{24}=R^{26}=H, R^{25}=COCH_2\text{CH}(\text{CH}_3)_2, M=Z=O;$

(IV-U)  $R^{20}=R^{22}=R^{23}=R^{26}=H, R^{25}=\text{CH}_2\emptyset, \text{where } \emptyset=\text{phenyl}, M=Z=O;$

30 (IV-V)  $R^{20}=R^{22}=R^{23}=R^{26}=H, R^{25}=\text{Me}, M=Z=O;$

(IV-W)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{26}=H, R^{25}=\text{---}\begin{array}{c} \text{C} \\ \text{H} \\ \text{C} \\ \text{C} \\ \text{C} \\ \text{O} \\ \text{C} \end{array}\text{---}, M=Z=O;$

(IV-X)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H$ ,  $R^{25}=Me$ ,  $R^{26}=acyl$ ,  $M=Z=O$ ;

(IV-Y)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H$ ,  $R^{25}=\text{cyclohexyl}$ ,  $R^{26}=COCH_2CH(CH_3)_2$ ,  $M=Z=O$ ;

(IV-Z)  $R^{20}=R^{21}=R^{22}=R^{23}=R^{24}=H$ ,  $R^{25}=CH_2-\emptyset$ ,  $R^{26}=acyl$ ,  $M=Z=O$ ;

Non-limiting examples of suksdorfin analogs according to  
5 formula (V) include the following combinations of  $R^{28}$ ,  $R^{29}$ ,  $R^{30}$ ,  
 $R^{31}$ ,  $R^{32}$ ,  $R^{33}$ ,  $R^{34}$ ,  $X$ ,  $Z$  and  $M$ .

(V-A)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{33}=R^{34}=H$ ,  $M=Z=O$ ,  $X=NH$

(V-B)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{34}=H$ ,  $R^{33}=\text{alkyl}$ ,  $M=Z=O$ ,  $X=NH$

(V-C)  $R^{28}=R^{30}=R^{31}=R^{32}=R^{33}=R^{34}=H$ ,  $R^{29}=O\text{-alkyl}$ ,  $M=Z=O$ ,  $X=NH$

10 (V-D)  $R^{28}=R^{30}=R^{31}=R^{32}=R^{33}=R^{34}=H$ ,  $R^{29}=O\text{-CH}_2CONH\text{-alkyl}$ ,  $M=Z=O$ ,  $X=NH$

(V-E)  $R^{33}=R^{34}=acyl$ ,  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H$ ,  $M=Z=O$ ,  $X=NH$

(V-F)  $R^{33}=R^{34}=acyl$ ,  $R^{32}=O\text{-alkyl}$ ,  $R^{28}=R^{29}=R^{30}=R^{31}=H$ ,  $M=Z=O$ ,  $X=NH$

(V-G)  $R^{33}=R^{34}=acyl$ ,  $R^{30}=\text{alkyl}$ ,  $CF_3$  or  $CH_2COO\text{-alkyl}$ ,  
 $R^{28}=R^{29}=R^{31}=R^{32}=H$ ,  $M=Z=O$ ,  $X=NH$

15 (V-H)  $R^{33}=R^{34}=acyl$ ,  $R^{28}=R^{30}=R^{31}=R^{32}=H$ ,  $R^{29}=O\text{-CH}_2CONH\text{-alkyl}$ ,  $M=Z=O$ ,  
 $X=NH$

(V-J)  $R^{33}=R^{34}=acyl$ ,  $R^{28}=R^{31}=R^{32}=H$ ,  $R^{29}=\text{halogen or } CH_2CH_2N\text{-alkyl}$ ,  
 $R^{30}=\text{alkyl}$ ,  $M=Z=O$ ,  $X=NH$

(V-K)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{34}=H$ ,  $R^{33}=\text{alkyl or } COCH(CH_3)C_2H_5$ ,  $M=Z=O$ ,  
20  $X=NH$

(V-L)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{34}=H$ ,  $R^{33}=\text{alkyl or } COCH(CH_3)C_2H_5$ ,  
 $M=Z=O$ ,  $X=NH$

(V-M)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H$ ,  $R^{33}=R^{34}=acyl$ ,  $M=Z=O$ ,  $X=NH$

(V-N)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H$ ,  $R^{33}=R^{34}=COCH(CH_3)C_2H_5$ ,  $M=Z=O$ ,  $X=NH$

25 (V-O)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H$ ,  $R^{33}=R^{34}=COCH_2CH(CH_3)_2$ ,  $M=Z=O$ ,  $X=NH$

(V-P)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H$ ,  $R^{33}=R^{34}=\text{cyclohexyl}$ ,  $M=Z=O$ ,  $X=NH$

(V-Q)  $R^{28}=R^{29}=R^{30}=R^{32}=R^{32}=H$ ,  $R^{33}=acyl$ ,  $R^{34}=COCH(CH_3)C_2H_5$ ,  $M=Z=O$ ,  
 $X=NH$

(V-R)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H$ ,  $R^{34}=COCH(CH_3)C_2H_5$ ,  $R^{33}=acyl$ ,  $M=Z=O$ ,  
30  $X=NH$

(V-S)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{33}=H$ ,  $R^{34}=acyl$ ,  $M=Z=O$ ,  $X=NH$

(V-T)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{33}=H$ ,  $R^{34}=COCH_2CH(CH_3)_2$ ,  $M=Z=O$ ,  $X=NH$

(V-U)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{33}=H$ ,  $R^{34}=\text{CH}_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  $M=Z=O$ ,  
 $X=NH$

(V-V)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{33}=H, R^{34}=Me, M=Z=O, X=NH$

(V-W)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=R^{33}=H, R^{34}=-C(=O)-C(CH_3)_2-C(CH_3)_2-C(=O)-O-$ ,  $M=Z=O, X=NH$

(V-X)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H, R^{34}=Me, R^{33}=acyl, M=Z=O, X=NH$

5 (V-Y)  $R^{28}=R^{39}=R^{30}=R^{31}=R^{32}=H, R^{34}=-C(CH_3)_2-C(=O)-$ ,  $R^{33}=COCH_2CH(CH_3)_2, M=Z=O, X=NH$

(V-Z)  $R^{28}=R^{29}=R^{30}=R^{31}=R^{32}=H, R^{34}=CH_2-\emptyset, R^{33}=acyl, M=Z=O, X=NH$

Non-limiting examples of suksdorfin analogs according to formula (VI) include the following combinations of  $R^{36}, R^{37}, R^{38}, 10 R^{39}, R^{40}, R^{41}, X, Z$  and  $M$ .

(VI-A)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{40}=R^{41}=H, M=Z=O, X=NH$

(VI-B)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{41}=H, R^{40}=alkyl, M=Z=O, X=NH$

(VI-C)  $R^{37}=R^{38}=R^{39}=R^{40}=R^{41}=H, R^{36}=O-alkyl, M=Z=O, X=NH$

(VI-D)  $R^{37}=R^{38}=R^{39}=R^{40}=R^{41}=H, R^{36}=O-CH_2CONH-alkyl, M=Z=O, X=NH$

15 (VI-E)  $R^{40}=R^{41}=acyl, R^{36}=R^{37}=R^{38}=R^{39}=H, M=Z=O, X=NH$

(VI-F)  $R^{40}=R^{41}=acyl, R^{39}=O-alkyl, R^{36}=R^{37}=R^{38}=H, M=Z=O, X=NH$

(VI-G)  $R^{40}=R^{41}=acyl, R^{36}=O-alkyl, O-CF_3, O-CH_2COO-alkyl, R^{37}=R^{38}=R^{39}=H, M=Z=O, X=NH$

(VI-H)  $R^{40}=R^{41}=acyl, R^{37}=R^{38}=R^{39}=H, R^{36}=O-CH_2CONH-alkyl, M=Z=O, X=NH$

20

(VI-J)  $R^{40}=R^{41}=acyl, R^{38}=R^{39}=H, R^{36}=halogen \text{ or } CH_2CH_2N-alkyl, R^{37}=alkyl, M=Z=O, X=NH$

(VI-K)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{41}=H, R^{40}=alkyl \text{ or } COCH(CH_3)C_2H_5, M=Z=O, X=NH$


25 (VI-L)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{40}=H, R^{41}=alkyl \text{ or, } COCH(CH_3)C_2H_5, M=Z=O, X=NH$

(VI-M)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{40}=R^{41}=acyl, M=Z=O, X=NH$

(VI-N)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{40}=R^{41}=COCH(CH_3)C_2H_5, M=Z=O, X=NH$

(VI-O)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{40}=R^{41}=COCH_2CH(CH_3)_2, M=Z=O, X=NH$

25

(VI-P)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{40}=R^{41}=$   ,  $M=Z=O, X=NH$

(VI-Q)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{40}=acyl, R^{41}=COCH(CH_3)C_2H_5, M=Z=O, X=NH$


(VI-R)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{41}=COCH(CH_3)C_2H_5, R^{41}=acyl, M=Z=O, X=NH$

(VI-S)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{40}=H, R^{41}=acyl, M=Z=O, X=NH$

5 (VI-T)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{40}=H, R^{41}=COCH_2CH(CH_3)_2, M=Z=O, X=NH$

(VI-U)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{40}=H, R^{41}=CH_2\emptyset, \text{ where } \emptyset=\text{phenyl}, M=Z=O,$   
 $X=NH$

(VI-V)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{40}=H, R^{41}=Me, M=Z=O, X=NH$

10 (VI-W)  $R^{36}=R^{37}=R^{38}=R^{39}=R^{40}=H, R^{41}=$   ,  $M=Z=O,$   
 $X=NH$

(VI-X)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{41}=Me, R^{40}=acyl, M=Z=O, X=NH$

(VI-Y)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{41}=$   ,  $R^{40}=COCH_2CH(CH_3)_2, M=Z=O,$   
 $X=NH$

(VI-Z)  $R^{36}=R^{37}=R^{38}=R^{39}=H, R^{41}=CH_2\emptyset, R^{40}=acyl, M=Z=O, X=NH$

15 Non-limiting examples of suksdorfin analogs according to formula (VII) include the following combinations of  $R^{43}, R^{44}, R^{45},$   
 $R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, Z$  and  $M$ .

(VII-A)  $R^{43}=R^{44}=R^{45}=R^{46}=R^{47}=R^{48}=R^{49}=R^{50}=H, M=Z=O;$

(VII-B)  $R^{43}=R^{44}=R^{45}=R^{46}=R^{47}=R^{48}=R^{50}=H, R^{49}\text{=alkyl, } M=Z=O;$

20 (VII-C)  $R^{43}=R^{44}=R^{46}=R^{47}=R^{48}=R^{49}=R^{50}=H, R^{45}\text{=O-alkyl, } M=Z=O;$

(VII-D)  $R^{43}=R^{44}=R^{46}=R^{47}=R^{48}=R^{49}=R^{50}=H, R^{45}\text{=O-CH}_2CONH\text{-alkyl, } M=Z=O;$

(VII-E)  $R^{49}=R^{50}\text{=acyl, } R^{43}=R^{44}=R^{45}=R^{46}=R^{47}=R^{48}=H, M=Z=O;$

(VII-F)  $R^{49}=R^{50}\text{=acyl, } R^{48}\text{=O-alkyl, } R^{43}=R^{44}=R^{45}=R^{46}=R^{47}=H, M=Z=O;$

25 (VII-G)  $R^{49}=R^{50}\text{=acyl, } R^{45}\text{=O-alkyl, } O-CF_3, O-CH_2COO\text{-alkyl, }$   
 $R^{43}=R^{44}=R^{46}=R^{47}=R^{48}=H, M=Z=O;$

(VII-H)  $R^{49}=R^{50}\text{=acyl, } R^{43}=R^{44}=R^{46}=R^{47}=R^{48}=H, R^{45}\text{=O-CH}_2CONH\text{-alkyl, }$   
 $M=Z=O;$

(VII-J)  $R^{49}=R^{50}\text{=acyl, } R^{47}=R^{48}=H, R^{45}\text{=halogen or } CH_2CH_2N\text{-alkyl, }$   
 $R^{46}\text{=alkyl, } M=Z=O;$


30 (VII-K)  $R^{45}=R^{46}=R^{47}=R^{48}=R^{50}=H, R^{49}\text{=alkyl or } COCH(CH_3)C_2H_5, M=Z=O;$

(VII-L)  $R^{45}=R^{46}=R^{47}=R^{48}=R^{49}=H, R^{50}\text{=alkyl or, } COCH(CH_3)C_2H_5, M=Z=O;$

(VII-M)  $R^{45}=R^{46}=R^{47}=R^{48}=H, R^{49}=R^{50}\text{=acyl, } M=Z=O;$

(VII-N)  $R^{45}=R^{46}=R^{47}=R^{48}=H, R^{49}=R^{50}=COCH(CH_3)C_2H_5, M=Z=O;$

(VII-O)  $R^{45}=R^{46}=R^{47}=R^{48}=H$ ,  $R^{49}=R^{50}=COCH_2CH(CH_3)_2$ ,  $M=Z=O$ ;



(VII-Q)  $R^{45}=R^{46}=R^{47}=R^{48}=H$ ,  $R^{49}=\text{acyl}$ ,  $R^{50}=COCH(CH_3)C_2H_5$ ,  $M=Z=O$ ;


(VII-R)  $R^{45}=R^{46}=R^{47}=R^{48}=H$ ,  $R^{50}=COCH(CH_3)C_2H_5$ ,  $R^{49}=\text{acyl}$ ,  $M=Z=O$ ;

5 (VII-S)  $R^{45}=R^{46}=R^{47}=R^{48}=R^{49}=H$ ,  $R^{50}=\text{acyl}$ ,  $M=Z=O$ ;


(VII-T)  $R^{45}=R^{46}=R^{47}=R^{48}=R^{49}=H$ ,  $R^{50}=COCH_2CH(CH_3)_2$ ,  $M=Z=O$ ;

(VII-U)  $R^{45}=R^{46}=R^{47}=R^{48}=R^{49}=H$ ,  $R^{50}=CH_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  $M=Z=O$ ;

(VII-V)  $R^{45}=R^{46}=R^{47}=R^{48}=R^{49}=H$ ,  $R^{50}=Me$ ,  $M=Z=O$ ;



10 (VII-X)  $R^{45}=R^{46}=R^{47}=R^{48}=H$ ,  $R^{50}=Me$ ,  $R^{49}=\text{acyl}$ ,  $M=Z=O$ ;



(VII-Z)  $R^{45}=R^{46}=R^{47}=R^{48}=H$ ,  $R^{50}=CH_2\emptyset$ ,  $R^{49}=\text{acyl}$ ,  $M=Z=O$ ;

Non-limiting examples of suksdorfin analogs according to  
15 formula (VIII) include the following combinations of  $R^{52}$ ,  $R^{53}$ ,  
 $R^{54}$ ,  $R^{55}$ ,  $R^{57}$ ,  $X$ ,  $Y$ ,  $Z$  and  $M$ .

(VIII-A)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{56}=R^{57}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(VIII-B)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{57}=H$ ,  $R^{56}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(VIII-C)  $R^{52}=R^{54}=R^{55}=R^{56}=R^{57}=H$ ,  $R^{53}=O\text{-alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

20 (VIII-D)  $R^{52}=R^{54}=R^{55}=R^{56}=R^{57}=H$ ,  $R^{53}=O\text{-CH}_2CONH\text{-alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(VIII-E)  $R^{56}=R^{57}=\text{acyl}$ ,  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(VIII-F)  $R^{56}=R^{57}=\text{acyl}$ ,  $R^{55}=O\text{-alkyl}$ ,  $R^{52}=R^{53}=R^{54}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(VIII-G)  $R^{56}=R^{57}=\text{acyl}$ ,  $R^{53}=O\text{-alkyl}$ ,  $O\text{-CF}_3$ ,  $O\text{-CH}_2COO\text{-alkyl}$ ,  
 $R^{52}=R^{54}=R^{55}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

25 (VIII-H)  $R^{56}=R^{57}=\text{acyl}$ ,  $R^{52}=R^{54}=R^{55}=H$ ,  $R^{53}=O\text{-CH}_2CONH\text{-alkyl}$ ,  $M=Y=Z=O$ ,  
 $X=NH$

(VIII-J)  $R^{56}=R^{57}=\text{acyl}$ ,  $R^{52}=R^{55}=H$ ,  $R^{53}=\text{halogen or } CH_2CH_2N\text{-alkyl}$ ,  
 $R^{54}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$


(VIII-K)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{57}=H$ ,  $R^{56}$ =alkyl or  $COCH(CH_3)C_2H_5$ ,  $M=Y=Z=0$ ,  $X=NH$

(VIII-L)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{57}=H$ ,  $R^{56}$ =alkyl or,  $COCH(CH_3)C_2H_5$ ,  $M=Y=Z=0$ ,  $X=NH$

5 (VIII-M)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{56}=R^{57}$ =acyl,  $M=Y=Z=0$ ,  $X=NH$

(VIII-N)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{56}=R^{57}=COCH(CH_3)C_2H_5$ ,  $M=Y=Z=0$ ,  $X=NH$

(VIII-O)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{56}=R^{57}=COCH_2CH(CH_3)_2$ ,  $M=Y=Z=0$ ,  $X=NH$

(VIII-P)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{56}=R^{57}=$   ,  $M=Y=Z=0$ ,  $X=NH$

(VIII-Q)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{56}$ =acyl,  $R^{57}=COCH(CH_3)C_2H_5$ ,  $M=Y=Z=0$ ,  $X=NH$


10 (VIII-R)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{57}=COCH(CH_3)C_2H_5$ ,  $R^{56}$ =acyl,  $M=Y=Z=0$ ,  $X=NH$

(VIII-S)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{56}=H$ ,  $R^{57}$ =acyl,  $M=Y=Z=0$ ,  $X=NH$

(VIII-T)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{56}=H$ ,  $R^{57}=COCH_2CH(CH_3)_2$ ,  $M=Y=Z=0$ ,  $X=NH$

15 (VIII-U)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{56}=H$ ,  $R^{57}=CH_2\emptyset$ , where  $\emptyset$ =phenyl,  $M=Y=Z=0$ ,  $X=NH$

(VIII-V)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{56}=H$ ,  $R^{57}=Me$ ,  $M=Y=Z=0$ ,  $X=NH$

(VIII-W)  $R^{52}=R^{53}=R^{54}=R^{55}=R^{56}=H$ ,  $R^{57}=C-$   ,  $M=Y=Z=0$ ,  $X=NH$

20 (VIII-X)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{57}=Me$ ,  $R^{56}$ =acyl,  $M=Y=Z=0$ ,  $X=NH$

(VIII-Y)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{57}=$   ,  $R^{56}=COCH_2CH(CH_3)_2$ ,  $M=Y=Z=0$ ,  $X=NH$


(VIII-Z)  $R^{52}=R^{53}=R^{54}=R^{55}=H$ ,  $R^{57}=CH_2-\emptyset$ ,  $R^{56}$ =acyl,  $M=Y=Z=0$ ,  $X=NH$

Non-limiting examples of suksdorfin analogs according to  
25 formula (IX) include the following combinations of  $R^{59}$ ,  $R^{60}$ ,  $R^{61}$ ,  $R^{62}$ ,  $R^{63}$ ,  $R^{64}$ ,  $Z$  and  $M$ .


(IX-A)  $R^{59}=R^{60}=R^{61}=R^{62}=R^{63}=R^{64}=H$ ,  $M=Z=O$ ;

(IX-B)  $R^{59}=R^{60}=R^{61}=R^{62}=R^{64}=H$ ,  $R^{63}$ =alkyl,  $M=Z=O$ ;

(IX-C)  $R^{60}=R^{61}=R^{62}=R^{63}=R^{64}=H, R^{59}=O\text{-alkyl}, M=Z=O;$   
 (IX-D)  $R^{60}=R^{61}=R^{62}=R^{63}=R^{64}=H, R^{59}=O\text{-CH}_2\text{CONH-alkyl}, M=Z=O;$   
 (IX-E)  $R^{63}=R^{64}=\text{acyl}, R^{59}=R^{60}=R^{61}=R^{62}=H, M=Z=O;$   
 (IX-F)  $R^{63}=R^{64}=\text{acyl}, R^{62}=O\text{-alkyl}, R^{59}=R^{60}=R^{61}=H, M=Z=O;$   
 5 (IX-G)  $R^{63}=R^{64}=\text{acyl}, R^{59}=O\text{-alkyl}, O\text{-CF}_3, O\text{-CH}_2\text{COO-alkyl}, R^{60}=R^{61}=R^{62}=H, M=Z=O;$   
 (IX-H)  $R^{63}=R^{64}=\text{acyl}, R^{60}=R^{61}=R^{62}=H, R^{59}=O\text{-CH}_2\text{CONH-alkyl}, M=Z=O;$   
 (IX-J)  $R^{63}=R^{64}=\text{acyl}, R^{61}=R^{62}=H, R^{59}=\text{halogen or CH}_2\text{CH}_2\text{N-alkyl}, R^{60}=\text{alkyl}, M=Z=O;$   
 10 (IX-K)  $R^{59}=R^{60}=R^{61}=R^{62}=R^{64}=H, R^{63}=\text{alkyl or COCH(CH}_3\text{)C}_2\text{H}_5, M=Z=O;$   
 (IX-L)  $R^{59}=R^{60}=R^{61}=R^{62}=R^{63}=H, R^{69}=\text{alkyl or, COCH(CH}_3\text{)C}_2\text{H}_5, M=Z=O;$   
 (IX-M)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{63}=R^{64}=\text{acyl}, M=Z=O;$   
 (IX-N)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{63}=R^{64}=\text{COCH(CH}_3\text{)C}_2\text{H}_5, M=Z=O;$   
 (IX-O)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{63}=R^{64}=\text{COCH}_2\text{CH(CH}_3\text{)}_2, M=Z=O;$



(IX-Q)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{63}=\text{acyl}, R^{64}=\text{COCH(CH}_3\text{)C}_2\text{H}_5, M=Z=O;$   
 (IX-R)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{64}=\text{COCH(CH}_3\text{)C}_2\text{H}_5, R^{63}=\text{acyl}, M=Z=O;$   
 (IX-S)  $R^{59}=R^{60}=R^{61}=R^{62}=R^{63}=H, R^{64}=\text{acyl}, M=Z=O;$   
 (IX-T)  $R^{59}=R^{60}=R^{61}=R^{62}=R^{63}=H, R^{64}=\text{COCH}_2\text{CH(CH}_3\text{)}_2, M=Z=O;$   
 20 (IX-U)  $R^{59}=R^{60}=R^{62}=R^{63}=R^{64}=H, R^{65}=\text{CH}_2\text{O}, \text{ where O=phenyl, M=Z=O;}$   
 (IX-V)  $R^{59}=R^{60}=R^{61}=R^{62}=R^{63}=H, R^{64}=\text{Me, M=Z=O;}$



(IX-X)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{64}=\text{Me, R}^{63}=\text{acyl, M=Z=O, X=NH}$   
 (IX-Y)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{64}=-\text{C}(\text{O})-\text{C}(\text{O})-\text{C}(\text{O})-$   , R<sup>63</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 25 M=Z=O;  
 (IX-Z)  $R^{59}=R^{60}=R^{61}=R^{62}=H, R^{64}=\text{CH}_2\text{-O, R}^{63}=\text{acyl, M=Z=O;}$

Non-limiting examples of suksdorfin analogs according to formula (X) include the following combinations of R<sup>60</sup>, R<sup>67</sup>, R<sup>68</sup>, R<sup>69</sup>, R<sup>70</sup>, Z and M.

(X-A) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>69</sup>=R<sup>70</sup>=H, M=Z=O;

5 (X-B) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>70</sup>=H, R<sup>69</sup>=alkyl, M=Z=O;

(X-C) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>69</sup>=H, R<sup>70</sup>=O-alkyl, M=Z=O;

(X-D) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>69</sup>=H, R<sup>70</sup>=O-CH<sub>2</sub>CONH-alkyl, M=Z=O;

(X-E) R<sup>68</sup>=R<sup>69</sup>=acyl, R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, M=Z=O;

(X-F) R<sup>68</sup>=R<sup>69</sup>=acyl, R<sup>67</sup>=O-alkyl, R<sup>66</sup>=R<sup>70</sup>=H, M=Z=O;

10 (X-G) R<sup>68</sup>=R<sup>69</sup>=acyl, R<sup>70</sup>=O-alkyl, O-CF<sub>3</sub>, O-CH<sub>2</sub>COO-alkyl, R<sup>66</sup>=R<sup>67</sup>=H, M=Z=O;

(X-H) R<sup>68</sup>=R<sup>69</sup>=acyl, R<sup>66</sup>=R<sup>67</sup>=H, R<sup>70</sup>=O-CH<sub>2</sub>CONH-alkyl, M=Z=O;

(X-J) R<sup>68</sup>=R<sup>69</sup>=acyl, R<sup>67</sup>=H, R<sup>70</sup>=halogen or CH<sub>2</sub>CH<sub>2</sub>N-alkyl, R<sup>66</sup>=alkyl, M=Z=O;


15 (X-K) R<sup>66</sup>=R<sup>67</sup>=R<sup>69</sup>=R<sup>70</sup>=H, R<sup>68</sup>=alkyl or COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Z=O;

(X-L) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>70</sup>=H, R<sup>69</sup>=alkyl or COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Z=O;

(X-M) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>68</sup>=R<sup>69</sup>=acyl, M=Z=O;

(X-N) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>68</sup>=R<sup>69</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Z=O;

(X-O) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>68</sup>=R<sup>69</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, M=Z=O;

20 (X-P) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>68</sup>=R<sup>69</sup>=  , M=Z=O;

(X-Q) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>68</sup>=acyl, R<sup>69</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, M=Z=O;


(X-R) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>69</sup>=COCH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, R<sup>68</sup>=acyl, M=Z=O;

(X-S) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>70</sup>=H, R<sup>69</sup>=acyl, M=Z=O;

(X-T) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>70</sup>=H, R<sup>69</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, M=Z=O;

25 (X-U) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>70</sup>=H, R<sup>69</sup>=CH<sub>2</sub>Ø, where Ø=phenyl, M=Z=O;

(X-V) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>70</sup>=H, R<sup>69</sup>=Me, M=Z=O;

(X-W) R<sup>66</sup>=R<sup>67</sup>=R<sup>68</sup>=R<sup>70</sup>=H, R<sup>69</sup>=  , M=Z=O;

(X-X) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>69</sup>=Me, R<sup>68</sup>=acyl, M=Z=O;

(X-Y) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>69</sup>=  , R<sup>68</sup>=COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, M=Z=O;

30 (X-Z) R<sup>66</sup>=R<sup>67</sup>=R<sup>70</sup>=H, R<sup>69</sup>=CH<sub>2</sub>-Ø, R<sup>68</sup>=acyl, M=Z=O;

Non-limiting examples of suksdorfin analogs according to formula (XI) include the following combinations of  $R^{72}$ ,  $R^{73}$ ,  $R^{74}$ ,  $R^{75}$ ,  $X$ ,  $Y$ ,  $Z$  and  $M$ .

5 (XI-A)  $R^{72}=R^{73}=R^{74}=R^{75}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-B)  $R^{72}=R^{73}=R^{75}=H$ ,  $R^{74}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-C)  $R^{72}=R^{73}=R^{74}=R^{75}=H$ ,  $R^{72}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-D)  $R^{72}=R^{74}=R^{75}=H$ ,  $R^{72}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-E)  $R^{74}=R^{75}=\text{acyl}$ ,  $R^{72}=R^{73}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-F)  $R^{74}=R^{75}=\text{acyl}$ ,  $R^{73}=O\text{-alkyl}$ ,  $R^{72}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

10 (XI-G)  $R^{74}=R^{75}=\text{acyl}$ ,  $R^{72}=O\text{-alkyl}$ ,  $O\text{-CF}_3$ ,  $O\text{-CH}_2\text{COO-alkyl}$ ,  $R^{73}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-H)  $R^{74}=R^{75}=\text{acyl}$ ,  $R^{73}=H$ ,  $R^{72}=O\text{-CH}_2\text{CONH-alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-J)  $R^{74}=R^{75}=\text{acyl}$ ,  $R^{72}=\text{halogen or } \text{CH}_2\text{CH}_2\text{N-alkyl}$ ,  $R^{73}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$


15 (XI-K)  $R^{72}=R^{73}=R^{75}=H$ ,  $R^{74}=\text{alkyl or } \text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-L)  $R^{72}=R^{73}=R^{74}=H$ ,  $R^{75}=\text{alkyl or } \text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-M)  $R^{72}=R^{73}=H$ ,  $R^{74}=R^{75}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-N)  $R^{72}=R^{73}=H$ ,  $R^{74}=R^{75}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-O)  $R^{72}=R^{73}=H$ ,  $R^{74}=R^{75}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Y=Z=O$ ,  $X=NH$



(XI-Q)  $R^{72}=R^{73}=H$ ,  $R^{74}=\text{acyl}$ ,  $R^{75}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$


(XI-R)  $R^{72}=R^{73}=H$ ,  $R^{75}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $R^{74}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XI-S)  $R^{72}=R^{73}=R^{74}=H$ ,  $R^{75}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$


(XI-T)  $R^{72}=R^{73}=R^{74}=H$ ,  $R^{75}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Y=Z=O$ ,  $X=NH$

25 (XI-U)  $R^{72}=R^{73}=R^{74}=H$ ,  $R^{75}=\text{CH}_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  $M=Y=Z=O$ ,  $X=NH$




















(XI-V)  $R^{72}=R^{73}=R^{74}=H$ ,  $R^{75}=\text{Me}$ ,  $M=Y=Z=O$ ,  $X=NH$



(XI-X)  $R^{72}=R^{73}=H$ ,  $R^{75}=\text{Me}$ ,  $R^{74}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$



Non-limiting examples of suksdorfin analogs according to  
5 formula (XII) include the following combinations of  $R^{77}$ ,  $R^{78}$ ,  $R^{79}$ ,  
 $R^{80}$ ,  $R^{81}$ ,  $R^{82}$ ,  $R^{83}$ ,  $R^{84}$ ,  $Z$  and  $M$ .



(XII-V)  $R^{77}=R^{78}=R^{79}=R^{80}=R^{81}=R^{82}=R^{83}=H$ ,  $R^{84}=Me$ ,  $M=Z=O$ ;

(XII-W)  $R^{77}=R^{78}=R^{79}=R^{80}=R^{81}=R^{82}=R^{83}=H$ ,  $R^{84}=-\text{C}(=\text{O})-\text{C}(\text{CH}_3)(\text{CH}_2)-\text{C}(=\text{O})-$   
 $M=Z=O$ ;

(XII-X)  $R^{77}=R^{78}=R^{79}=R^{80}=R^{81}=R^{82}=H$ ,  $R^{84}=Me$ ,  $R^{83}=\text{acyl}$ ,  $M=Z=O$ ;

5 (XII-Y)  $R^{77}=R^{78}=R^{79}=R^{80}=R^{81}=R^{82}=H$ ,  $R^{84}=-\text{C}(\text{CH}_3)(\text{CH}_2)-$   
 $R^{83}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Z=O$ ;

(XII-Z)  $R^{77}=R^{78}=R^{79}=R^{80}=R^{81}=R^{82}=H$ ,  $R^{84}=\text{CH}_2-\emptyset$ ,  $R^{83}=\text{acyl}$ ,  $M=Z=O$ ;

Non-limiting examples of suksdorfin analogs according to formula (XIII) include the following combinations of  $R^{86}$ ,  $R^{87}$ ,  
10  $R^{88}$ ,  $R^{89}$ ,  $R^{90}$ ,  $R^{91}$ ,  $R^{92}$ ,  $R^{93}$ ,  $R^{94}$ ,  $R^{95}$  and  $M$ .

(XIII-A)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{94}=R^{95}=H$ ,  $M=O$ ;

(XIII-B)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{95}=H$ ,  $R^{94}=\text{alkyl}$ ,  $M=O$ ;

(XIII-C)  $R^{86}=R^{87}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{94}=R^{95}=H$ ,  $R^{88}=\text{O-alkyl}$ ,  $M=O$ ;

(XIII-D)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{91}=R^{92}=R^{93}=R^{94}=R^{95}=H$ ,  $R^{88}=\text{O-CH}_2\text{CONH-alkyl}$ ,  
15  $M=O$ ;

(XIII-E)  $R^{94}=R^{95}=\text{acyl}$ ,  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $M=Y=Z=O$ ;

(XIII-F)  $R^{94}=R^{95}=\text{acyl}$ ,  $R^{93}=\text{O-alkyl}$ ,  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=H$ ,  $M=O$ ;

(XIII-G)  $R^{94}=R^{95}=\text{acyl}$ ,  $R^{88}=\text{O-alkyl}$ ,  $O-\text{CF}_3$ ,  $O-\text{CH}_2\text{COO-alkyl}$ ,  
20  $R^{86}=R^{87}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $M=O$ ;

(XIII-H)  $R^{94}=R^{95}=\text{acyl}$ ,  $R^{86}=R^{87}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{88}=\text{O-CH}_2\text{CONH-alkyl}$ ,  $M=O$ ;

(XIII-J)  $R^{94}=R^{95}=\text{acyl}$ ,  $R^{86}=R^{87}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{88}=\text{halogen}$  or  
 $\text{CH}_2\text{CH}_2\text{N-alkyl}$ ,  $R^{89}=\text{alkyl}$ ,  $M=O$ ;


25 (XIII-K)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{94}=\text{alkyl}$  or  $\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  
 $M=O$ ;

(XIII-L)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{94}=H$ ,  $R^{95}=\text{alkyl}$  or,  
 $\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=O$ ;

(XIII-M)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{94}=R^{95}=\text{acyl}$ ,  $M=O$ ;

30 (XIII-N)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{94}=R^{95}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=O$ ;

(XIII-O)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{94}=R^{95}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=O$ ;



(XIII-Q)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{94}=\text{acyl}$ ,  $R^{95}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=O$ ;


(XIII-R)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{95}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $R^{94}=\text{acyl}$ ,  $M=O$ ;

(XIII-S)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{94}=H$ ,  $R^{95}=\text{acyl}$ ,  $M=O$ ;

(XIII-T)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{94}=H$ ,  $R^{95}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=O$ ;

(XIII-U)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{94}=H$ ,  $R^{95}=\text{CH}_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  $M=O$ ;

(XIII-V)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=R^{94}=H$ ,  $R^{95}=\text{Me}$ ,  $M=O$ ;



(XIII-X)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{95}=\text{Me}$ ,  $R^{94}=\text{acyl}$ ,  $M=O$ ;

(XIII-Y)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{95}=-\text{O}-\text{C}_6\text{H}_4-$ ,  $R^{94}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=O$ ;

(XIII-Z)  $R^{86}=R^{87}=R^{88}=R^{89}=R^{90}=R^{91}=R^{92}=R^{93}=H$ ,  $R^{95}=\text{CH}_2\emptyset$ ,  $R^{94}=\text{acyl}$ ,  $M=O$ ;

Non-limiting examples of suksdorfin analogs according to formula (XIV) include the following combinations of  $R^{97}$ ,  $R^{98}$ ,  $R^{99}$ ,  $R^{100}$ ,  $X$ ,  $Y$ ,  $Z$  and  $M$ .

(XIV-A)  $R^{97}=R^{98}=R^{99}=R^{100}=H$ ,  $M=Y=Z=O$ ,  $X=\text{NH}$

(XIV-B)  $R^{97}=R^{98}=R^{100}=H$ ,  $R^{99}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=\text{NH}$

(XIV-C)  $R^{98}=R^{99}=R^{100}=H$ ,  $R^{97}=\text{O-alkyl}$ ,  $M=Y=Z=O$ ,  $X=\text{NH}$

(XIV-D)  $R^{14}=R^{15}=R^{16}=R^{17}=R^{18}=H$ ,  $R^{97}=\text{O-CH}_2\text{CONH-alkyl}$ ,  $M=Y=Z=O$ ,  $X=\text{NH}$

(XIV-E)  $R^{99}=R^{100}=\text{acyl}$ ,  $R^{97}=R^{14}=R^{15}=R^{16}=H$ ,  $M=Y=Z=O$ ,  $X=\text{NH}$

(XIV-F)  $R^{99}=R^{100}=\text{acyl}$ ,  $R^{98}=\text{O-alkyl}$ ,  $R^{97}=H$ ,  $M=Y=Z=O$ ,  $X=\text{NH}$

(XIV-G)  $R^{99}=R^{100}=\text{acyl}$ ,  $R^{97}=\text{O-alkyl}$ ,  $\text{O-CF}_3$ ,  $\text{O-CH}_2\text{COO-alkyl}$ ,  $R^{98}=H$ ,  $M=Y=Z=O$ ,  $X=\text{NH}$

(XIV-H)  $R^{99}=R^{100}=\text{acyl}$ ,  $R^{98}=\text{H}$ ,  $R^{97}=\text{O}-\text{CH}_2\text{CONH-alkyl}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$   
 (XIV-J)  $R^{99}=R^{100}=\text{acyl}$ ,  $R^{97}=\text{halogen or } \text{CH}_2\text{CH}_2\text{N-alkyl}$ ,  $R^{98}=\text{alkyl}$ ,  
 $M=Y=Z=\text{O}$ ,  $X=\text{NH}$


(XIV-K)  $R^{97}=R^{98}=R^{100}=\text{H}$ ,  $R^{99}=\text{alkyl or } \text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

5 (XIV-L)  $R^{97}=R^{98}=R^{99}=\text{H}$ ,  $R^{100}=\text{alkyl or, } \text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

(XIV-M)  $R^{97}=R^{98}=\text{H}$ ,  $R^{99}=R^{100}=\text{acyl}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

(XIV-N)  $R^{97}=R^{98}=\text{H}$ ,  $R^{99}=R^{100}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

(XIV-O)  $R^{97}=R^{98}=\text{H}$ ,  $R^{99}=R^{100}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$



10 (XIV-Q)  $R^{97}=R^{98}=\text{H}$ ,  $R^{99}=\text{acyl}$ ,  $R^{100}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$


(XIV-R)  $R^{97}=R^{98}=\text{H}$ ,  $R^{100}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $R^{99}=\text{acyl}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

(XIV-S)  $R^{97}=R^{98}=R^{99}=\text{H}$ ,  $R^{100}=\text{acyl}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

(XIV-T)  $R^{97}=R^{98}=R^{99}=\text{H}$ ,  $R^{100}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

(XIV-U)  $R^{97}=R^{98}=R^{99}=\text{H}$ ,  $R^{100}=\text{CH}_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

15 (XIV-V)  $R^{97}=R^{98}=R^{99}=\text{H}$ ,  $R^{100}=\text{Me}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$



(XIV-X)  $R^{97}=R^{98}=\text{H}$ ,  $R^{100}=\text{Me}$ ,  $R^{99}=\text{acyl}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$



20 (XIV-Z)  $R^{97}=R^{98}=\text{H}$ ,  $R^{100}=\text{CH}_2\emptyset$ ,  $R^{99}=\text{acyl}$ ,  $M=Y=Z=\text{O}$ ,  $X=\text{NH}$

Non-limiting examples of suksdorfin analogs according to formula (XV) include the following combinations of  $R^{102}$ ,  $R^{103}$ ,  $R^{104}$ ,  $R^{105}$ ,  $R^{106}$ ,  $R^{107}$ ,  $X$ ,  $Z$  and  $M$ .


(XV-A)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{106}=R^{107}=\text{H}$ ,  $M=Z=\text{O}$ ,  $X=\text{NH}$

25 (XV-B)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{107}=\text{H}$ ,  $R^{106}=\text{alkyl}$ ,  $M=Z=\text{O}$ ,  $X=\text{NH}$


(XV-C)  $R^{103}=R^{104}=R^{105}=R^{106}=R^{107}=\text{H}$ ,  $R^{102}=\text{O-alkyl}$ ,  $M=Z=\text{O}$ ,  $X=\text{NH}$

(XV-D)  $R^{103}=R^{104}=R^{105}=R^{106}=R^{107}=\text{H}$ ,  $R^{102}=\text{O-CH}_2\text{CONH-alkyl}$ ,  $M=Z=\text{O}$ ,  $X=\text{NH}$

(XV-E)  $R^{106}=R^{107}=\text{acyl}$ ,  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $M=Z=O$ ,  $X=NH$   
 (XV-F)  $R^{106}=R^{107}=\text{acyl}$ ,  $R^{103}=O\text{-alkyl}$ ,  $R^{102}=R^{103}=R^{104}=H$ ,  $M=Z=O$ ,  $X=NH$   
 (XV-G)  $R^{106}=R^{107}=\text{acyl}$ ,  $R^{102}=O\text{-alkyl}$ ,  $O\text{-CF}_3$ ,  $O\text{-CH}_2\text{COO}\text{-alkyl}$ ,  
 $R^{103}=R^{104}=R^{105}=H$ ,  $M=Z=O$ ,  $X=NH$   
 5 (XV-H)  $R^{106}=R^{107}=\text{acyl}$ ,  $R^{103}=R^{104}=R^{105}=H$ ,  $R^{102}=O\text{-CH}_2\text{CONH}\text{-alkyl}$ ,  $M=Z=O$ ,  
 $X=NH$   
 (XV-J)  $R^{106}=R^{107}=\text{acyl}$ ,  $R^{104}=R^{105}=H$ ,  $R^{102}=\text{halogen or } \text{CH}_2\text{CH}_2\text{N}\text{-alkyl}$ ,  
 $R^{103}=\text{alkyl}$ ,  $M=Z=O$ ,  $X=NH$   
 (XV-K)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{107}=H$ ,  $R^{106}=\text{alkyl or } \text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Z=O$ ,  
 10  $X=NH$   
 (XV-L)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{106}=H$ ,  $R^{107}=\text{alkyl or, } \text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  
 $M=Z=O$ ,  $X=NH$   
 (XV-M)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{106}=R^{107}=\text{acyl}$ ,  $M=Z=O$ ,  $X=NH$   
 (XV-N)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{106}=R^{107}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Z=O$ ,  $X=NH$   
 15 (XV-O)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{106}=R^{107}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Z=O$ ,  $X=NH$



(XV-Q)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{106}=\text{acyl}$ ,  $R^{107}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Z=O$ ,  
 $X=NH$   
 (XV-R)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{107}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $R^{106}=\text{acyl}$ ,  $M=Z=O$ ,  
 20  $X=NH$   
 (XV-S)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{106}=H$ ,  $R^{107}=\text{acyl}$ ,  $M=Z=O$ ,  $X=NH$   
 (XV-T)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{106}=H$ ,  $R^{107}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Z=O$ ,  $X=NH$   
 (XV-U)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{106}=H$ ,  $R^{107}=\text{CH}_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  $M=Z=O$ ,  
 $X=NH$   
 25 (XV-V)  $R^{102}=R^{103}=R^{104}=R^{105}=R^{106}=H$ ,  $R^{107}=\text{Me}$ ,  $M=Z=O$ ,  $X=NH$



(XV-X)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{107}=\text{Me}$ ,  $R^{106}=\text{acyl}$ ,  $M=Z=O$ ,  $X=NH$   
 (XV-Y)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{107}=\text{cyclohexyl}$ ,  
 30  $R^{106}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Z=O$ ,  $X=NH$

(XV-Z)  $R^{102}=R^{103}=R^{104}=R^{105}=H$ ,  $R^{107}=CH_2-\emptyset$ ,  $R^{106}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

Non-limiting examples of suksdorfin analogs according to formula (XVI) include the following combinations of  $R^{109}$ ,  $R^{110}$ ,  $R^{111}$ ,  $R^{112}$ ,  $R^{113}$ ,  $R^{114}$ ,  $X$ ,  $Y$ ,  $Z$ , and  $M$ .

5 (XVI-A)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{113}=R^{114}=H$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-B)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{114}=H$ ,  $R^{113}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-C)  $R^{110}=R^{111}=R^{112}=R^{113}=R^{114}=H$ ,  $R^{109}=O\text{-alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-D)  $R^{110}=R^{111}=R^{112}=R^{113}=R^{114}=H$ ,  $R^{109}=O\text{-CH}_2\text{CONH-alkyl}$ ,  $M=Y=Z=O$ ,  
 $X=NH$




10 (XVI-E)  $R^{113}=R^{114}=\text{acyl}$ ,  $R^{109}=R^{110}=R^{111}=R^{112}=H$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-F)  $R^{113}=R^{114}=\text{acyl}$ ,  $R^{112}=O\text{-alkyl}$ ,  $R^{109}=R^{110}=R^{111}=H$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-G)  $R^{113}=R^{114}=\text{acyl}$ ,  $R^{109}=O\text{-alkyl}$ ,  $O\text{-CF}_3$ ,  $O\text{-CH}_2\text{COO-alkyl}$ ,  
 $R^{110}=R^{111}=R^{112}=H$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-H)  $R^{113}=R^{114}=\text{acyl}$ ,  $R^{110}=R^{111}=R^{112}=H$ ,  $R^{109}=O\text{-CH}_2\text{CONH-alkyl}$ ,  
 15  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-J)  $R^{113}=R^{114}=\text{acyl}$ ,  $R^{111}=R^{112}=H$ ,  $R^{109}=\text{halogen or CH}_2\text{CH}_2\text{N-alkyl}$ ,  
 $R^{110}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-K)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{114}=H$ ,  $R^{113}=\text{alkyl or COCH(CH}_3\text{)C}_2\text{H}_5$ ,  
 $M=Y=Z=O$ ,  $X=NH$

20 (XVI-L)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{113}=H$ ,  $R^{114}=\text{alkyl or COCH(CH}_3\text{)C}_2\text{H}_5$ ,  
 $M=Y=Z=O$ ,  $X=NH$   
 (XVI-M)  $R^{109}=R^{110}=R^{111}=R^{112}=H$ ,  $R^{113}=R^{114}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-N)  $R^{109}=R^{110}=R^{111}=R^{112}=H$ ,  $R^{113}=R^{114}=\text{COCH(CH}_3\text{)C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-O)  $R^{109}=R^{110}=R^{111}=R^{112}=H$ ,  $R^{113}=R^{114}=\text{COCH}_2\text{CH(CH}_3\text{)}_2$ ,  $M=Y=Z=O$ ,  $X=NH$

25 (XVI-P)  $R^{109}=R^{110}=R^{111}=R^{112}=H$ ,  $R^{113}=R^{114}=$  ,  $M=Y=Z=O$ ,  $X=NH$

(XVI-Q)  $R^{109}=R^{110}=R^{111}=R^{112}=H$ ,  $R^{113}=\text{acyl}$ ,  $R^{114}=\text{COCH(CH}_3\text{)C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-R)  $R^{109}=R^{110}=R^{111}=R^{112}=H$ ,  $R^{114}=\text{COCH(CH}_3\text{)C}_2\text{H}_5$ ,  $R^{113}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

30 (XVI-S)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{113}=H$ ,  $R^{114}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-T)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{113}=H$ ,  $R^{114}=\text{COCH}_2\text{CH(CH}_3\text{)}_2$ ,  $M=Y=Z=O$ ,  $X=NH$   
 (XVI-U)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{113}=H$ ,  $R^{114}=\text{CH}_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  
 $M=Y=Z=O$ ,  $X=NH$   
 (XVI-V)  $R^{109}=R^{110}=R^{111}=R^{112}=R^{113}=H$ ,  $R^{114}=\text{Me}$ ,  $M=Y=Z=O$ ,  $X=NH$



Non-limiting examples of suksdorfin analogs according to formula (XVII) include the following combinations of  $R^{116}$ ,  $R^{117}$ ,  $R^{118}$ ,  $R^{119}$ ,  $R^{120}$ ,  $R^{121}$ ,  $R^{122}$ ,  $R^{123}$ ,  $X$ ,  $Y$ ,  $Z$  and  $M$ .

10 (XVII-A)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=R^{123}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVII-B)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{123}=H$ ,  $R^{122}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVII-C)  $R^{116}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=R^{123}=H$ ,  $R^{117}=\text{O-alkyl}$ ,  $M=Y=Z=O$ ,  
15  $X=NH$

(XVII-D)  $R^{116}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=R^{123}=H$ ,  $R^{117}=\text{O-CH}_2\text{CONH-alkyl}$ ,  
 $M=Y=Z=O$ ,  $X=NH$

(XVII-E)  $R^{122}=R^{123}=\text{acyl}$ ,  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVII-F)  $R^{122}=R^{123}=\text{acyl}$ ,  $R^{121}=\text{O-alkyl}$ ,  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=H$ ,  
20  $M=Y=Z=O$ ,  $X=NH$

(XVII-G)  $R^{122}=R^{123}=\text{acyl}$ ,  $R^{117}=\text{O-alkyl}$ ,  $\text{O-CF}_3$ ,  $\text{O-CH}_2\text{COO-alkyl}$ ,  
 $R^{116}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVII-H)  $R^{122}=R^{123}=\text{acyl}$ ,  $R^{116}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $R^{117}=\text{O-CH}_2\text{CONH-alkyl}$ ,  
25  $M=Y=Z=O$ ,  $X=NH$

(XVII-I)  $R^{122}=R^{123}=\text{acyl}$ ,  $R^{116}=R^{118}=R^{120}=R^{121}=H$ ,  $R^{117}=\text{halogen}$  or  
 $\text{CH}_2\text{CH}_2\text{N-alkyl}$ ,  $R^{119}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

30 (XVII-K)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{123}=H$ ,  $R^{122}=\text{alkyl or COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  
 $M=Y=Z=O$ ,  $X=NH$


(XVII-L)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=H$ ,  $R^{123}=\text{alkyl}$  or,  
 $\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVII-M)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $R^{122}=R^{123}=\text{acyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVII-N)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $R^{122}=R^{123}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  
35  $X=NH$

(XVII-O)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $R^{122}=R^{123}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Y=Z=O$ ,

X=NH



5 (XVII - Q)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $R^{122}=acyl$ ,  $R^{123}=COCH(CH_3)C_2H_5$ ,  
 $M=Y=Z=O$ ,  $X=NH$




(XVII - R)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=H$ ,  $R^{123}=COCH(CH_3)C_2H_5$ ,  $R^{122}=acyl$ ,  
 $M=Y=Z=O$ ,  $X=NH$

(XVII - S)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=H$ ,  $R^{123}=acyl$ ,  $M=Y=Z=O$ ,  $X=NH$

10 (XVII - T)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=H$ ,  $R^{123}=COCH_2CH(CH_3)_2$ ,  $M=Y=Z=O$ ,  
 $X=NH$

(XVII - U)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=H$ ,  $R^{123}=CH_2\emptyset$ , where  $\emptyset=phenyl$ ,  
 $M=Y=Z=O$ ,  $X=NH$

(XVII - V)  $R^{116}=R^{117}=R^{118}=R^{119}=R^{120}=R^{121}=R^{122}=H$ ,  $R^{123}=Me$ ,  $M=Y=Z=O$ ,  $X=NH$



Non-limiting examples of suksdorfin analogs according to formula (XVIII) include the following combinations of  $R^{125}$ ,  $R^{126}$ ,  $R^{127}$ ,  $R^{128}$ ,  $R^{129}$ ,  $R^{130}$ ,  $R^{131}$ ,  $X$ ,  $Z$ ,  $Z$  and  $M$ .

25 (XVIII - A)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{130}=R^{131}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII - B)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{131}=H$ ,  $R^{130}=alkyl$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-C)  $R^{125}=R^{126}=R^{128}=R^{129}=R^{130}=R^{131}=H$ ,  $R^{127}=O\text{-alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-D)  $R^{125}=R^{126}=R^{128}=R^{129}=R^{130}=R^{131}=H$ ,  $R^{127}=O\text{-CH}_2\text{CONH-alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

5 (XVIII-E)  $R^{130}=R^{131}=acyl$ ,  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-F)  $R^{130}=R^{131}=acyl$ ,  $R^{129}=O\text{-alkyl}$ ,  $R^{125}=R^{126}=R^{127}=R^{128}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

10 (XVIII-G)  $R^{130}=R^{131}=acyl$ ,  $R^{127}=O\text{-alkyl}$ ,  $O\text{-CF}_3$ ,  $O\text{-CH}_2\text{COO-alkyl}$ ,  $R^{125}=R^{126}=R^{128}=R^{129}=H$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-H)  $R^{130}=R^{131}=acyl$ ,  $R^{125}=R^{126}=R^{128}=R^{129}=H$ ,  $R^{127}=O\text{-CH}_2\text{CONH-alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

15 (XVIII-J)  $R^{130}=R^{131}=acyl$ ,  $R^{125}=R^{15}=R^{16}=H$ ,  $R^{127}=\text{halogen}$  or  $\text{CH}_2\text{CH}_2\text{N-alkyl}$ ,  $R^{128}=\text{alkyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-K)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{131}=H$ ,  $R^{130}=\text{alkyl}$  or  $\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

20 (XVIII-L)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{130}=H$ ,  $R^{131}=\text{alkyl}$  or,  $\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-M)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=H$ ,  $R^{130}=R^{131}=acyl$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-N)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=H$ ,  $R^{130}=R^{131}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

25 (XVIII-O)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=H$ ,  $R^{130}=R^{131}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-P)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=H$ ,  $R^{130}=R^{131}=-\text{C}(=\text{O})-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)=\text{C}(=\text{O})-\text{C}(=\text{O})-$ ,  $M=Y=Z=O$ ,  $X=NH$

30 (XVIII-Q)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=H$ ,  $R^{130}=acyl$ ,  $R^{131}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-R)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=H$ ,  $R^{131}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $R^{130}=acyl$ ,  $M=Y=Z=O$ ,  $X=NH$





(XVIII-S)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{130}=H$ ,  $R^{131}=acyl$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-T)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{130}=H$ ,  $R^{131}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Y=Z=O$ ,  $X=NH$
















(XVIII-U)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{130}=H$ ,  $R^{131}=\text{CH}_2\text{O}$ , where  $\text{O}=\text{phenyl}$ ,  $M=Y=Z=O$ ,  $X=NH$

(XVIII-V)  $R^{125}=R^{126}=R^{127}=R^{128}=R^{129}=R^{130}=H$ ,  $R^{131}=\text{Me}$ ,  $M=Y=Z=O$ ,  $X=NH$

40



Non-limiting examples of suksdorfin analogs according to formula (XIX) include the following combinations of  $R^{133}$ ,  $R^{134}$ ,  
 10  $R^{135}$ ,  $R^{136}$ ,  $R^{137}$ ,  $R^{138}$ ,  $R^{139}$ ,  $R^{140}$ , Z and M.



SUBSTITUTE SHEET (RULE 26)

(XIX-Q)  $R^{133}=R^{134}=R^{135}=R^{136}=R^{137}=R^{138}=H$ ,  $R^{139}=\text{acyl}$ ,  $R^{140}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $M=Z=O$ ;





(XIX-R)  $R^{133}=R^{134}=R^{135}=R^{136}=R^{137}=R^{138}=H$ ,  $R^{140}=\text{COCH}(\text{CH}_3)\text{C}_2\text{H}_5$ ,  $R^{139}=\text{acyl}$ ,  $M=Z=O$ ;

5 (XIX-S)  $R^{133}=R^{134}=R^{135}=R^{136}=R^{137}=R^{138}=R^{139}=H$ ,  $R^{140}=\text{acyl}$ ,  $M=Z=O$ ;

(XIX-T)  $R^{133}=R^{134}=R^{135}=R^{136}=R^{137}=R^{138}=R^{139}=H$ ,  $R^{140}=\text{COCH}_2\text{CH}(\text{CH}_3)_2$ ,  $M=Z=O$ ;

(XIX-U)  $R^{133}=R^{134}=R^{135}=R^{136}=R^{137}=R^{138}=R^{139}=H$ ,  $R^{140}=\text{CH}_2\emptyset$ , where  $\emptyset=\text{phenyl}$ ,  $M=Z=O$ ;

10 (XIX-V)  $R^{133}=R^{134}=R^{135}=R^{136}=R^{137}=R^{138}=R^{139}=H$ ,  $R^{140}=\text{Me}$ ,  $M=Z=O$ ;



Non-limiting examples of suksdorfin analogs according to formula (XX) include the following combinations of  $R^{142}$ ,  $R^{143}$ ,  $R^{144}$ ,  $R^{145}$ ,  $R^{146}$ ,  $Z$  and  $M$ .

20 (XX-A)  $R^{142}=R^{143}=R^{144}=R^{145}=R^{146}=H$ ,  $M=Z=O$ ;

(XX-B)  $R^{142}=R^{143}=R^{144}=R^{146}=H$ ,  $R^{145}=\text{alkyl}$ ,  $M=Z=O$ ;

(XX-C)  $R^{143}=R^{144}=R^{145}=R^{146}=H$ ,  $R^{142}=\text{O-alkyl}$ ,  $M=Z=O$ ;

(XX-D)  $R^{143}=R^{144}=R^{145}=R^{146}=H$ ,  $R^{142}=\text{O-CH}_2\text{CONH-alkyl}$ ,  $M=Z=O$ ; (XX-E)  $R^{145}=R^{146}=\text{acyl}$ ,  $R^{142}=R^{143}=R^{144}=H$ ,  $M=Z=O$ ;


25 (XX-F)  $R^{145}=R^{146}=\text{acyl}$ ,  $R^{144}=\text{O-alkyl}$ ,  $R^{142}=R^{143}=H$ ,  $M=Z=O$ ;

(XX-G)  $R^{145}=R^{146}=\text{acyl}$ ,  $R^{142}=\text{O-alkyl}$ ,  $\text{O-CF}_3$ ,  $\text{O-CH}_2\text{COO-alkyl}$ ,  $R^{143}=R^{144}=H$ ,  $M=Z=O$ ;



(XX-H)  $R^{145}=R^{146}=\text{acyl}$ ,  $R^{143}=R^{144}=H$ ,  $R^{142}=\text{O-CH}_2\text{CONH-alkyl}$ ,  $M=Z=O$ ;

(XX-J)  $R^{145}=R^{146}=\text{acyl}$ ,  $R^{144}=H$ ,  $R^{142}=\text{halogen or CH}_2\text{CH}_2\text{N-alkyl}$ ,  $R^{143}=\text{alkyl}$ ,  $M=Z=O$ ;

(XX-K)  $R^{142}=R^{143}=R^{144}=R^{146}=H$ ,  $R^{145}$ =alkyl or  $COCH(CH_3)C_2H_5$ ,  $M=Z=0$ ;  
 (XX-L)  $R^{142}=R^{143}=R^{144}=R^{145}=H$ ,  $R^{146}$ =alkyl or,  $COCH(CH_3)C_2H_5$ ,  $M=Z=0$ ;  
 (XX-M)  $R^{142}=R^{143}=R^{144}=H$ ,  $R^{145}=R^{146}$ =acyl,  $M=Z=0$ ;  
 (XX-N)  $R^{142}=R^{143}=R^{144}=H$ ,  $R^{145}=R^{146}=COCH(CH_3)C_2H_5$ ,  $M=Z=0$ ;  
 5 (XX-O)  $R^{142}=R^{143}=R^{144}=H$ ,  $R^{145}=R^{146}=COCH_2CH(CH_3)_2$ ,  $M=Z=0$ ;



(XX-Q)  $R^{142}=R^{143}=R^{144}=H$ ,  $R^{145}$ =acyl,  $R^{146}=COCH(CH_3)C_2H_5$ ,  $M=Z=0$ ;  
 (XX-R)  $R^{142}=R^{143}=R^{144}=H$ ,  $R^{146}=COCH(CH_3)C_2H_5$ ,  $R^{145}$ =acyl,  $M=Z=0$ ;  
 (XX-S)  $R^{142}=R^{143}=R^{144}=R^{145}=H$ ,  $R^{146}$ =acyl,  $M=Z=0$ ;  
 10 (XX-T)  $R^{142}=R^{143}=R^{144}=R^{145}=H$ ,  $R^{146}=COCH_2CH(CH_3)_2$ ,  $M=Z=0$ ;  
 (XX-U)  $R^{142}=R^{143}=R^{144}=R^{145}=H$ ,  $R^{146}=\text{CH}_2\text{O}$ , where  $\text{O}$ =phenyl,  $M=Z=0$ ;  
 (XX-V)  $R^{142}=R^{143}=R^{144}=R^{145}=H$ ,  $R^{146}=\text{Me}$ ,  $M=Z=0$ ;



15 (XX-Y)  $R^{142}=R^{143}=R^{144}=H$ ,  $R^{146}=-$    $, R^{145}=COCH_2CH(CH_3)_2$ ,  $M=Z=0$ ;



Such suksdorfin analogs are unexpectedly discovered to have anti-retroviral activity, thus providing suitable 20 compounds and compositions for treating retroviral infections, optionally with additional pharmaceutically active ingredients, such as anti-retroviral, anti-HIV, and/or immuno-stimulating compounds or antiviral antibodies or fragments thereof.

By the term "anti-retroviral activity" or "anti-HIV 25 activity" is intended the ability to inhibit at least one of (1) retroviral attachment to cells, (2) viral entry into cells,

(3) cellular metabolism which permits viral replication, (4) inhibition of intercellular spread of the virus, (5) synthesis and/or cellular expression of viral antigens, (6) activity of virus-coded enzymes (such as reverse transcriptase and 5 protease), and/or (7) any known retroviral or HIV pathogenic actions, such as, for example, immunosuppression. Thus, any activity which tends to inhibit any of these mechanisms is "anti-retroviral activity" or "anti-HIV activity."


The present invention also provides a process for 10 purifying suksdorfin analogs having anti-HIV activity from a sample containing such a compound, such as, but not limited to, the fruit of the plant *Lomatium suksdorfi*, the method comprising: (a) extracting sample preparations with hexane to provide active fractions; (b) centrifuging the active fractions 15 at least once; (c) recovering the supernatant; and (d) purifying the precipitate by silica gel chromatography to recover the suksdorfin analog, thereby purifying the protein.

The present invention also provides alternative synthetic methods for obtaining suksdorfin analogs according to formula 20 (I) or formula (II).

The following scheme 1 provides one set of alternative synthetic steps for producing compounds synthesis of suksdorfin analogs according to formula (I), can base on a synthesis of seselin (2) from 7-hydroxy coumarin 1.

25 The construction of the pyran ring from commercially available 7-hydroxycoumarin (1) involved two steps (1 and 2), which have been described, e.g. by Hlubucek, et al. *Aust. J. Chem.* 24:2347 (1971) the contents of which is incorporated entirely herein by references. The crude product of the first 30 step can be used directly in the next rearrangement reaction, which will produce seselin (2) in good yield. Seselin can then be used as the starting material for the synthesis of other pyranocoumarin derivatives as presented in Scheme 1, as further described herein, using at least one intermediate compounds 35 designated compounds 3-7, to produce suksdorfin analogs of the present invention, non-limiting as examples of compounds according to formula (I), e.g., as analogs designated compounds 8-11 in scheme 1 and 3; 4'-di-0-acyl *cis* - khellactone

derivatives designated 12-21 in scheme 1.




### Scheme 1. Synthesis of $\mathbf{Y}_1^{\text{d}}$ -capped heptulone derivatives

The 3',4'-di-O-acyl- *cis*-khellactone derivatives (12-21) can be prepared by two routes e.g., as presented in scheme 1. In the first route, seselin (2) can be functionalized at the 3',4'positions by oxidation with *m*-chloroperoxybenzoic acid to 5 give the ( $\pm$ )-3'-hydroxy-4'-O-acyl derivative 3 (Schroeder et al, *Chem. Ber.* 92, 2388, (1959), entirely incorporated herein by reference). Tosic acid catalyzed dehydration transformed compound 3 to an optically inactive 3-keto derivative compound 10 4 (Willette et al *J. Pharm. Sci.* 51, 149 (1962), entirely incorporated by reference). According to a disclosed method 15 of procedure (e.g., as presented S.N. Shanbhag et al *Tetrahedron*, 21:3591 (1965), entirely incorporated herein by reference), treatment of compound 4 with lead tetraacetate in acetic acid can yield the racemic 5. After saponification and 20 reesterification at C-4' to give a 3'-keto-4'-O-acyl intermediate compound 6, the ketone can be reduced to an hydroxyl group with NaBH<sub>4</sub> (Shanbhag, *supra*). Further esterification of this ( $\pm$ )-mono ester khellactone with RCOCl or (RCO)<sub>2</sub>O can furnish the desired ( $\pm$ )-di-O-acyl-khellactone 25 derivatives followed by careful chromatographic separation of their *cis* racemic mixture to provide compounds 8 - 21 as presented in scheme 1, or other compounds according to Formula I of the present invention.

In a second route, e.g., as presented in Scheme 1, seselin 25 compound 2 can be oxidized with OsO<sub>4</sub> to give the *cis*-khellactone intermediate compound 7 in good yield (Schroeder et al, *supra*). The 3',4'-diester- *cis*-khellactone compounds 12-17, in which the two ester groups at 3' and 4' are identical, can be produced using standard esterification 30 conditions. However, by using equal molar reagents and mild reaction conditions, selective esterification can be achieved giving the 3'-mono compounds 8 and 9 and the 4'-mono ester khellacetone compounds 10 and 11 in a mixture with the diesters. Separation and further esterification of these mono 35 ester compounds 8-11, using acetic anhydride, can yield the desired ( $\pm$ )-3',4'-di-O-acyl- *cis*-khellactone derivative compounds 18-21, which have different ester moieties at the 3'

and 4' positions. This method can have fewer steps and can give better yields than route 1, through compound 4. However, route 2 can be more expensive and require more extensive safety precautions.


5 Suksdorfin analogs according to formula (I) of the present invention can be synthesized as jatamansinol derivatives according to Scheme 2, e.g., using published method steps (e.g., Murry et al *Tetrahedron letters*, entirely incorporated herein by reference 27:4901 (1971)). For example, a phenyl 10 group can be introduced at C-8 of 7-hydroxycoumarin compound 1 in a three-step sequence, which involves a Claisen rearrangement. Under slightly acidic conditions, cyclization of intermediate compound 23 can furnish jatamansinol compound 24. Using standard esterification conditions, 15 ( $\pm$ )-3'-0-acyl-jatamansinol derivative compounds 25 and/or 26 can be synthesized in recoverable amounts.



Scheme 2. Synthesis of 3'-acyl jatamansinol derivatives

( $\pm$ ) -3',4'-Di-O-acyl-*trans*-khellactone derivatives and 3'-O-alkyl-4'-O-acyl-*trans*-khellactone derivative compounds according to formula (I) can be prepared according to Scheme 3.

5 Preparation of the 3',4'-*trans* derivatives proceeds from intermediate compound 3A. Compound 3A can be esterified by treatment with the appropriate acyl chloride or acid anhydride to produce the 3',4'-di-O-acyl-*trans*-khellactone compounds 27, 28, 33, and 34. Reaction of compound 3A with various 10 alkylating reagents (e.g., MeI, benzyl bromide, dihydropyran) can give the 3'-O-alkyl intermediate compounds 29-32\*. Saponification of these compounds can yield the 3'-O-alkyl-4'-hydroxy derivative compounds 35-38. After esterification with an acyl chloride or acid anhydride, the 15 ( $\pm$ ) -3'-O-alkyl-4'-O-acyl-*trans*-khellactone derivatives 39-42 can be synthesized, as presented in scheme 3.



#### • diagnostic


**Scheme 2.** Syntheses of 3,4'-trans-dihydroxyan and benzodihydroxyan derivatives

Alternatively ( $\pm$ )-Benzodihydropyran derivatives according to formula (II) can be synthesized according to Scheme 3. The lactone ring in compound 3A or in the 3',4'-di-0-acyl-trans derivatives can be abolished by using a known hydrolysis method 5 step(s) to give ( $\pm$ )-benzodihydropyran compound 43 according to formula (II). The base (KOH, Ag<sub>2</sub>O, or NaH) cleaves the lactone ring and the ester groups. The free acid or the hydroxyl groups can then undergo alkylation in MeOH or by MeI; to provide suksdorfin analogs according to formula (II) of the 10 presented invention.


Optically pure ester derivative compounds 8-11, 14-21, 33 and 34 according to formula (I) can be obtained using an optically active acyl chloride or acid anhydride as presented in scheme 3. The products are diastereoisomers, which can be 15 separated with repeated chromatography.

Formula (III):

Compounds, represented by formula (III), can be prepared from the following commercially available starting materials 34 and 35, according to the procedures as for preparing 20 compounds according to formula (I) as presented herein.





(34)



(35)

The following starting materials are also prepared by the procedure described in the literature (E.A. Clarke and M.F. Grundon, *J. Chem. Soc.*, 1964, 348), which can also be used to 25 prepare compounds according to formula (III), according to known method steps.




#### Formula (IV) :

41

42

A commercially available starting material 43 can be used to prepare compounds according to formula (IV), using known 5 methods steps, e.g., as presented herein.




(43)

### Formula (V) :

Starting materials for the compounds represented by formula (V) can be obtained by the reduction of the intermediate of (I), i.e., seselin (2), by reduction with diisobutylaluminum hydride (DIBAL). The same procedure as for (I) will give the product 45 as shown by the formula (V), as

SUBSTITUTE SHEET (RULE 26)

presented herein, or according to other known method steps.




### Formula (VI) :

A procedure for preparing seselin can be applied  
5 to phenols, such as resorcinol or orcinol, for the synthesis of  
the compounds as shown by formula (VI), according to known  
method steps.


### Formula (VIII) :

10 Procedures for synthesis of couromones [R.G. Cooker et al., *Aus. J. Chem.*, 24, 1257 (1971); A Ueno et al., *Chem. Pharm. Bull.*, 26, 2407 (1978)] can be applied for preparing the starting material for the compounds represented by formula (VI), according to known method steps.



### 15 Formula (X) :


The following commercially available starting material 49 can be used for the synthesis of (X) by the procedures as for (I), or according to known method steps.




(49)

### Formula (XII) :

The following compounds 50 and 51 are commercially available as the starting materials for the desired compounds (XII), according to known method steps.




(50)



(51)

Formula (XIV) :


Reduction of the following commercially available compound 52 will yield the starting compound for preparing compounds according to formula (XIV), as presented herein for (I) and/or according to known method steps.




(52)

### Formula (XV) :

1.5 The following compounds 53 and 54 are commercially available starting materials for preparing compounds according to formulae (XV), according to known method steps.



(53)




(54)

## Formula (XVI):

The compounds represented by formula (XVI) can be prepared from the commercially available 5,7-dihydroxycoumarin by the 5 procedure as for (I), and/or according to known method steps.

## Formula (XVII):


Reduction of the commercially available 7-nitro-3,4-benzocoumarin will yield an amine derivative, which can be further treated as for (I) to give a compound 55 10 according to formula (XVII), according to known method steps.



(55)



## Formula (XVIII):

Noracronycine derivatives can be prepared according to the procedure described in the literature (J. Hlubucek et al., Aust. 15 J. Chem., 23, 1881 (1970), which will be further treated by a similar procedure as for (I) giving compound according to formula (XVIII), according to known method steps.



Formula (XIX) :

The following compounds 57 and 58 can be used as commercially available starting materials for preparing 5 compounds according to formula (XIX), according to known method steps.



Formula (XX) :

A commercially available substituted phenol, i.e., 10 orcinol, olivetol, etc., can be used as a starting material for the compounds according to formula (XX), according to known method steps.

**Testing HIV activity in vitro**

The following are examples of methods which can be used 15 to screen suksdorfin analogs according to Formula G-1, G-2, and/or one or more of (I)-(XX), for determining at least one therapeutic utility and/or mechanism of action as an anti-viral compound, such as anti-HIV compound; without undue experimentation, based on the teaching and guidance presented 20 herein.

First various concentrations of suksdorfin analogs can be incubated with a chronically HIV-1 infected T cell line, e.g., ACH-2, and a chronically HIV-1 infected monocytic cell line, e.g., U1. These cell lines are useful in predicting if

suksdorfin analogs of the present invention could induce virus expression *in vivo* when given to an individual who is latently infected with HIV and not actively expressing virus. In addition, when these two cell lines are incubated with the 5 phorbol ester, PMA, HIV-1 expression is increased. Since suksdorfin analogs of the present invention can inhibit virus replication during an acute HIV-1 infection of H9 cells, it will be of interest to determine if it can also suppress HIV-1 expression from these two chronically infected cell lines when 10 they are stimulated with PMA.

Suksdorfin analogs of the present invention can be tested with other cell types (e.g., freshly isolated cells and/or cell lines) which are infected with HIV. Freshly isolated monocyte/macrophages and peripheral blood mononuclear cells 15 (PBMCs) can be infected with a monotropic isolate of HIV-1, Ba-L and/or a laboratory isolate (e.g., IIIB) of HIV-1, respectively. In addition, virus suppression can be evaluated when a suksdorfin analog is added to acutely HIV-1 (IIIB isolate) infected monocytic cell line, U937, and/or the HIV-2 20 (D194 isolate) infected T cell line, HUT-78. These studies will determine if the suppressive effect of various suksdorfin analogs are specific to a particular cell phenotype or a virus isolate.

Other studies can also be used to screen for the mechanism 25 of action (MOA) of suksdorfin analogs according to at least one of formula (G-1), (G-2), and (I)-(XX), e.g., by:

- (a) determining if the compound is capable of inactivating HIV-1 by culturing suksdorfin with HIV-1 for 1 hour before adding the virus to H9 cells;
- 30 (b) determining if the compounds' MOA is by competing with HIV for the same receptor (CD4) on the cell surface. This can be tested by adding HIV-1, suksdorfin analogs and H9 cells together and then monitoring the amount of virus produced in the presence and absence of suksdorfin analogs;
- 35 (c) H9 cells will also be pretreated with suksdorfin analogs to determine if the effect of the drug is on the cells or on the virus.
- (d) Molecular biology studies, wherein DNA and/or RNA

levels can be measured in cells that had been treated with various concentrations of suksdorfin. This will be preferred where negative results are obtained from one or more of methods (a) - (c). Both cellular and/or viral regulatory elements can 5 be examined.

Suksdorfin analogs can also be tested in the presence of nucleoside analogs (AZT, ddI, ddC) or other accepted anti-HIV agents, to determine if suksdorfin analogs are synergistic with any of these currently licensed anti-retroviral agents which 10 can ultimately enhance their individual suppressive capability especially at lower concentrations.

A suksdorfin analog of the present invention can be used for treatment of retroviral (e.g., HIV) infection either alone, or in combination with other modes of therapy known in the art. 15 Such modes of therapy can include chemotherapy with drugs, such as, but not limited to, at least one of AZT, ddC, ddA, ddT, ddI, or any other anti-retroviral antibodies in combination with each other, or associated with a biologically based therapeutic, such as, for example, soluble CD4, antibodies to 20 CD4, and conjugates of CD4 or anti-CD4, or as additionally presented herein.

Because suksdorfin analogs of the present invention are relatively less or substantially non-toxic to normal cells, their utility is not limited to the treatment of established 25 retroviral infections. For example, a suksdorfin analog according to formulae (I) to (XX) can be used in the treatment of blood products, such as those maintained in blood banks. The nation's blood supply is currently tested for antibodies to HIV. However, the test is still imperfect and samples which 30 yield negative tests can still contain HIV virus. Treating blood and blood products with the proteins and derivatives of the present invention can add an extra margin of safety, to kill any retrovirus that can have gone undetected.

#### Pharmaceutical Compositions

35 Pharmaceutical compositions of the present invention can comprise at least one suksdorfin analog according to at least one of formulae (I), (II), (G-1), (G-2), and (III)-(XX). Pharmaceutical compositions according to the present invention

can also further comprise other anti-viral agents, such as, but not limited to, AZT, ddI, 2'- $\beta$ -fluoro-ddI, ddA, ddG, ddC, 2'- $\beta$ -fluoro-ddC, d4T, AzddU, phosphonylmethoxyethyl-adenine, or soluble CD4, or immunomodulators, e.g., as presented below.

5 For a review of therapeutic agents in HIV infection, see, e.g., Mitsuya, H. et al., *FASEB J.* 5:2369-2381 (1991), which reference is hereby incorporated by reference.

Additional suitable antiviral agents for optimal use with a coumarin compound of the present invention can include, but 10 are not limited to, AL-721 (lipid mixture) manufactured by Ethigen Corporation and Matrix Research Laboratories; Amphotericin B methyl ester; Ampligen (mismatched RNA) developed by DuPont/HEM Research; anti-AIDS antibody (Nisshon Food); AS-101 (heavy metal based immunostimulant); AZT 15 (azidothymidine/ Retrovir/Zidovudine) manufactured by Burroughs Wellcome; Betaseron ( $\beta$ -interferon) manufactured by Triton Biosciences (Shell Oil); butylated hydroxytoluene; Carrosyn (polymannoacetate) Castanospermine; Contracan (stearic acid derivative); Creme Pharmatex (contains benzalkonium chloride) 20 manufactured by Pharmelac; CS-87 (5-unsubstituted derivative of Zidovudine); Cytovene (ganciclovir) manufactured by Syntex Corporation; DDC (dideoxycytidine) manufactured by Hoffmann-La Roche and other nucleoside analogues; dextran sulphate; D-penicillamine (3-mercaptop-D-valine) manufactured by 25 Carter-Wallis and Degussa Pharmaceutical; Foscarnet (trisodium phosphonoformate) manufactured by Astra AB; fusidic acid manufactured by Leo Lovens; glycyrrhizin (a constituent of liquorice root); HPA-23 (ammonium-21-tungsto-9-antimonate) manufactured by Rhone-Poulenc Sante; human immunevirus 30 antiviral developed by Porton Products International; Ornidyl (eflornithine) manufactured by Merrell-Dow; Nonoxinol; pentamidine isethionate (PENTAM-300) manufactured by Lypho Med; Peptide T (octapeptide sequence) manufactured by Peninsula Laboratories; Phenytoin (Warner-Lambert); Ribavirin; Rifabutin 35 (ansamycin) manufactured by Adria Laboratories; rsT4 (recombinant soluble T4) manufactured by Biogen, Genentech and Smith Kline & French; Trimetrexate manufactured by Warner-Lambert Company; SK-818 (germanium-derived antiviral)

manufactured by Sanwa Kagaku; suramin and analogues thereof manufactured by Miles Pharmaceuticals; UA001 manufactured by Ueno Fine Chemicals Industry; Wellferon ( $\alpha$ -interferon) manufactured by Burroughs Wellcome; Zovirex (acyclovir, AZT) 5 manufactured by Burroughs Wellcome.

Pharmaceutical compositions of the present invention can also further comprise immunomodulators. Suitable immunomodulators for optional use with a coumarin compound of the present invention in accordance with the invention can 10 include, but are not limited to:

ABPP (Bropirimine): Ampligen (mismatched RNA) (DuPont/HEM Research); anti-human interferon- $\alpha$  antibody (Advance Biotherapy and Concepts); anti-AIDS antibody (Nisshon Food): AS-101 (heavy metal based immunostimulant), ascorbic acid and 15 derivatives thereof; interferon- $\beta$ ; Carrosyn (polymannoacetate); Ciamexon (Boehringer-Mannheim); Cyclosporin; Cimetidine; CL-246,738 (American Cyanamid); colony stimulating factors, including GM-CSF (Sandoz; Genetics Institute; dinitrochlorobenzene; interferon- $\alpha$ ; interferon-gamma; glucan; 20 hyperimmune gamma-globulin (BAYER); IMREG-1 (leucocyte dialyzate) and IMREG-2 (IMREG Corp.); immuthiol (sodium diethylthiocarbamate) (Institut Merieux); interleukin-1 or interleukin-2 (Cetus Corporation; Hoffman-La Roche; Immunex); isoprinosine (inosine pranobex); Krestin (Sankyo); LC-9018 25 (Yakult); lentinan (Ajinomoto/Yamanouchi); LF-1695 (Fournier); methionine-enkephalin (TNI Pharmaceuticals; Sigma Chemicals); Minophagen C; muramyl tripeptide, MTP-PE (Ciba-Geigy); naltrexone ("Trexan" (DuPont); Neutropin; RNA immunomodulator (Nippon Shingaku); shosaikoto and ginseng; thymic humoral 30 factor; TP-5 (Thymopentin) (Ortho Pharmaceuticals; Thymosin fraction 5 and Thymosin 1; Thymostimulin; TNF (tumor necrosis factor) manufactured by Genentech; and vitamin B preparations.

The preferred animal subject of the present invention is a mammal. By the term "mammal" is meant an individual 35 belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.

By the term "treating" is intended the administering to subjects of a suksdorfin analog or derivative for purposes

which can include prevention, amelioration, or cure of a retroviral-related pathology.

Medicaments are considered to be provided "in combination" with one another if they are provided to the patient 5 concurrently or if the time between the administration of each medicament is such as to permit an overlap of biological activity.

In one preferred embodiment, at least one suksdorfin analog comprises a single pharmaceutical composition.

10 Pharmaceutical compositions for administration or diagnosis of the present invention can comprise at least one suksdorfin analog according to at least one of Formulae (G-1), (I) and/or (II) in pharmaceutically acceptable form optionally combined with a pharmaceutically acceptable carrier. Such 15 compositions can be administered by any means that achieve their intended purpose. Amounts and regimens for the administration of a suksdorfin analog of the present invention can be determined readily by those with ordinary skill in the clinical art of treating a retroviral related pathology.

20 For example, administration can be by parenteral, such as subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration can be by the oral route. The dosage administered will be dependent upon the age, health, and weight 25 of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

Compositions within the scope of this invention include all compositions wherein at least one suksdorfin analog according to formula (I), (II) or (G-1) is comprised in an 30 amount effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 0.1 to 100 mg/kg/body weight. The preferred dosages comprise 1 to 100 mg/kg/body weight. The 35 most preferred dosages comprise 10 to 100 mg/kg/body weight.

Therapeutic administration can also include prior, concurrent, subsequent or adjunctive administration of at least one additional sukdorfin or other therapeutic agent, as an

anti-viral or immune stimulating agent. In such an approach, the dosage of the second drug can preferably be the same or different than as the dosage of the first therapeutic agent. Preferably, the drugs are administered on alternate days in the 5 recommended amounts of each drug.

Administration of a compound of the present invention can also optionally include previous, concurrent, subsequent or adjunctive therapy using immune system boosters or immunomodulators. In addition to the pharmacologically active 10 compounds, a pharmaceutical composition of the present invention can also contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Preferably, the preparations, 15 particularly those preparations which can be administered orally and which can be used for the preferred type of administration, such as tablets, dragees, and capsules, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration 20 by injection or orally, contain from about 0.01 to 99 percent, preferably from about 20 to 75 percent of active compound(s), together with the excipient.

Pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, 25 by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after 30 adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.

Suitable excipients are, e.g., fillers such as saccharide, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, 35 tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium

carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents can be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or 5 a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if 10 desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order 15 to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate are used. Dye stuffs or pigments can be added to the tablets or dragee 20 coatings, for example, for identification or in order to characterize combinations of active compound doses.

Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the 25 active compounds in the form of granules which can be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as 30 fatty oils or liquid paraffin. In addition, stabilizers can be added.

Possible pharmaceutical preparations which can be used rectally include, for example, suppositories which consist of a combination of the active compounds with a suppository base. 35 Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a

base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.

Suitable formulations for parenteral administration include aqueous solutions of the active compounds in 5 water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions can be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for 10 example, ethyl oleate or triglycerides. Aqueous injection suspensions that can contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension can also contain stabilizers.

15 A pharmaceutical formulation for systemic administration according to the invention can be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulation can be used simultaneously to achieve systemic administration of the active ingredient.

20 Suitable formulations for oral administration include hard or soft gelatin capsules, dragees, pills tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof.

25 Solid dosage forms in addition to those formulated for oral administration include rectal suppositories

At least one suksdorfin analog can also be administered in the form of an implant.

30 Suitable formulations for topical administration include creams, gels, jellies, mucilages, pastes and ointments. The compounds can also be formulated for transdermal administration, for example, in the form of transdermal patches so as to achieve systemic administration.

35 Suitable injectable solutions include intravenous subcutaneous and intramuscular injectable solutions. At least one suksdorfin analog can also be administered in the form of an infusion solution or as a nasal inhalation or spray.

Having now generally described the invention, the same will be more readily understood through reference to the

following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

**EXAMPLE I:** Isolation and purification of Suksdorfin analog  
5 of the present invention

Suksdorfin was obtained as colorless needles (m.p. 140-141°C) by silica gel chromatography of the active hexane fractions. Its molecular formula was determined to be C<sub>21</sub>H<sub>24</sub>O<sub>7</sub> by high resolution mass spectroscopy, and a comparison of the 10 UII, IR, and <sup>1</sup>H-NMR spectral data with those described in the literature identified 1 as suksdorfin, which had been previously isolated from this same plant by Willette and Soine (Willette, R.E.; Soine, T.O. *J. Pharm. Sci.*, 1962, 51, 149).

Suksdorfin demonstrated potent inhibitory activity against 15 HIV-1 replication in acutely infected H9 cells with an EC<sub>50</sub> of 1.3 $\mu$ M as determined by a p24 antigen ELISA assay and it inhibited uninfected H9 cell growth with an IC<sub>50</sub> of >52 $\mu$ M (Table 1). The therapeutic index (IC<sub>50</sub> for cell growth inhibition divided by EC<sub>50</sub> for HIV inhibition) for suksdorfin compound 1 20 was >40. In comparison, the therapeutic index of dideoxyinasins (ddI), a dideoxynucleoside which inhibits reverse transcriptase, when tested in our assay system was only 10-fold greater (>400) than that observed with suksdorfin.

In order to elucidate structure-activity relationships, 25 the HIV-replication inhibitory effects of ten coumarins, which are isolated from various plant sources (Soine, T.; *O. J. Pharm. Sci.*, 1964, 53, 231), was determined and compared with that of 1. The compounds include an additional dihydroseselin type angular pyranocoumarin, 2 (pteryxin), a dihydro-angelicin 30 type angular coumarin, 3 (columbianadin), three dihydroangelicin linear furanocoumarins, 4 (nodakenetin), 5 (nodakenin), and 6 (acetylnodakenin), four psoralen type linear furanocoumarins, 7 (imperatorin), 8 (bergapten), 9 (isoimperatorin), and 10 (oxypeucedanin), and a dicoumaryl 35 ether, 11 (daphnoretin).

As shown in Table 1, only 1 showed potent anti-HIV-1 activity at nontoxic concentrations. All other compounds

(2-11) were either inactive or were less active and more toxic. The 4'-isovaleryl group of 1 was important for selective HIV-1 inhibition. Replacement of this group with an angeloyl moiety as in pteryxin (2) increased the toxicity by 5-fold and 5 slightly reduced anti-HIV-1 activity. The furanocoumarins (3-10) were inactive or active only at toxic concentrations, (e.g., the therapeutic index of 3 was >1.3). The dicoumaryl ether (11) showed no activity.

10 Table 1. HIV Inhibition<sup>5</sup> by Suksdorfin (1) and Related Compounds (2-11).

Compound	IC <sub>50</sub> (μM) <sup>a</sup>	EC <sub>50</sub> (μM) <sup>b</sup>	Therapeutic Index
1 Suksdorfin	>52	1.3	>40
2 Pteryxin	>10.4	4.6	>3.7
3 Columbianadin	>6.1	4.6	>1.3
4 Nodakenetin	ND <sup>c</sup>	Inactive <sup>d</sup>	ND
5 Nodakenin	ND	Inactive	ND
6 Acetylnode-kenin	ND	Inactive	ND
7 Imperatorin	>74.1	11.1	>6.7
8 Bergapten	>92.6	30.1	>3.1
9 Isoimperatorin	>185.2	40.7	>4.6
10 Oxypeucedanin	>69.9	31.5	>2.2
11 Daphnoretin	ND	Inactive	ND

25 <sup>a</sup>Concentration which inhibits uninfected cell growth by 50%

<sup>b</sup>Concentration which inhibits viral replication by 50%

<sup>c</sup>ND - not determined


<sup>d</sup>No suppression of HIV-1 replication in H9 cells

30 EXAMPLE III: *In vitro* HIV inhibition activity assays H I V inhibition assay. The HIV inhibition was measured as described herein. Briefly, H9 cells, a T cell line, ( $3.5 \times 10^6$  cells/ml) were incubated in the presence or absence of HIV-1 (IIIB strain, 0.01-0.1 TCID<sub>50</sub>/cell) for 1 hour at 37°C. Cells were washed thoroughly and resuspended at a final concentration of 35  $2 \times 10^5$  cells/ml in the presence or absence of compound. After

incubation for 3-4 days at 37°C, the cell density of uninfected cultures was determined by cell count to assess toxicity of the drug. An aliquot of each cell-free supernatant was assayed by p24 antigen ELISA to quantitate the amount of HIV-1 present in 5 the infected cultures. Test compounds were considered to be active at a particular concentration if p24 antigen levels were less than 70% of infected, untreated controls and were nontoxic to uninfected H9 cells.

**EXAMPLE III: SYNTHESIS OF SUKSDORFIN ANALOGS****Synthesis of Seselin (2) (Scheme 1)**

The construction of the pyran ring from commercially available 7-hydroxycoumarin (1) involved two steps, which have 5 been described by Hlubucek, et al. *Aust. J. Chem.* 24:2347 (1971). The crude product of the first step was used directly in the next rearrangement reaction, which produced seselin (2) in good yield. Seselin was then used as the starting material for the synthesis of other pyranocoumarin derivatives as 10 described below.



Scheme 1. Synthesis of 3',4'-cis-4-hydroxy-4-alkylbiflavanone derivatives


( $\pm$ )-3',4'-Di-0-acyl- *cis*-khellactone derivatives (Scheme 1). The 3',4'-di-0-acyl- *cis*-khellactone derivative compounds 12-21 can be prepared by two routes. In the first, seselin (compound 2) was functionalized at the 3',4' positions by oxidation with 5 *m*-chloroperoxybenzoic acid to give the ( $\pm$ )-3'-hydroxy-4'-0-acyl derivative compound 3 (Schroeder et al, *Chem. Ber.* 92, 2388, (1959)). Tosic acid catalyzed dehydration transformed compound 3 to an optically inactive 3-keto derivative compound 4 (Willette et al *J. Pharm. Sci.* 51, 149 (1962)). According to 10 a literature method (S.N. Shanbhag et al *Tetrahedron*, 21:3591 (1965)), treatment of compound 4 with lead tetraacetate in acetic acid should yield the racemic compound 5, despite the low yield reported in this transformation. After 15 saponification and reesterification at C-4' to give a 3'-keto-4'-0-acyl intermediate compound 6, the ketone can be reduced to a hydroxyl group with NaBH<sub>4</sub> (Shanbhag, *supra*). Further esterification of this ( $\pm$ )-mono ester khellactone with RCOCl or (RCO)<sub>2</sub>O could furnish the desired 20 ( $\pm$ )-di-0-acyl-khellactone derivatives, followed by careful chromatographic separation of their *cis* racemic mixture.

In the second route, seselin compound 2 was oxidized with OsO<sub>4</sub> to give the *cis*-khellactone intermediate compound 7 in good yield (Schroeder et al, *supra*). The 3',4'-di-0-ester-*cis*-khellactone derivative compounds 12-17, in which the two 25 ester groups at 3' and 4' are identical, were produced using standard esterification conditions. However, by using equal molar reagents and mild reaction conditions, selective esterification could be achieved giving the 3'-mono compounds 8,9\* and 4'-mono ester khellactone compounds 10,11\* in a 30 mixture with the diesters. Separation and further esterification of these mono ester compounds 8-11\* using acetic anhydride yielded the desired ( $\pm$ )-3',4'-di-0-acyl-*cis*-khellactone derivative compounds 18-21\*, which have 35 different ester moieties at the 3' and 4' positions. This method has fewer steps and gives better yields than the previous route through compound 4. However, OsO<sub>4</sub> is very toxic and expensive, which limits its extensive use.

( $\pm$ )-3'-O-acyl-jatamansinol derivatives (Scheme 2)

Jatamansinol derivatives were synthesized using a literature method (Murry et al *Tetrahedron letters* 27:4901 (1971)). A phenyl group was introduced at C-8 of 5 7-hydroxycoumarin (1) in a three-step sequence, which involved a Claisen rearrangement. Under slightly acidic conditions, cyclization of intermediate compound 23 furnished jatamansinol compound 24. Using standard esterification conditions, ( $\pm$ )-3'-O-acyl-jatamansinol derivatives (compounds 25, 26) were 10 synthesized.


71



Scheme 2. Synthesis of 3'-acetyl janthmanzole derivatives

**( $\pm$ ) -3',4'-Di-O-acyl-trans-khellactone derivatives and  
3'-O-alkyl-4'-O-acyl-trans-khellactone derivatives (Scheme 3)**

Preparation of the 3',4'-trans derivatives proceeds from intermediate compound 3. Compound 3 was esterified by 5 treatment with the appropriate acyl chloride or acid anhydride to produce the 3',4'-di-O-acyl-trans-khellactones (compounds 27,28,33,34). Reaction of compound 3 with various alkylating reagents (MeI, benzyl bromide, dihydropyran) gave the 3'-alkyl intermediate compounds 29-32. Saponification of these 10 compounds gave the 3'-alkyl-4'-hydroxy derivative compounds 35-38. After esterification with an acyl chloride or acid anhydride, the ( $\pm$ )-3'-O-alkyl-4'-O-acyl-trans-khellactone derivative compounds 39-42 were synthesized.



\* diastereoisomer

Scheme 3. Syntheses of 3',4'-trans-4-hydroxy-3-hydroxy-4-oxo-2,2-dimethylbicyclo[2.2.1]hept-5-en-3-ylidene-1,1-dioxine and benzodihydropyran derivatives

( $\pm$ ) -Benzodihydropyran derivatives (Scheme 3)

The lactone ring in compound 3 or in the 3',4'-diacyl-*trans* derivatives was abolished using a basic hydrolysis procedure to give new ( $\pm$ )-benzodihydropyran compound 5 43. The base (KOH, Ag<sub>2</sub>O, or NaH) cleaves the lactone ring and the ester groups. The free acid or the hydroxyl groups can then undergo alkylation by MeI.


Optically pure ester derivatives (compounds 8-11\*, 14-21\*, 33, 10 34\*) were obtained using an optically active acyl chloride or acid anhydride. The products are diastereoisomers, which can be separated with repeated chromatography.

EXAMPLE IV: Anti-HIV activity of Suksdorfin analogs against HIV-infected H9 lymphocytes


The inhibitory activities of the synthesized suksdorfin 15 analogs against HIV-replication in H9 lymphocytes were examined. The compounds include *cis*- (compounds 8-15) and *trans*- (compounds 27-32) khellactone derivatives, jatamansinol derivatives (compounds 25-26), and optically pure *cis*- (compounds 16-17) and *trans*- (compounds 44-45) khellactone 20 derivatives.

As shown in Table 2, compound 16 exhibited potent anti-HIV activity. The ED<sub>50</sub> value of compound 16 is at least 0.00041  $\mu$ M and its therapeutic index is over 78,125 but less than 390,625. This activity is much better than that of suksdorfin. Since 25 the ED<sub>50</sub> value and therapeutic index of AZT in this assay system are 0.04  $\mu$ M and 50,000, respectively, the anti-HIV activity of compound 16 is more potent than that of AZT.


The diastereomer of compounds 16(17), as well as compounds 44 and 45, which are *trans*-khellactone derivatives with same 30 acyl groups, showed much less activity than that of compound 16.




(16)



(17)



(44)



(45)

Table 2  
HIV Inhibition by Synthesized Suksdorfin Derivatives

Compound	IC <sub>50</sub> (μM)	EC <sub>50</sub> (μM)	Therapeutic Index
8 and 9	ND	> 57.8	ND
5 10 and 11	ND	> 57.8	ND
12	ND	> 289	ND
13	ND	> 232	ND
14 and 15	>47 but <233	7.0	>6.7 but <33.3
10 25	ND	> 69	ND
26	ND	> 12	ND
27	ND	> 45	ND
28	10	8.3	1.2
29	>48	241	>0.2
30	>8 but <41	6.1	>1.3 but <6.7
15 31	ND	> 41	ND
32	>40 but <200	8.3	>5 but <25
16	>32 but <160	0.00041	>78,125 but <390,625
17	1,700	51	> 33.3
20 44	>6.4 but <32	>6.4 but <32	> 1
45	<32	32	> 1
AZT	2000	0.04	50,000

EXAMPLE V: ACTIVITY OF SUKSDORFIN AGAINST HIV-INFECTED ACH-2 AND U1 CELLS

Effects of suksdorfin analogs on Chronically HIV-1 infected cells. The experimental design is as follows: The phorbol ester, PMA ( $10^{-8}$ M) and various concentrations of suksdorfin were either added or not added to both the chronically HIV-1 infected T cell line (ACH-2) and to the chronically HIV-1 infected monocytic cell line (U1). Cell-free supernatant was collected 72 hours post culture for p24 antigen ELISA.

The chronically HIV-1 infected cell lines, ACH-2 and U1 have been used extensively in the literature. When either cell line is cultured with PMA or various cytokines the level of HIV-1 expression as determined by p24 antigen ELISA is 5 increased. Since suksdorfin suppressed virus replication in acutely HIV-1 infected H9 cells, it was important to determine if it would have an effect on chronically HIV-1 infected cells. In addition, these two cell lines are helpful in predicting whether a drug might increase the *in vivo* replication of HIV 10 in an individual who is latently virally-infected.

Therefore, the questions which this experiment addressed were the following:

1. Does suksdorfin cause an increase in the amount of virus replication from either chronically T or 15 monocyte/macrophage infected cell line. The answer is no. This information is important to the FDA, since they will not permit administering an agent *in vivo* to an individual that might cause an increase in virus replication.
2. Does suksdorfin alter the amount of virus replication 20 from PMA-stimulated chronically HIV-1 infected cells? The answer is no. There was no significant alteration in the level of virus expression as measured by p24 antigen ELISA when PMA was added to cells which were also cultured in the presence of suksdorfin. Suksdorfin did not increase the amount of virus 25 produced by PMA alone. The above determinations were based in part on the data presented in Table 3.

TABLE 3

	Suksdorfin Concentration	ACH-2 Cells		U1 Cells	
		-PMA	+PMA	-PMA	+PMA
5	0 $\mu$ g/ml	3,676 pg/ml	52,122 pg/ml	0 pg/ml	6,963 pg/ml
10	20 $\mu$ g/ml	4,541 pg/ml	49,914 pg/ml	0 pg/ml	5,096 pg/ml
15	4 $\mu$ g/ml	4,723 pg/ml	61,235 pg/ml	0 pg/ml	9,728 pg/ml
	0.8 $\mu$ g/ml	3,821 pg/ml	55,910 pg/ml	0 pg/ml	7,360 pg/ml
	0.16 $\mu$ g/ml	3,688 pg/ml	50,775 pg/ml	0 pg/ml	6,611 pg/ml

There was a higher background in the ACH-2 cells (3,676 pg/ml) than compared to the U1 cells (0 pg/ml). A known viral inducer, when added to each cell line, caused a significant increase in the amount of p24 antigen in those cultures.

EXAMPLE VI:

**COMBINATION STUDY OF SUKSDORFIN WITH AZT, ddI and ddC.**

The data present in Table 4 shows toxicity data on a suksdorfin. The IC<sub>50</sub> value has decreased from >20 but <100 to >4 but <20 and the EC<sub>50</sub> value has increased from 0.5-0.8 to 1.5-2.8  $\mu$ g/ml.

Suksdorfin is found to act synergistically with AZT, ddI and ddC. The 20  $\mu$ g/ml concentration of suksdorfin was toxic to H9 cells. The 4  $\mu$ g/ml concentration of suksdorfin inhibited HIV-1 replication by 64% but when it was added to HIV-1 infected cultures containing AZT (0.0001  $\mu$ g/ml) the EC<sub>50</sub> concentration decreased by 400-fold and the TI value increased by 400-fold. Likewise, 4000-fold less ddI was needed when 4  $\mu$ g/ml of suksdorfin was present in the cultures as when ddI was used alone. Forty-fold less ddC was needed when it was added to cultures containing 4  $\mu$ g/ml of suksdorfin. This is significant data demonstrating that suksdorfin is expected to be useful in increasing the anti-HIV activity and/or decreasing the toxicity of these other FDA-approved drugs.

TABLE 4

	Compound	Purity	IC <sub>50</sub> (μg/ml)	EC <sub>50</sub> (μg/ml)	Therapeutic Index
5	Suksdorfin	pure	>4 but <20	2.8	>1.4 but <7.1
10	AZT	pure	>1	0.04	>25
15	ddI	pure	>1	0.4	>2.5
20	ddC	pure	>1	0.004	>250
25	4 μg/ml Suksdorfin + AZT	pure	>1	<0.0001	>10,000
	μg/ml Suksdorfin + ddI	pure	>1	<0.0001	>10,000
	μg/ml Suksdorfin + ddC	pure	>1	<0.0001	>10,000

EXAMPLE VII:Anti-HIV activity of suksdorfin

30       Suksdorfin was tested on peripheral blood mononuclear cells (PBMCs) which were stimulated for 3 days with PHA (1 μg/ml). The cells were collected and then infected with the 20X stock HIV-1 (IIIB). This is the same virus that is used in the drug screening assay. PBMCs were used for the following 35 reasons: (1) It is another type of T cell infection. (2) PBMCs are freshly isolated cells not a cell line as are H9 cells. (3) We need to know if the effects of suksdorfin were limited to only an acute HIV-1 infection of a T cell line such as H9 cells. After the cells were infected with HIV-1, the 40 cells were washed and then placed in medium with the cytokine, interleukin 2 (IL-2). IL-2 is needed to keep the cells activated which is necessary also for virus replication.

45       Suksdorfin was also tested on an acute HIV-1 infection of the promonocytic cell line, U937. This was done again to determine drug specificity but this time on a monocytic cell line.

As the data indicates, suksdorfin can suppress an acute HIV-1 replication in fresh PBMCS (a T cell infection) and in U937 cells (a monocytic cell line). The data from the PBMCS infection correlates with other data in which H9 cells (a T cell line) were infected with HIV-1 and then suksdorfin was added. The EC<sub>50</sub> was 1.5, as presented in Table 5. The EC<sub>50</sub> value determined from the U937 cells was approximately one third of that for the PBMCS.

TABLE 5

Compound	Purity	IC <sub>50</sub> ( $\mu$ g/ml)	EC <sub>50</sub> ( $\mu$ g/ml)	Therapeutic Index
Suksdorfin	pure			
+PBMCS		>4 but <20	1.5	>2.7 but <13.3
U937 cell line		>20	0.58	>34.5

**EXAMPLE VIII: Anti-HIV Activity Results for Suksdorfin Analog Compounds**

Table 6 shows results from 4 separate assays as presented in the above examples on compound 16 (LH70C1-4L) when tested alone and data from 1 experiment when tested in combination with either AZT, ddI, or ddC.

Compound 16 was tested for its ability to inhibit HIV-1 replication in H9 cells. An activity was found of 256 pg/ml (0.00041  $\mu$ M). The IC<sub>50</sub> range (>32 but <160) was consistent and showed low toxicity. EC<sub>50</sub> results: 3 assays demonstrated significant suppression. During the assays the agent mediated 44% and 35% suppression at 0.000256  $\mu$ g/ml, respectively. The EC<sub>50</sub> value was at least about 0.000256  $\mu$ g/ml (256 pg/ml [0.00041  $\mu$ M]). Based on an EC<sub>50</sub> value of 256 pg/ml, the TI was >78,125 but <390,625 for 16 (LH70C1-4L).

Table 6

16 (LH70C1-4L)	Purity	IC <sub>50</sub> (μg/ml)	EC <sub>5</sub> (μg/ml) [μM]	Therapeutic Index
	pure	>20 but <100 (>32 but <160)	0.000256 (0.00041)	>78,125 but >390,625

5      **Results from chronic U1 experiment with 16**

Compound 16 was also assayed on ACH-2 (chronically HIV-1 infected T cell line). U1 cells are also chronically HIV-1 infected cells but they are from the monocytic cell line, U937. The data presented in Table 7 indicates the following points:

10      Compound 16 (without PMA) did not induce the U1 cells to make virus. This was also the same for AZT. The amount of HIV-1 present in these supernatants is very low and not significantly above assay background. The fact that the drug did not induce virus replication is important since individuals 15 tend to be latently infected with HIV; therefore, it is important that a drug not increase *in vivo* viral burden during therapy, as shown by this data.

15      Compound 16 (with PMA) did not suppress virus replication. The results were identical to AZT. This is not surprising 20 since AZT does not have an effect on chronically HIV infected cells (in the literature) since reverse transcription has already occurred.

25      There was good virus expression in the control U1 sample as compared to background. The various drug-treated samples were not significantly different than control. For there to be a significant increase, the amount of p24 antigen in the supernatant needs to increase at least 4-5 fold. This was not the case.

30      Results of testing the ability of compound 16 to suppress virus replication during an HIV-2 infection of HUT-78 cells.

During this experiment, HIV-2 was used. The basic assay system is identical to that used for HIV-1 except that a different virus stock was used and rather than a p24 antigen ELISA determination a reverse transcriptase assay was used to

detect the presence of the virus.

As the data indicates in Table 8, compound 16 had no effect on the virus replication of HIV-2. This data will help in designing future experiments especially as they relate to 5 animal model system for testing the *in vivo* activity of compound 16. Compound 16 will also be tested in simian immunodeficiency virus (SII)-infected cells since SII and HIV are similar.

AZT was used as a positive drug control and it inhibited 10 HIV-2 replication.

Table 7

Sample Identification		P24 - PMA	pg/ml + PMA
U1 control		0	5660
5	U1+LH70C1-4L 16 [ $\mu$ m] (20 $\mu$ g/ml) [32]	95	9530
	(4 $\mu$ g/ml) [6.4]	41	8742
	(0.8 $\mu$ g/ml) [1.3]	88	8390
	(0.16 $\mu$ g/ml) [0.26]	76	7162
	(0.032 $\mu$ g/ml) [0.051]	101	8090
	(0.0064 $\mu$ g/ml) [0.010]	90	6419
	(0.00128 $\mu$ g/ml) [0.0021]	99	6335
	(0.000256 $\mu$ g/ml) [0.00040]	78	7757
	(0.0000512 $\mu$ g/ml) [0.000084]	56	8710
	(0.0000102 $\mu$ g/ml) [0.000016]	52	7328
10	U1+AZT (10 $\mu$ g/ml) [37] (1 $\mu$ g/ml) [3.7]		97
	(0.1 $\mu$ g/ml) [0.37]	72	7898
	(0.01 $\mu$ g/ml) [0.037]	53	4363
		50	9626
15	U1+AZT (10 $\mu$ g/ml) [37] (1 $\mu$ g/ml) [3.7]		97
	(0.1 $\mu$ g/ml) [0.37]	72	7898
	(0.01 $\mu$ g/ml) [0.037]	53	4363
		50	9626

Table 8

Sample Identification		RT Activity (CPM)	
20	LH70C1-4L at: [ $\mu$ m] 4 $\mu$ g/ml [6.4]		13,664
	0.8 $\mu$ g/ml [1.3]	14,871	
	0.16 $\mu$ g/ml [0.26]	11,535	
	0.032 $\mu$ g/ml [0.051]	16,463	
	0.0064 $\mu$ g/ml [0.010]	18,403	
	0.00128 $\mu$ g/ml [0.0021]	9,568	
	0.000256 $\mu$ g/ml [0.00040]	15,625	
	0.0000512 $\mu$ g/ml [0.000084]	16,937	
	0.0000102 $\mu$ g/ml [0.000016]	13,992	
25	AZT at: [ $\mu$ m] 10 $\mu$ g/ml [37]		1,990
	1 $\mu$ g/ml [3.7]	1,826	
	0.1 $\mu$ g/ml [0.37]	2,662	
	0.01 $\mu$ g/ml [0.037]	1,919	
30	Infected Control (no drug)		17,264
	Uninfected Control		719
35			

40 Results of testing the ability of compound 16 (LH70C1-4L) to suppress virus replication during an HIV-1 infection of primary monocytes.

In order to determine if compound 16 suppressive activity was limited to only fresh T cells infected with HIV-1,

elutriated monocytes were infected with HIV-1 and then cultured with various concentrations of compound 16 or AZT. As the data indicates in Table 9, 16 is also able to suppress HIV-1 replication in fresh elutriated monocytes. This illustrates 5 that the effect of the drug is not only limited to T cells but also can effect virally infected monocytes.

AZT was used as a positive drug control and it inhibited HIV-1 replication in the human monocytes.

Table 9

	Sample Identification	p24 antigen (pg/ml) Day 17	p24 antigen (pg/ml) Day 28
16 at: [μM]	20 μg/ml [32]	5	0
	4 μg/ml [6.4]	6	0
	0.8 μg/ml [1.3]	6	0
	0.16 μg/ml [0.26]	7	0
	0.032 μg/ml [0.051]	94	0
	0.0064 μg/ml [0.010]	66	584
	0.00128 μg/ml [0.0021]	306	208
	0.000256 μg/ml [0.00040]	70	760
	0.0000512 μg/ml [0.000084]	52	824
	0.0000102 μg/ml [0.000016]	49	1536
AZT at: [μM]			
	10 μg/ml [37]	0.1	0
	1 μg/ml [3.7]	2	0
	0.1 μg/ml [0.37]	5	0
	0.01 μg/ml [0.037]	7	0
	0.001 μg/ml [0.0037]	100	0
	0.0001 μg/ml [0.00037]	83	0
Infected Control (no drug)		205	2944
	Uninfected Control	7	14

Table 10

Sample Identification	P24 - PMA	pg/ml + PMA
ACH-2 control	928	25,572
5 ACH-2+ 16 at: [μM] (20 μg/ml) [3.2] (4 μg/ml) [6.4] (0.8 μg/ml) [1.3] (0.16 μg/ml) [0.26]	1509 1194 976 1174	24,858 23,547 20,183 21,865
10 (0.032 μg/ml) [0.051] (0.064 μg/ml) [0.010] (0.00128 μg/ml) [0.0021] (0.00025 μg/ml) [0.00040]	1319 955 811 777	24,650 24,364 22,344 22,756
15 (0.0000512 μg/ml) [0.000084] (0.0000102 μg/ml) [0.000016]	659 666	16,079 17,938
U1+AZT (10 μg/ml) [37] (1 μg/ml) [3.7] (0.1 μg/ml) [0.37] (0.01 μg/ml) [0.037]	939 904 942 796	16,584 17,088 10,621 21,373

20 Results (table 10) from adding compound 16 to the chronically HIV-infected T cell line, ACH-2, according to methods in above examples. ACH-2 are a chronically HIV-1 infected T cell line. It was derived from A3.01 cells which is a subclone of the CEM cell line. The data below indicates 25 the following points:

There was a 27-fold induction of virus replication when PMA was added to ACH-2 cells as compared to medium alone. This result indicates suitability for *in vivo* treatment of HIV infection.

30 Compound 16 (without PMA) did not induce the ACH-2 cells to make virus. This was also the same for AZT. These cells make a greater quantity of HIV-1 constitutively than do the U1 cells. However, there was no significant increase in the level 35 of virus expression in the presence of either compound 16 or AZT as compared to medium alone. These are good results indicating suitability for *in vivo* treatment of HIV infection.

Compound 16 (with PMA) did not suppress virus replication. The results were identical to AZT. This is not surprising since AZT does not have an effect on chronically HIV infected 40 cells (in the literature) since reverse transcription has already occurred. This data agrees with the U1 results sent

earlier this week.

The various drug-treated samples were not significantly different than PMA-induced control. For there to be a significant increase, the amount of p24 antigen in the supernatant needs to increase or decrease at least 4-5 fold.

Results (table 11) from adding Suksdorfin to fresh monocytes infected with HIV-1, as presented herein.

The monocytes which were used for this experiment were obtained by adherence and not by elutriation; therefore, this cell population is not as pure as what was used for the LH70C1-4L-(16) monocyte data above.

Suksdorfin at 20 and 4  $\mu$ g/ml did suppress HIV-1 replication in fresh monocytes. This was more pronounced at day 12, which was approximately the peak of virus replication. AZT was used as the positive drug control and it was suppressive.

Table 11

	Sample Identification	p24 pg/ml (%suppression)		
		Day 6	Day 12	Day 18
20	Infected Control	59,648	270,541	105,882
25	Infected + Suksdorfin at: (20 $\mu$ g/ml) (4 $\mu$ g/ml) (0.8 $\mu$ g/ml) (0.16 $\mu$ g/ml) (0.032 $\mu$ g/ml)	16,712 (72) 48,748 (18) 53,043 (0) 70,195 (0) 64,614 (0)	25,567 (91) 89,467 (67) 163,656 (40) 203,633 (0) 173,998 (0)	23,506 (78) 103,834 (0) 130,970 (0) 125,440 (0) 105,882 (0)
30	Infected + AZT at: (5 $\mu$ g/ml) (1 $\mu$ g/ml) (0.2 $\mu$ g/ml) (0.04 $\mu$ g/ml) (0.008 $\mu$ g/ml)	13,542 8,705 34,360 23,234 42,004	10,170 5,354 32,778 17,144 70,380	12,330 6,830 31,759 22,993 75,428

Table 12

Sample Identification	Purity	IC <sub>50</sub> (μg/ml)	EC <sub>50</sub> (μg/ml)	Therapeutic Index
LH70C1-4L (16)				
+U937 cells	pure	>4 but <20	0.00128	>3,125 but <15,625
+ PBMCS	pure	>4 but <20	0.018	>222 but <1,111

The effect of compound 16 was tested on HIV-1 infected U937 cells and PBMCS (Table 12).

As part of efforts to biologically characterize 16 the 10 monocytic cell line, U937 and peripheral blood mononuclear cells (PBMCS) were separately infected with HIV-1 and then had various concentrations of the analog added for 4 days of culture. As shown in table 12, there was suppression detected with both types of cellular infections.

15 EXAMPLE IX: SUKSDORFIN ANALOG PURIFICATION AND ACTIVITY

Chemistry

Suksdorfin 1 was obtained according to Example I. Suksdorfin was also isolated previously from the roots of *Angelica Morii* Hayata (Shan Du Huo), a drug of folk remedy in Taiwan (Hata, 20 et al., *Chem. Pharm. Bull.* 1974, 22, 957).

Biological Results

Suksdorfin 1 suppressed virus replication in acutely HIV-1 (IIIB isolate) infected H9 cells as presented in Example I. Compound 1 also suppressed acute HIV-1 replication in fresh 25 peripheral blood mononuclear cells (a T cell infection) with an EC<sub>50</sub> value of 3.9 μM and in U937 cells (a promonocytic cell line) with an EC<sub>50</sub> value of 1.5 μM.

When compound 1 was added for 72 hours to the chronically HIV-1 infected T cell line, ACH-2, and to the chronically HIV-1 30 infected promonocytic cell line, U1, there was no increase in the induction of virus expression from either cell line. Even

when both chronically HIV-1 infected cell lines were cultured in the presence of a known virus inducer such as the phorbol ester, PMA (phorbol 12-myristate 13-acetate), there was no alteration in the level of virus expression (Table 2). In 5 addition, compound 1 was found to potentiate the anti-HIV effects of three nucleosides AZT, ddi, and ddc. Combination of 4  $\mu$ g/ml of 1 with these nucleosides reduced their EC<sub>50</sub> values by 40-fold (for ddc), 400-fold (for AZT), and 4000-fold (for ddi) (Table 15).

10 As shown in Table 1, only 1 showed potent anti-HIV-1 activity at nontoxic concentrations. All other compounds (2-11) were either inactive or were less active and more toxic. The furanocoumarins (3-10) were inactive or active only at toxic concentrations (e.g., the therapeutic index of 4 was 15 1.3). The dicoumaryl ether 11 showed no activity.

#### Discussion

The inhibition of virus replication mediated by suksdorfin 1 in both T (H9) and promonocytic (U937) cell line acute HIV-1 infections designates this compound as a lead structure in a 20 new class of potential anti-HIV agents. To further demonstrate suksdorfin's broad cellular specificity and potential clinical relevance, HIV-1 replication in fresh PHA-stimulated PBMCs (T cell) was found also to be suppressed in its presence. The absence of increased levels of viral replication in chronically 25 infected cells treated with compound 1 suggests that it would not increase the *in vivo* replication of HIV in a patient who is latently infected. The synergistic effects of compound 1 with the reverse transcriptase inhibitors AZT, ddi, and ddc are significant results demonstrating that compound 1 and analogs 30 accord to formulae (I)-(XX) are expected to have increased anti-HIV activity and/or decreased toxicity of these known nucleoside drugs. In the preliminary structure-activity relationship study, the 4'-isovaleryl group of 1 was important for selective HIV-1 inhibition. Replacement of this group with 35 an angeloyl moiety as in pteryxn compound 2 increased the toxicity by -fold and slightly reduced anti-HIV-1 activity.

In summary, suksdorfin analogs as compounds according to formulae (I)-(XX) are expected to be useful for chemotherapy

of HIV infection and/or AIDS, either alone or in combination with FDA-approved nucleosides. Preliminary *in vitro* results have shown good anti-HIV activities in a variety of cell lines.

#### Experimental Section

##### 5 Chemistry

*Isolation of Suksdorfin as presented herein, in Examples I-VI,* The *Lomatium suksdorffii* plant used was collected in Washington state. The ground, air-dried fruits (100 g) were extracted with MeOH. The active MeOH extract was partitioned between 10 hexane and 90% MeOH (1:1). Evaporation of the active hexane extract gave a crystalline residue. Recrystallization of this residue with hexane yielded 1 as colorless needles (1 g, 1% yield): mp 140-141°;  $[\alpha]D^{24}+4^\circ$  (c 0.5, EtOH). The IR and NMR data of compound 1 are identical to those reported (Willette, 15 et al. *J.Pharm.Sci.* 1962, 51, 149) (Hata, et al., *Chem.Pharm.Cull.* 1974, 22, 957) for suksdorfin, which was previously isolated from this same species. (Willette, et al. *J.Pharm.Sci.* 1962, 51, 149)

##### *Suksdorfin-related Coumarins*

20 Compounds 2 (pteryxin), (Lee, et al., *J. Pharm. Sci.* 1968, 57, 865) 3 (columbianadin), (Soine, et al., *J. Pharm. Sci.* 1967, 56, 655) (Willette, et al. *J. Pharm. Sci.* 1964, 53, 275) 4 (nodakenetin), (Lee, et al., *J.Pharm.Sci.* 1969, 58, 675) 5 (nodakenin), (Lee, et al., *J.Pharm.Sci.* 1969, 58, 675) 6 25 ) (acetyl nodakenin), (Lee, et al., *J.Pharm.Sci.* 1969, 58, 675) 7 (imperatorin), (Lee, et al., *J.Pharm.Sci.* 1969, 58, 675) 8 (bergapten), (Lee, et al., *J. Pharm.Sci.* 1969, 58, 681) 9 (isoimperatorin), (Lee, et al., *J.Pharm.Sci.* 1969, 58, 675) 10 (oxypeucedanin), (Lee, et al., *J.Pharm.Sci.* 1969, 58, 675) and 30 11 (daphnoretin) (Lee, et al., *J. Nat. Prod.* 1981, 44, 530) were obtained according to published methods.

##### *Biology*


35 Chronically HIV-1 infected cell lines. HIV-1 chronically infected T cell line, ACH-2<sup>12</sup>, and HIV-1 chronically infected promonocytic cell line, U1 13, were continuously maintained in RPMI 1640 with 10% fetal calf serum (FCS). For experiments, the cell lines were only used in the low phase of growth.


Cells ( $0.5 \times 10^6$  cells/well) and either various concentrations of suksdorfin or medium alone were added to 24-well plates in the presence or absence of PMA ( $10^{-8}$  M). After 72 hours at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ , an aliquot of the cell-free supernatants were 5 collected and analyzed for p24 antigen by ELISA (see below for details of p24 antigen ELISA).

*HIV Growth Inhibition Assay:* The T cell line, H9, and the promonocytic cell line, U937, were maintained separately in continuous culture with complete medium (RPMI 1640 and 10% 10 fetal calf serum (FCS) at 5%  $\text{CO}_2$  and  $37^\circ\text{C}$ . Cell lines were used in experiments only when in log phase of growth; whereas, uninfected peripheral blood mononuclear cells (PBMCs) were first stimulated with PHA (1  $\mu\text{g}/\text{ml}$ ) for 3 days. All cell targets were incubated with HIV-1 (IIIB isolate,  $\text{TCID}_{50}$   $10^4$  15 IU/ml, at a multiplicity of infection of 0.1-0.01 IU/cell) for 1 hour at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ . The cell lines and PBMCs were washed thoroughly to remove unabsorbed virions and resuspended at  $4 \times 10^5$  cells/ml in complete medium or complete medium with 10% v/v interleukin (Pettinato, et al. *J. Amer. Pharm. Asso.* 20 1959, 48, 423) IL-2, respectively. Aliquots (1 ml) were placed in wells of 24-well culture plates containing an equal volume of test compound (diluted in the appropriate culture medium). After incubation for 4 days at  $37^\circ\text{C}$ , cell density of uninfected cultures was determined by counting cells in a Coulter counter 25 to assess toxicity of the test compound. A p24 antigen ELISA assay was used to determine the level of virus released in the medium of the HIV-infected cultures. The p24 antigen assay uses a HIV-1 anti-p24 specific monoclonal antibody as the capture antibody coated-on 96-well plates. Following a sample 30 incubation period, rabbit serum containing antibodies for HIV-1 p24 is used to tag any p24 "captured" onto the microtiter well surface. Peroxidase conjugated goat anti-rabbit serum is then used to tag HIV-1 p24 specific rabbit antibodies which have complexed with captured p24. The presence of p24 in test 35 samples is then revealed by addition of substrate. The cut-off for the p24 ELISA assay is 12. pg/ml. P24 in the culture medium was quantitated against a standard curve containing known amounts of p24. The effective ( $\text{EC}_{50}$ ) and inhibitory ( $\text{IC}_{50}$ )

concentrations (for anti-HIV activity and cytotoxicity, respectively) were determined graphically. Both the EC<sub>50</sub> and IC<sub>50</sub> values were calculated by plotting drug concentration versus percent inhibition, and then identifying a 50% inhibition value from the graph.


5 *Combination Study:* The experimental design is identical to the growth inhibition assay except that various concentrations of AZT, ddI or ddC were also added to cultures of acutely HIV-1 infected H9 cells that either have or have no 10 received different concentrations of suksdorfin. The concentrations of AZT, ddI and ddC were 5 ten-fold dilutions starting at 1  $\mu$ g/ml.



 $R_1$  $R_2$ 

7 (imperatorin)

H




8 (bergapten)

OCH<sub>3</sub>


H

9 (isoimperatorin)




H

10 (oxypeucedanin)



H



11 (daphnoretin)

Table 13. HIV Inhibition of HIV-1 Replication in H9 Lymphocytes by Suksdorfin 1 and Related Compounds 2-11.

Compound	IC <sub>50</sub> (μM) <sup>a</sup>	IC <sub>50</sub> (μM) <sup>b</sup>	Therapeutic Index
1 Suksdorfin	> 52.0	1.3	>40.0
2 Pteryxin	> 10.4	4.6	> 3.7
3 Columbianadin	> 6.1	4.6	> 1.3
4 Nodakenetin	ND <sup>c</sup>	Inactive <sup>d</sup>	ND
5 Nodakenin	ND	Inactive	ND
6 Acetyl Nodakenin	ND	Inactive	ND
7 Impratorin	> 74.1	11.1	> 6.7
8 Bergapten	> 92.6	30.1	> 3.1
9 Isoimperatorin	>185.2	40.7	> 4.6
10 Oxypeucedanin	> 69.9	31.5	> 2.2
11 Daphnoretin	ND	Inactive	ND

<sup>a</sup> Concentration which inhibits uninfected cell growth by 50%

<sup>b</sup> Concentration which inhibits viral replication by 50%

<sup>c</sup> ND = not determined

<sup>d</sup> No suppression of HIV-1 replication in H9 cells

Table 14. Inhibition of HIV-1 Replication in ACH-2 and U1 Cells by Suksdorfin 1

Suksdorfin Concentration	ACH-2 Cells <sup>a</sup>		U 1 Cells <sup>b</sup>	
	-PMA <sup>c</sup>	+PMA <sup>d</sup>	-PMA	+PMA
0 μg/ml	3,676 pg/ml	52,122 pg/ml	0 pg/ml	6,963 pg/ml
20 μg/ml	4,541 pg/ml	49,914 pg/ml	0 pg/ml	5,096 pg/ml
4 μg/ml	4,723 pg/ml	61,235 pg/ml	0 pg/ml	9,728 pg/ml
0.8 μg/ml	3,821 pg/ml	55,910 pg/ml	0 pg/ml	7,360 pg/ml
0.16 μg/ml	3,688 pg/ml	50,775 pg/ml	0 pg/ml	6,611 pg/ml

<sup>a</sup> Chronically HIV-1 infected T cell line

<sup>b</sup> Chronically HIV-1 infected promonocytic cell line

<sup>c</sup> p24 antigen level after 72 hours in culture

<sup>d</sup> PMA 10<sup>-8</sup> M

Table 15. Inhibition of HIV-1 replication in H9 Lymphocytic Cells by Combination of Suksdorfin 1 and AZT, ddI, and ddC.

Compound	IC <sub>50</sub> (μM) <sup>a</sup>	IC <sub>50</sub> (μM) <sup>b</sup>	Therapeutic Index
Suksdorfin	> 4 but <20	2.8	>1.4 but < 7.1
AZT	> 1	0.04	> 25
ddI	> 1	0.4	> 2.5
ddC	> 1	0.004	>250
4 μg/ml Suksdorfin + AZT	> 1	< 0.0001	>10,000
4 μg/ml Suksdorfin + ddI	> 1	< 0.0001	>10,000
4 μg/ml Suksdorfin + ddC	> 1	< 0.0001	>10,000

<sup>a</sup> Concentration which inhibits uninfected cell growth by 50%

<sup>b</sup> Concentration which inhibits viral replication by 50%

#### EXAMPLE X: SUKSDORFIN ANALOG SYNTHESIS AND ACTIVITY

Recently, much effort has been focused on the search for compounds effective in the inhibition of HIV, the etiologic agent of AIDS. The result has been the identification of numerous inhibitors of HIV reverse transcriptase (RT) and HIV protease. These include nucleoside analogs and peptide mimics, respectively. Although the RT inhibitors, such as AZT, ddI, and ddC, are available as anti-AIDS drugs, their clinical effectiveness is limited by their toxicity as well as the development of drug resistant virus. The discovery and development of a new class of anti-HIV agents with structures and mechanisms of action different from those of nucleoside analogs mentioned above are of current interest.

In the course of our continuing search for novel anti-HIV agents from natural products, suksdorfin compound 1 was isolated as an active principle from the fruits of *Lomatium suksdorffii* (Umbelliferae) e.g., as presented in Example VI. Compound 1 exhibited inhibitory activity against HIV-1 replication in acutely infected H9 lymphocytes with an EC<sub>50</sub> value of 1.3 μM and a therapeutic index of > 40. Moreover, compound 1 was found to demonstrate a synergistic effect

against HIV replication when it was co-administered with either AZT, ddI, or ddC (data not shown). This discovery has prompted our synthesis of the dihydroseselin type pyranocoumarin derivatives (**compounds 2-5**) as a new class of anti-HIV agents.

5 The synthesis of **2-5** is shown in Scheme 1 as present in Example IV. Seselin compound **7** was prepared from the commercially available 7-hydroxycoumarin **6** according to a procedure reported in the literature. (Hlubuek, et al., Aust. J. Chem., 1971, 62, 2347-2354) Subsequent oxidation 10 (El-Antably, et al., J. Pharm. Sci., (1973) 62 1643-1648) of compound **7** with  $\text{OSO}_4$  gave the racemic *cis*-khellactone compound **8**. Alternatively, compound **7** was treated with m-chloroperbenzoic acid (Schroeder, et al., Chem. Ber., 1959, 9 3 , 2 3 8 8 - 2 3 6 3 ) to furnish 15 **4'-O-m-chlorobenzoyl-(+/-)-trans-khellactone 9**, which was then hydrolyzed to produce the racemic *trans*-khellactone **10**. Treatment of **8** and **10** with (-)-camphanoyl chloride (Gerlach, et al., J. Chem. Soc., Chem. Commun., 1973, 274-275) afforded diastereoisomers in each case. The diastereoisomers were 20 separated by repeated column chromatography to yield four isomers of di-O-(-)-campanoylkhellactone (**2-5**).

The stereochemistries of **2-5** were assigned as follows: the naturally occurring di-O-acyl-(+)-*cis*-khellactone (e.g., **11**) was hydrolyzed with base to give (+)-*cis*-**11** as well as 25 (+)-*trans*-**12** khellactones. (Willette, et al., J. Pharm. Sci. 1962, 51, 149-156) Treatment of **11** and **12** with (-)-camphanoyl chloride afforded their corresponding diesters, which were found to be identical with **2** and **4**, respectively, by direct spectral comparison (Scheme 2).

30 As shown in Table 16, compound **2** demonstrated extremely potent inhibitory activity against HIV-1 replication in acutely infected H9 lymphocytes with an  $\text{EC}_{50}$  value of 0.00041  $\mu\text{M}$ . The  $\text{IC}_{50}$  range against uninfected H9 cell growth was >32 but <160  $\mu\text{M}$ , which was less toxic than the active principle (compound 35 **1**). The therapeutic index for **2** was > 78,049 but < 390,244. Since the  $\text{EC}_{50}$  value and the therapeutic index of AZT in this assay system are 0.15  $\mu\text{M}$  and 12,500, respectively, compound **2** is more potent than AZT as an anti-HIV agent.

Compound 3, the diastereoisomer of 2, as well as the *trans*-khellactone derivatives with same acyl groups (4 and 5) showed much less anti-HIV activity than 2. Since only 1 and 2 show potent anti-HIV activity and both contain the same 5 configuration at C-3' and C-4', the (+)-*cis*-khellactone skeleton can be required for the enhanced anti-HIV activity.


In order to determine whether the anti-HIV activity of 2 was limited to acute HIV-1 infections of the T cell line, H9, both PHA-stimulated peripheral blood mononuclear cells (PBMCs) 10 and the promonocytic cell line, U937, were separately infected with HIV-1. The results showed that there was suppression detected no matter which type of target cell was used. This indicates that compound 2 was an effective suppressor of virus replication no matter if fresh T cells (PBMCs) or a T cell line 15 (H9) was used or a monocytic cell (U937) was infected with HIV-1. The EC<sub>50</sub> value and the therapeutic index against PBMCs were 0.029  $\mu$ M and >222 but <1,111, while those against U937 were 0.0021  $\mu$ M and >3,125 but <15,625.

Studies on the mechanism of action for 1, 2 and other 20 related compounds are in progress.


In conclusion, compound 2 and its related compounds, such as 1, represent a new class of potent anti-HIV agents, which are structurally unique compared with other known anti-AIDS drugs.

25 Table 16 HIV Inhibition by Di-O-(-)-camphanoylkhellactones (2-5), Suksdorfin 1, and AZT


Compounds	IC <sub>50</sub> ( $\mu$ M)	EC <sub>50</sub> ( $\mu$ M)	Therapeutic Index
2	>32 but <160	0.00041	>78,049 but <390,244
3	1,700	51	>33.3
4	>6.4 but <32	>6.4 but <32	>1
5	>32	32	>1
Suksdorfin1	>52	1.3	>40
AZT	1,875	0.15	12,500




(1)




(2)




(3)



(4)




(5)



Scheme 10 Synthesis of 3',4'-Di-O-Camphanoylkhellactones (2-5)

(a) 3-Chloro-3-methylbut-1-yne, KI,  $K_2CO_3$  In acetone (b) diethylaniline, reflux  
 (c)  $OsO_4$ , dioxane (d)  $NaHSO_3$  (e) *m*-chloroperbenzoic acid,  $Cl:Cl_3$  (f) 0.5 N  $KClCl_3$  1-dioxane  
 (g) (-)-camphanoyl chloride, pyridine



Scheme 20

## Detailed Analytical Data for 2-5

3', 4'-Di-O-(-)-Camphanoyl-(+)-cis-Khellactone (2):  
 Colorless needles (from EtOH); mp 200-202°C;  
 $[\alpha]_D/20+31.1^\circ$  (c=0.5, CHCl<sub>3</sub>); Positive FAB MS m/z 623 (M+H)+,  
 5 425 (M-camphanic acid)+, 227 (M-2xcamphanic acid)+; IR (KBr)  
 1790, 1745 (COO), 1605 (C=C); 1H NMR (300 MHz, CDCl<sub>3</sub>) ? 7.62  
 (1H, d, J=9.5 Hz, H-4), 7.41 (1H, d, J=8.5 Hz, H-5), 6.82 (1H,  
 d, J=8.5 Hz, H-6), 6.66 (1H, d, J=5 Hz, H-4'), 6.24 (1H, d,  
 J=9.5 Hz, H-3), 5.39 (1H, d, J=5 Hz, H-3'), 2.50, 2.23, 1.94,  
 10 1.70 (each 2H, m, camphanoyl CH<sub>2</sub>), 1.50, 1.45 (each 3H, s,  
 2'-CH<sub>3</sub>), 1.12, 1.11, 1.10, 1.08, 1.01, 0.98 (each 3H, s,  
 camphanoyl CH<sub>3</sub>). Anal. Calcd for C<sub>34</sub>H<sub>38</sub>O<sub>11</sub>:CF, 65.58; H, 6.15.  
 Found: C, 65.41; H, 6.21.

3', 4'-Di-O-(-)-Camphanoyl-(-)-cis-Khellactone (3):  
 15 Colorless needles (from EtOH); mp 242-244°C;  
 $[\alpha]_D/20-67.7^\circ$  (c=0.5, CHCl<sub>3</sub>); Positive FAB MS m/z 623 (M+H)+,  
 425 (M-camphanic acid)+, 227 (M-2xcamphanic acid)+; IR (KBr)  
 1780, 1750 (COO), 1605 (C=C); 1H NMR (300 MHz, CDCl<sub>3</sub>) ? 7.61  
 (1H, d, J=9.5 Hz, H-4), 7.40 (1H, d, J=8.5 Hz, H-5), 6.82 (1H,  
 20 d, J=8.5 Hz, H-6), 6.74 (1H, d, J=4.5 Hz, H-4'), 6.22 (1H, d,  
 J=9.5 Hz, H-3), 5.47 (1H, d, J=4.5 Hz, H-3'), 2.55, 2.34, 2.10,  
 1.93, 1.70 (8H in total, each m, camphanoyl CH<sub>2</sub>), 1.56, 1.45  
 (each 3H, s, 2'-CH<sub>3</sub>), 1.13, 1.12, 1.06, 1.04, 0.94 (18H in  
 total, each s, camphanoyl CH<sub>3</sub>). Anal. Calcd for C<sub>34</sub>H<sub>38</sub>O<sub>11</sub>:CF,  
 25 65.58; H, 6.15. Found: C, 65.46; H, 6.12.

3', 4'-Di-O-(-)-Camphanoyl-(-)-trans-Khellactone (4):  
 Colorless needles (from EtOH); mp 249-251°C;  
 $[\alpha]_D/20+18.4^\circ$  (c=0.5, CHCl<sub>3</sub>); Positive FAB MS m/z 623 (M+H)+,  
 425 (M-camphanic acid)+, 227 (M-2xcamphanic acid)+; IR (KBr)  
 30 1790, 1770, 1750 (COO), 1610 (C=C); 1H NMR (300 MHz, CDCl<sub>3</sub>) ?  
 7.63 (1H, d, J=9.5 Hz, H-4), 7.42 (1H, d, J=8.5 Hz, H-5), 6.86  
 (1H, d, J=8.5 Hz, H-6), 6.30 (1H, d, J=3.5 Hz, H-4'), 6.24 (1H,  
 d, J=9.5 Hz, H-3), 5.39 (1H, d, J=3.5 Hz, H-3'), 2.50, 2.46,  
 2.07, 1.93, 1.66 (8H in total, each m, camphanoyl CH<sub>2</sub>), 1.50,  
 35 1.41 (each 3H, s, 2'-CH<sub>3</sub>), 1.12, 1.09, 1.08, 1.00, 0.98, 0.97  
 (each 3H, s, camphanoyl CH<sub>3</sub>). Anal. Calcd for C<sub>34</sub>H<sub>38</sub>O<sub>11</sub>:CF,

65.58; H, 6.15. Found: C, 65.60; H, 6.17.

3', 4'-Di-O-(-)-Camphanoyl-(-)-*trans*-Khellactone (5): Colorless needles (from EtOH); mp 253-254 °C;  $[\alpha]_D^{20}$  -42.0° (c=0.5, CHCl<sub>3</sub>); Positive FAB MS m/z 623 (M+H)+, 5 425 (M-camphanic acid)+, 227 (M-2x camphanic acid)+; IR (KBr) 1800, 1750, 1735, (COO), 1605 (C=C); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.64 (1H, d, J=9.5 Hz, H-4), 7.41 (1H, d, J=8.5 Hz, H-5), 6.84 (1H, d, J=8.5 Hz, H-6), 6.29 (1H, d, J=3.5 Hz, H-4'), 6.26 (1H, d, J=9.5 Hz, H-3), 5.40 (1H, d, J=3.5 Hz, H-3'), 2.49, 2.12, 10 1.92, 1.68 (each 2H, m, camphanoyl CH<sub>2</sub>), 1.50, 1.41 (each 3H, s, 2'-CH<sub>3</sub>), 1.10, 1.09, 1.07, 1.06, 0.99, (18H in total, each s, camphanoyl CH<sub>3</sub>). Anal. Calcd for C<sub>34</sub>H<sub>38</sub>O<sub>11</sub>: CF, 65.58; H, 6.15. Found: C, 65.66; H, 6.19.

All references cited herein, including journal articles 15 or abstracts, published or corresponding U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the 20 references cited within the references cited herein are also entirely incorporated by reference.


Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way 25 an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will 30 so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to 35 be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented

herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

WHAT IS CLAIMED IS:

1. A compound according to formula (I):



wherein R<sup>1</sup>, R<sup>2</sup> are either cis -  $\beta$  or cis -  $\alpha$ , or trans-3'- $\alpha$  or 5 trans-3'- $\beta$  oriented, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> O-acyl, O-alkyl, amide or CH<sub>2</sub>OOR', where R' is C<sub>1-10</sub> alkyl, acyl or amide; R<sup>5</sup> is H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, CF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>7</sup>, where R<sup>7</sup> is C<sub>1-10</sub> alkyl, amide or acyl; and R<sup>6</sup> is H, halogen,  
10 C<sub>1-10</sub> alkyl, or CH<sub>2</sub>CH<sub>2</sub>NR<sup>1</sup>R<sup>8</sup>, where R<sup>8</sup> is C<sub>1-10</sub> alkyl, and wherein C3' and C4', C<sub>3</sub> and C<sub>4</sub> can be bound by a single or double bond.

2. A compound according to claim 1, wherein R<sup>1</sup> is COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, R<sup>2</sup> is OCOCH<sub>3</sub>, and R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are H.

3. A compound according to claim 2, wherein C3 and C4 15 form a double bond or single bond.

4. A compound according to claim 3, wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are H.

5. A compound according to claim 1, wherein R<sup>5</sup> is C<sub>1-10</sub> alkyl, CF<sub>3</sub>, or CH<sub>2</sub>COOR<sup>1</sup>, and R<sup>1</sup> is a C<sub>1-10</sub> alkyl.

20 6. A compound according to claim 1, wherein R<sup>6</sup> is H, halogen or CH<sub>2</sub>CH<sub>2</sub>NR<sup>7</sup>R<sup>8</sup> where R<sup>7</sup> and R<sup>8</sup> are the same or different C<sub>1-10</sub> alkyl.

7. A compound according to claim 1, wherein said compound is selected from the group consisting of (I-A), (I-B), 25 (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), (I-K), (I-L), (I-M), (I-N), (I-O), (I-P), (I-Q), (I-R), (I-S), (I-T), (I-U), (I-V), (I-W), (I-X), (I-Y), (I-Z) and isomers thereof.

8. A compound according to claim 7, wherein said compound is an isomer of (I-P).

30 9. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide or salt thereof, and a

pharmaceutically acceptable carrier.

10. A pharmaceutical composition according to claim 9, further comprising a drug selected from an anti-viral agent or an immunostimulating agent.

5 11. A method according to claim 10, wherein said antiviral agent is selected from the group consisting of gamma globulin, amantadine, guanidine, hydroxybenzimidazole, interferon- $\alpha$ , interferon- $\beta$ , interferon- $\gamma$ , thiosemicarbazones, methisazone, rifampin, ribvirin, a pyrimidine analog, a purine 10 analog, foscarnet, phosphonoacetic acid, acyclovir, dideoxynucleosides, and ganciclovir.

12. A method for inhibiting a retroviral infection in cells or tissue of an animal, comprising administering an effective retroviral inhibiting amount of a pharmaceutical 15 composition according to claim 9.

13. The method of claim 12, wherein said composition is administered to provide said compound in an amount ranging from 0.1 to 100 mg/kg body weight.

14. The method of claim 13, wherein said composition is 20 administered to provide said compound in an amount ranging from 1 to 100 mg/kg.


15. The method of claim 12, wherein said animal is selected from the group consisting of mammals and birds.

16. The method of claim 15, wherein said mammal is a 25 human.

17. A method for treating a patient suffering from a retroviral related pathology, comprising administering to said subject a retroviral inhibiting effective amount of a pharmaceutical composition according to claim 9.

30 18. A method according to claim 16, wherein said retroviral related pathology is an HIV infection.

19. A compound of formula (II):



wherein R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> are H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, acyl, alkyl, or acyl or CH<sub>2</sub>OOR<sup>1</sup>, where R<sup>1</sup> is C<sub>1-10</sub> alkyl or acyl.

20. A compound according to claim 19, wherein R<sub>1</sub> is COCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, R<sup>9</sup> is COCH<sub>3</sub> and R<sup>10</sup>, R<sup>11</sup>, and R<sup>12</sup> are H.

5 21. A compound according to claim 20, wherein C3 and C4 form a double bond.

22. A compound according to claim 21, wherein R<sup>10</sup>, R<sup>11</sup>, and R<sup>12</sup> are H.

23. A compound according to claim 19, wherein R<sup>12</sup> is C<sub>1-10</sub> alkyl, CF<sub>3</sub> or CH<sub>2</sub>COOR<sup>1</sup>, wherein R<sup>1</sup> is a C<sub>1-10</sub> alkyl.

24. A compound according to claim 19, wherein R<sup>12</sup> is H, halogen or CH<sub>2</sub>CH<sub>2</sub>NR<sup>7</sup>R<sup>8</sup> where R<sup>7</sup> and R<sup>8</sup> are the same or different C<sub>1-10</sub> alkyl.

25. A compound according to claim 19, wherein said compound is selected from the group consisting of (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (II-I), (II-J), (II-K), (II-L), (II-M), (II-N), (II-O), (II-P), (II-Q), (II-R), (II-S), (II-T), (II-U), (II-V), (II-W), (II-X), (II-Y), (II-Z).

20 26. A pharmaceutical composition comprising a compound according to claim 19, or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide or salt thereof, and a pharmaceutically acceptable carrier.

27. A pharmaceutical composition according to claim 26, further comprising a drug selected from an anti-viral agent or an immunostimulating agent.

28. A method according to claim 27, wherein said antiviral agent is selected from the group consisting of gamma globulin, amantadine, guanidine, hydroxybenzimidazole, 30 interferon- $\alpha$ , interferon- $\beta$ , interferon- $\gamma$ , thiosemicarbazones, methisazone, rifampin, ribvirin, a pyrimidine analog, a purine analog, foscarnet, phosphonoacetic acid, acyclovir, dideoxynucleosides, ganciclovir.

29. A method for inhibiting a retroviral infection in 35 cells or tissue of an animal, comprising administering an effective retroviral inhibiting amount of a pharmaceutical composition according to claim 26.

30. The method of claim 29, wherein said composition is

administered to provide said compound in an amount ranging from about 0.1 to 100 mg/kg.

31. The method of claim 29, wherein said composition is administered to provide said compound in an amount ranging from 5 about 1 to 50 mg/kg.

32. The method of claim 29, wherein said animal is selected from the group consisting of mammals and birds.

33. The method of claim 29, wherein said mammal is a human.

10 34. A method for treating a patient suffering from a retroviral related pathology, comprising administering to said subject a retroviral inhibiting effective amount of a pharmaceutical composition according to claim 26.

15 35. A method according to claim 34, wherein said retroviral related pathology is HIV infection.

36. A method for isolating a suksdorfin compound according to claim 1, comprising

20 (a) extracting a sample preparation containing a suksdorfin or suksdorfin analog with hexane to provide active fractions having anti-HIV activity;

(b) centrifuging the active fractions to obtain a supernatant;

(c) recovering the supernatant; and

25 (d) purifying the supernatant by silica gel chromatography to recover the suksdorfin or suksdorfin analog.

37. A method according to claim 36, wherein said sample preparation is derived from the fruit of the plant *Lomatium suksdorfi*.

38. A method for isolating a suksdorfin compound 30 according to claim 1, comprising

(a) extracting a sample preparation containing a suksdorfin or suksdorfin analog with hexane to provide active fractions having anti-HIV activity;

35 (b) centrifuging the active fractions to obtain a supernatant;

(c) recovering the supernatant; and


(d) purifying the supernatant by silica gel chromatography to recover the suksdorfin or suksdorfin analog.

39. A method according to claim 36, wherein said sample preparation is derived from the fruit of the plant *Lomatium suksdorfi*.

40. A suksdorfin analog, comprising a suksdorfin analog obtained by a method according to claim 36.


41. A suksdorfin analog, comprising a suksdorfin analog obtained by a method according to claim 38.

42. A compound according to claim 1, wherein  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  is hydrogen, and wherein




43. A compound according to claim 41, wherein said compound is a specific isomer.

44. A compound according to formula (G-1):



15 wherein M is O or NH; Z is O, NH or S;  $R^{240}$ , and  $R^{250}$  are each H,  $C_{1-10}$  alkyl,  $C_{1-10}$  aryl, alkyl, amide, or  $CH_2COOR^{260}$ , where  $R^{260}$  is  $C_{1-10}$  alkyl or acyl;  $R^{200}$ ,  $R^{210}$ ,  $R^{220}$  and  $R^{230}$  are each H, halogen, hydroxyl,  $NH_2$ ,  $NH$ -alkyl,  $N$ -(alkyl) $_2$ , O-alkyl, O-acyl,  $COCF_3$ ,  $OCF_3$  or  $CH_2COO$   $NH$ -alkyl; or  $R^{200}$  and  $R_{210}$  form  $C_5-C_{10}$  cyclo or 20 heterocyclo optionally substituted with one or more halogen, hydroxyl,  $NH_2$ ,  $NH$ -alkyl,  $N$ -(alkyl) $_2$ , O-acyl, O-alkyl, CO,  $CF_3$ ,  $OCF_3$  or  $CH_2COONH$ -alkyl, and wherein C3 and C4 can be bound by a single or double bond,  $R^{240}$  and  $R^{250}$  are either *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*- $3'$ - $\alpha$  or *trans*- $3'$ - $\beta$  oriented.

45. A compound according to claim 44, wherein said compound is according to formula III.



wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, and R<sup>16</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>17</sup> and R<sup>18</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>19</sup>, where R<sup>18</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl or (+)-camphanoyl or (-)-camphanoyl; and wherein the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>17</sup> and R<sup>18</sup> can each be *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$ -oriented.

46. A compound according to claim 45, wherein said compound is selected from the group consisting of (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-G), (III-H), (III-I), (III-J), (III-K), (III-L), (III-M), (III-N), (III-O), (III-P), (III-Q), (III-R), (III-S), (III-T), (III-U), (III-V), (III-W), (III-X), (III-Y), (III-Z) and isomers thereof.

47. A compound according to claim 46, wherein said compound is an isomer of (III-P).

48. A pharmaceutical composition comprising a compound according to claim 44, or a pharmaceutically acceptable ester, ether, sulfate, carbonate, glucuronide or salt thereof, and a pharmaceutically acceptable carrier.

49. A pharmaceutical composition according to claim 48, further comprising a drug selected from an anti-viral agent or an immunostimulating agent.

50. A composition according to claim 48, wherein said antiviral agent is selected from the group consisting of gamma globulin, amantadine, guanidine, hydroxybenzimidazole, interferon- $\alpha$ , interferon- $\beta$ , interferon- $\gamma$ , thiosemicarbazones,

methisazone, rifampin, ribvirin, a pyrimidine analog, a purine analog, foscarnet, phosphonoacetic acid, acyclovir, dideoxynucleosides, and ganciclovir.

51. A method for inhibiting a retroviral infection in  
5 cells or tissue of an animal, comprising administering an effective retroviral inhibiting amount of a pharmaceutical composition according to claim 48.

52. The method of claim 51, wherein said composition is administered to provide said compound in an amount ranging from  
10 0.1 to 100 mg/kg body weight.

53. The method of claim 52, wherein said composition is administered to provide said compound in an amount ranging from 1 to 100 mg/kg.


54. The method of claim 51, wherein said animal is  
15 selected from the group consisting of mammals and birds.

55. The method of claim 54, wherein said mammal is a human.

56. A method for treating a patient suffering from a retroviral related pathology, comprising administering to said  
20 subject a retroviral inhibiting effective amount of a pharmaceutical composition according to claim 48.

57. A method according to claim 56, wherein said retroviral related pathology is an HIV infection.

58. A compound of claim 44, according to formula (IV):



wherein M is O or NH; Z is O, NH or S; R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>25</sup> and R<sup>26</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub>acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>26</sup>, where R<sup>26</sup> is C<sub>1-10</sub>alkyl,  
30 C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single;


configurations at 3' or 4' can be (R) or (S); and R<sup>25</sup> and R<sup>26</sup> can be oriented *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

59. A compound according to claim 44, wherein C3 and C4 form a double bond or single bond.

5 60. A compound according to claim 58, wherein said compound is selected from the group consisting of (IV-A), (IV-B), (IV-C), (IV-D), (IV-E), (IV-F), (IV-G), (IV-H), (IV-I), (IV-J), (IV-K), (IV-L), (IV-M), (IV-N), (IV-O), (IV-P), (IV-Q), (IV-R), (IV-S), (IV-T), (IV-U), (IV-I), (IV-W), (IV-X), (IV-Y), 10 (IV-Z) and isomers thereof.

61. A compound according to claim 60, wherein said compound is an isomer of (IV-P).

62. A compound of claim 44, according to formula (V):




15 wherein M is O or NH; X and Z = O, NH or S; R<sup>28</sup>, R<sup>29</sup>, R<sup>30</sup>, R<sup>31</sup> and R<sup>32</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>33</sup> and R<sup>34</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub>acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COO R<sup>35</sup>, where R<sup>35</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl 20 and where the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>33</sup> and R<sup>34</sup> can be oriented *cis*- $\beta$  or *cis*- $\alpha$  or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

63. A compound according to claim 62, wherein said compound is selected from the group consisting of (V-A), (V-B), (V-C), (V-D), (V-E), (V-F), (V-G), (V-H), (V-I), (V-J), (V-K), (V-L), (V-M), (V-N), (V-O), (V-P), (V-Q), (V-R), (V-S), (V-T), (V-U), (V-V), (V-W), (V-X), (V-Y), (V-Z) and isomers thereof.

64. A compound according to claim 63, wherein said compound is an isomer of (V-P).

65. A compound of claim 44, according to formula (VI):




5 wherein M is O or NH; X and Z = O, NH or S; R<sup>36</sup>, R<sup>37</sup>, R<sup>38</sup>, and R<sup>39</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>40</sup> and R<sup>41</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>42</sup>, where R<sup>42</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl;  
 10 wherein the bond between C3 and C4 can be double or single; configurations at 3' and 4' can be (R) or (S); and R<sup>40</sup> and R<sup>41</sup> can be oriented *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

66. A compound according to claim 65, wherein said compound is selected from the group consisting of (VI-A), (VI-B), (VI-C), (VI-D), (VI-E), (VI-F), (VI-G), (VI-H), (VI-I), (VI-J), (VI-K), (VI-L), (VI-M), (VI-N), (VI-O), (VI-P), (VI-Q), (VI-R), (VI-S), (VI-T), (VI-U), (VI-V), (VI-W), (VI-X), (VI-Y), (VI-Z) and isomers thereof.

67. A compound according to claim 66, wherein said compound is an isomer of (VI-P).

68. A compound of claim 44, according to formula (VII):



wherein M is O or NH; Z = O, NH or S; R<sup>44</sup>, R<sup>45</sup>, R<sup>46</sup>, R<sup>47</sup>, R<sup>48</sup>, are


SUBSTITUTE SHEET (RULE 26)

each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, or CH<sub>2</sub>CONH-alkyl; R<sup>49</sup> and R<sup>50</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR, where R<sup>51</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond 5 between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>49</sup> and R<sup>50</sup> can be oriented *cis*- $\beta$  or *cis*- $\alpha$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

69. A compound according to claim 68, wherein said compound is selected from the group consisting of (VII-A), (VII-B), (VII-C), (VII-D), (VII-E), (VII-F), (VII-G), (VII-H), (VII-I), (VII-J), (VII-K), (VII-L), (VII-M), (VII-N), (VII-O), (VII-P), (VII-Q), (VII-R), (VII-S), (VII-T), (VII-U), (VII-V), (VII-W), (VII-X), (VII-Y), (VII-Z) and isomers thereof.

70. A compound according to claim 69, wherein said compound is an isomer of (VII-P).

71. A compound of claim 44, according to formula (VIII):




wherein M is O or NH; X, Y and Z = O, NH or S; R<sub>52</sub>, R<sup>53</sup>, R<sup>54</sup>, R<sup>55</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, or CH<sub>2</sub>CONH-alkyl; R<sup>56</sup> and R<sup>57</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>58</sup>, where R<sup>58</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; wherein the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>56</sup> and R<sup>57</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$ , or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

72. A compound according to claim 71, wherein said compound is selected from the group consisting of (VIII-A), (VIII-B), (VIII-C), (VIII-D), (VIII-E), (VIII-F), (VIII-G), (VIII-H), (VIII-I), (VIII-J), (VIII-K), (VIII-L), (VIII-M),

(VIII-N), (VIII-O), (VIII-P), (VIII-Q), (VIII-R), (VIII-S), (VIII-T), (VIII-U), (VIII-V), (VIII-W), (VIII-X), (VIII-Y), (VIII-Z) and isomers thereof.

73. A compound according to claim 72, wherein said compound is an isomer of (VIII-P).

74. A compound of claim 44, according to formula (IX):




wherein M is O or NH; Z = O, NH or S; R<sup>59</sup>, R<sup>60</sup>, R<sup>61</sup> and R<sup>62</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, 10 CF<sub>3</sub>, OCF<sup>3</sup> or CH<sub>2</sub>CONH-alkyl; R<sup>63</sup> and R<sup>64</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>65</sup>, where R<sup>65</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>63</sup> and R<sup>64</sup> can be reoriented 15 cis- $\alpha$  or cis- $\beta$ , or trans-3'- $\beta$  or trans-3'- $\alpha$ .

75. A compound according to claim 74, wherein said compound is selected from the group consisting of (IX-A), (IX-B), (IX-C), (IX-D), (IX-E), (IX-F), (IX-G), (IX-H), (IX-I), (IX-J), (IX-K), (IX-L), (IX-M), (IX-N), (IX-O), (IX-P), (IX-Q), 20 (IX-R), (IX-S), (IX-T), (IX-U), (IX-V), (IX-W), (IX-X), (IX-Y), (IX-Z) and isomers thereof.

76. A compound according to claim 75, wherein said compound is an isomer of (IX-P).

77. A compound of claim 44, according to formula (X):




wherein M is O or NH; Z = O, NH or S; R<sup>66</sup> and R<sup>67</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>68</sup>, R<sup>69</sup>, R<sup>70</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>71</sup>, where R<sup>71</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl, the bond between C3 and C4 can be double or single; configurations at 5 3' or 4' can be (R) or (S); and R<sup>68</sup> and R<sup>69</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$  or *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

78. A compound according to claim 77, wherein said 10 compound is selected from the group consisting of (X-A), (X-B), (X-C), (X-D), (X-E), (X-F), (X-G), (X-H), (X-I), (X-J), (X-K), (X-L), (X-M), (X-N), (X-O), (X-P), (X-Q), (X-R), (X-S), (X-T), (X-U), (X-V), (X-W), (X-X), (X-Y), (X-Z) and isomers thereof.

79. A compound according to claim 78, wherein said 15 compound is an isomer of (X-P).

80. A compound of claim 44, according to formula (XI):




wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>72</sup> and R<sup>73</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, 20 CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>74</sup> and R<sup>75</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>76</sup>, where R<sup>76</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>74</sup> and R<sup>75</sup> can be oriented *cis*- $\alpha$  25 or *cis*- $\beta$ , or *trans* 3'- $\beta$  or *trans* 3'- $\alpha$ .

81. A compound according to claim 80, wherein said compound is selected from the group consisting of (XI-A), (XI-B), (XI-C), (XI-D), (XI-E), (XI-F), (XI-G), (XI-H), (XI-I), (XI-J), (XI-K), (XI-L), (XI-M), (XI-N), (XI-O), (XI-P), (XI-Q), (XI-R), (XI-S), (XI-T), (XI-U), (XI-V), (XI-W), (XI-X), (XI-Y), (XI-Z) and isomers thereof.

82. A compound according to claim 81, wherein said compound is an isomer of (XI-P).

83. A compound of claim 44, according to formula (XIII):




5 wherein M is O or NH; Z = O, NH or S; R<sup>77</sup>, R<sup>78</sup>, R<sup>79</sup>, R<sup>80</sup>, R<sup>81</sup>, R<sup>82</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>83</sup> and R<sup>84</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub>acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>85</sup>, where R<sup>85</sup> is C<sub>1-10</sub>alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>83</sup> and R<sup>84</sup> can be oriented cis- $\alpha$  or cis- $\beta$ , or trans-3'- $\beta$  or trans-3'- $\alpha$ .

15 84. A compound according to claim 83, wherein said compound is selected from the group consisting of (XIII-A), (XIII-B), (XIII-C), (XIII-D), (XIII-E), (XIII-F), (XIII-G), (XIII-H), (XIII-I), (XIII-J), (XIII-K), (XIII-L), (XIII-M), (XIII-N), (XIII-O), (XIII-P), (XIII-Q), (XIII-R), (XIII-S), (XIII-T), (XIII-U), (XIII-V), (XIII-W), (XIII-X), (XIII-Y), (XIII-Z) and isomers thereof.

20 85. A compound according to claim 84, wherein said compound is an isomer of (XIII-P).

86. A compound of claim 44, according to formula (XIII):




wherein M is O or NH; R<sup>86</sup>, R<sup>87</sup>, R<sup>88</sup>, R<sup>89</sup>, R<sup>90</sup>, R<sup>91</sup>, R<sup>92</sup>, R<sup>93</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>94</sup> and R<sup>95</sup>, are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>96</sup>, where R<sup>96</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>94</sup> and R<sup>95</sup> can be oriented cis- $\alpha$  or cis- $\beta$ , or trans-3'- $\beta$  or trans-3'- $\alpha$ .

87. A compound according to claim 86, wherein said compound is selected from the group consisting of (XIII-A), (XIII-B), (XIII-C), (XIII-D), (XIII-E), (XIII-F), (XIII-G), (XIII-H), (XIII-I), (XIII-J), (XIII-K), (XIII-L), (XIII-M), (XIII-N), (XIII-O), (XIII-P), (XIII-Q), (XIII-R), (XIII-S), (XIII-T), (XIII-U), (XIII-V), (XIII-W), (XIII-X), (XIII-Y), (XIII-Z) and isomers thereof.

88. A compound according to claim 87, wherein said compound is an isomer of (XIII-P).

89. A compound of claim 44, according to formula (XIV):




wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>97</sup> and R<sup>98</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>99</sup> and R<sup>100</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>101</sup>, where R<sup>101</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl group, wherein the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>99</sup> and R<sup>100</sup> can be oriented cis- $\alpha$  or cis- $\beta$ , or trans-3'- $\beta$  or trans-3'- $\alpha$ .

90. A compound according to claim 89, wherein said compound is selected from the group consisting of (XIV-A), (XIV-B), (XIV-C), (XIV-D), (XIV-E), (XIV-F), (XIV-G), (XIV-H), (XIV-I), (XIV-J), (XIV-K), (XIV-L), (XIV-M), (XIV-N), (XIV-O),

(XIV-P), (XIV-Q), (XIV-R), (XIV-S), (XIV-T), (XIV-U), (XIV-V), (XIV-W), (XIV-X), (XIV-Y), (XIV-Z) and isomers thereof.

91. A compound according to claim 90, wherein said compound is an isomer of (XIV-P).

5 92. A compound of claim 44, according to formula (XV):




wherein M is O or NH; X and Z = O, NH or S; R<sup>102</sup>, R<sup>103</sup>, R<sup>104</sup>, R<sup>105</sup>, are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>106</sup> and R<sup>107</sup>, are each H, 10 C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>108</sup>, where R<sup>108</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>106</sup> and R<sup>107</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$ , or *trans*-3'- $\beta$  or 15 *trans*-3'- $\alpha$ .

93. A compound according to claim 92, wherein said compound is selected from the group consisting of (XV-A), (XV-B), (XV-C), (XV-D), (XV-E), (XV-F), (XV-G), (XV-H), (XV-I), (XV-J), (XV-K), (XV-L), (XV-M), (XV-N), (XV-O), (XV-P), (XV-Q), 20 (XV-R), (XV-S), (XV-T), (XV-U), (XV-V), (XV-W), (XV-X), (XV-Y), (XV-Z) and isomers thereof.

94. A compound according to claim 93, wherein said compound is an isomer of (XV-P).

95. A compound of claim 44, according to formula (XVI):




wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>109</sup>, R<sup>110</sup>, R<sup>111</sup>, R<sup>112</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>113</sup> and R<sup>114</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sub>115</sub>, where R<sup>115</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>113</sup> and R<sup>114</sup> can be oriented, *cis*- $\alpha$ , *cis*- $\beta$ , *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

96. A compound according to claim 95, wherein said compound is selected from the group consisting of (XVI-A), (XVI-B), (XVI-C), (XVI-D), (XVI-E), (XVI-F), (XVI-G), (XVI-H), (XVI-I), (XVI-J), (XVI-K), (XVI-L), (XVI-M), (XVI-N), (XVI-O), (XVI-P), (XVI-Q), (XVI-R), (XVI-S), (XVI-T), (XVI-U), (XVI-V), (XVI-W), (XVI-X), (XVI-Y), (XVI-Z) and isomers thereof.

97. A compound according to claim 96, wherein said compound is an isomer of (XVI-P).

98. A compound of claim 44, according to formula (XVII):




20 wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>116</sup>, R<sup>117</sup>, R<sup>118</sup>, R<sup>119</sup>, R<sup>120</sup>, R<sup>121</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>122</sup> and R<sup>123</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>124</sup>, where R<sup>124</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>122</sup> and R<sup>123</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$  or *trans*-3'- $\alpha$  or *trans*-3'- $\beta$ .

99. A compound according to claim 98, wherein said

compound is selected from the group consisting of (XVII-A), (XVII-B), (XVII-C), (XVII-D), (XVII-E), (XVII-F), (XVII-G), (XVII-H), (XVII-I), (XVII-J), (XVII-K), (XVII-L), (XVII-M), (XVII-N), (XVII-O), (XVII-P), (XVII-Q), (XVII-R), (XVII-S), 5 (XVII-T), (XVII-U), (XVII-V), (XVII-W), (XVII-X), (XVII-Y), (XVII-Z) and isomers thereof.

100. A compound according to claim 99, wherein said compound is an isomer of (XVII-P).

101. A compound of claim 44, according to formula 10 (XVIII):




wherein M is O or NH; X, Y and Z = O, NH or S; R<sup>125</sup>, R<sup>126</sup>, R<sup>127</sup>, R<sup>128</sup> and R<sup>129</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>130</sup> and R<sup>131</sup>, are each H, 15 C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>132</sup>, where R<sup>132</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>130</sup> and R<sup>131</sup> can be oriented cis- $\alpha$ , cis- $\beta$ , trans-3'- $\beta$  or trans-3'- $\alpha$ .

102. A compound according to claim 101, wherein said compound is selected from the group consisting of (XVIII-A), (XVIII-B), (XVIII-C), (XVIII-D), (XVIII-E), (XVIII-F), (XVIII-G), (XVIII-H), (XVIII-I), (XVIII-J), (XVIII-K), (XVIII-L), (XVIII-M), (XVIII-N), (XVIII-O), (XVIII-P), 25 (XVIII-Q), (XVIII-R), (XVIII-S), (XVIII-T), (XVIII-U), (XVIII-V), (XVIII-W), (XVIII-X), (XVIII-Y), (XVIII-Z) and isomers thereof.

103. A compound according to claim 102, wherein said

compound is an isomer of (XVIII-P).

104. A compound of claim 44, according to formula (XIX):




wherein M is O or NH; Z = O, NH or S; R<sup>133</sup>, R<sup>134</sup>, R<sup>135</sup>, R<sup>136</sup>, R<sup>137</sup>, R<sup>138</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>139</sup> and R<sup>140</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>141</sup>, where R<sup>141</sup> is C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>139</sup> and R<sup>140</sup> can be oriented *cis*- $\alpha$  or *cis*- $\beta$ , *trans*-3'- $\beta$  or *trans*-3'- $\alpha$ .

105. A compound according to claim 104, wherein said compound is selected from the group consisting of (XIX-A), (XIX-B), (XIX-C), (XIX-D), (XIX-E), (XIX-F), (XIX-G), (XIX-H), (XIX-I), (XIX-J), (XIX-K), (XIX-L), (XIX-M), (XIX-N), (XIX-O), (XIX-P), (XIX-Q), (XIX-R), (XIX-S), (XIX-T), (XIX-U), (XIX-V), (XIX-W), (XIX-X), (XIX-Y), (XIX-Z) and isomers thereof.

106. A compound according to claim 105, wherein said compound is an isomer of (XIX-P).

107. A compound of claim 44, according to formula (XX):



wherein M is O or NH; Z = O, NH or S; R<sup>142</sup>, R<sup>143</sup> and R<sup>144</sup> are each H, halogen, OH, O-alkyl, O-acyl, NH<sub>2</sub>, NH-alkyl, N-(alkyl)<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub> or CH<sub>2</sub>CONH-alkyl; R<sup>145</sup>, R<sup>146</sup>, and R<sup>147</sup> are each H, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> acyl, aryl, COCF<sub>3</sub>, amide or CH<sub>2</sub>COOR<sup>148</sup>, where R<sup>148</sup> is C<sub>1-10</sub> alkyl, 5 C<sub>1-10</sub> acyl, or aryl or (+)-camphanoyl or (-)-camphanoyl; the bond between C3 and C4 can be double or single; configurations at 3' or 4' can be (R) or (S); and R<sup>146</sup>, R<sup>147</sup> and R<sup>148</sup> can be oriented *cis*- $\alpha$ , *cis* $\beta$ , *trans*-3'- $\alpha$ , *trans*-3'- $\beta$ .

108. A compound according to claim 107, wherein said 10 compound is selected from the group consisting of (XX-A), (XX-B), (XX-C), (XX-D), (XX-E), (XX-F), (XX-G), (XX-H), (XX-I), (XX-J), (XX-K), (XX-L), (XX-M), (XX-N), (XX-O), (XX-P), (XX-Q), (XX-R), (XX-S), (XX-T), (XX-U), (XX-V), (XX-W), (XX-X), (XX-Y), (XX-Z) and isomers thereof.

15 109. A compound according to claim 108, wherein said compound is an isomer of (XX-P).

# INTERNATIONAL SEARCH REPORT

Intern: 1 Application No  
PCT/US 94/12630

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 C07D493/04 C07D311/22 C07D407/12 A61K31/35  
 // (C07D493/04, 311:00, 311:00)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p><b>BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS,</b>            vol.4, no.4, 23 February 1994            pages 593 - 598            L. HUANG ET AL '3',4'-Di-O-(-)-camphanoyl-            (+)-cis-khellactone and related compounds:            a new class of potent anti-HIV agents'            see the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/-</p>	1-18, 36-43

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

31 March 1995

Date of mailing of the international search report

28.04.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+ 31-70) 340-3016

Authorized officer

Voyiazoglou, D

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/US 94/12630

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 79, no. 19, 12 November 1973, Columbus, Ohio, US; abstract no. 111980v, S. A. VICHKONOVA ET AL 'Antimicrobial and antiviral activity of some natural coumarins' page 49 ; see abstract & RAST. RESUR., vol.9, no.3, 1973 pages 370 - 379	1-18, 36-43
X	---	1-7
X	CHEMISCHE BERICHTE, vol.92, 1959, WEINHEIM DE pages 2338 - 2363 H. D. SCHROEDER ET AL 'Struktur der Visnagane; Synthese von (+)-trans-Samidin' see page 2340 - page 2348	19
X	see page 2344	1-7
X	---	1-7
X	CHEMICAL ABSTRACTS, vol. 96, no. 12, 22 March 1982, Columbus, Ohio, US; abstract no. 91638k, O. K. ANTONOVA ET AL 'Dihydrosamidin and visnadin' page 407 ; see abstract & OTKRYTIKA IZOBRET. PROM. OBRAZTSY TOVARNYE ZNAKI, no.40, 1983 page 13	1-7
X	---	1-7
X	CHEMISCHE BERICHTE, vol.104, 1971, WEINHEIM DE pages 3229 - 3233 F. BOHLMANN ET AL 'Synthese von racemischem Lomatin, Columbianetin, Angenomalin und Samidin' see page 3229 - page 3231	1-7
X	---	1-7
X	US,A,2 980 699 (E. SMITH ET AL) 18 April 1961 see claims 1-11	1-7
	-----	

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internat'l Application No  
PCT/US 94/12630

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-2980699	18-04-61	NONE	

# INTERNATIONAL SEARCH REPORT

! national application No.

PCT/US 94/ 12630

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 43-57, 58-109  
because they relate to subject matter not required to be searched by this Authority, namely:

Please see attached sheet

2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International Application No. PCT/US94/12630

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/210**

Remark - Although claims 11-18 & 28-39 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

As the drafting of the claims is not clear and concise (Art. 6, PCT) and encompasses such an enormous amount of products, a complete search is not possible on economic grounds (see Art.17(2), (a)(II), PCT).

Guided by the spirit of the application and the inventive concept as disclosed in the descriptive part of the present application the search has been based on the examples.

(Claims searched compl.: 1-43, searched incompl.: 43-57, not searched: 58-109)